# **Supplementary material**

### **GABA DOSE Supplemental Digital Content**

Supplemental Digital Content 1 Search strategies

### Preliminary searches performed 13 November 2013

Total number of references identified: 16895 references Number of duplicates removed: 3189 references Number of references in final list: 13706 references

Batch name: 131113\_J Wetterslev\_GABA

Cochrane Central Register of Controlled Trials (CENTRAL) (Issue 10 of 12, 2013) in The Cochrane Library (2411 hits in CENTRAL) #1 MeSH descriptor: [Amines] explode all trees and with qualifiers: [Adverse effects - AE, Therapeutic use - TU] #2 MeSH descriptor: [gamma-Aminobutyric Acid] explode all trees and with qualifiers: [Adverse effects - AE, Therapeutic use - TU] #3 MeSH descriptor: [Cyclohexanecarboxylic Acids] explode all trees and with qualifiers: [Adverse effects - AE, Therapeutic use - TU] #4 (gaba\* or neurontin\* or neurotonin\* or horizant\*) #5 #1 or #2 or #3 or #4 #6 MeSH descriptor: [Pain] explode all trees #7 pain\* #8 #6 or #7 #9 #5 and #8 #10 adult\* or middle age\* or aged #11 #9 and #10

### MEDLINE (Ovid SP)(1946 to November 2013)(7072 hits)

1. exp Amines/ae, tu [Adverse Effects, Therapeutic Use]

2. exp gamma-Aminobutyric Acid/ae, tu [Adverse Effects, Therapeutic Use]

3. exp Cyclohexanecarboxylic Acids/ae, tu [Adverse Effects, Therapeutic Use]

4. (gaba\* or neurontin\* or neurotonin\* or horizant\*).mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept, rare disease supplementary concept, unique identifier]

5.1 or 2 or 3 or 4

6. exp Pain/

7. pain\*.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept, rare disease supplementary concept, unique identifier]

8.6 or 7

9.5 and 8

10. limit 9 to (humans and ("all adult (19 plus years)" or "young adult (19 to 24 years)" or "adult (19 to 44 years)" or "young adult and adult (19-24 and 19-44)" or "middle age (45 to 64 years)" or "middle aged (45 plus years)" or "all aged (65 and over)" or "aged (80 and over)"))

EMBASE (1974 to November 2013)(3653 hits)

1. amine/ae, dt, th [Adverse Drug Reaction, Drug Therapy, Therapy]

2. 4 aminobutyric acid/ae, dt [Adverse Drug Reaction, Drug Therapy]

3. cyclohexanecarboxylic acid derivative/ae, dt [Adverse Drug Reaction, Drug Therapy]

4. (gaba\* or neurontin\* or neurotonin\* or horizant\*).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]

5. 1 or 2 or 3 or 4

6. exp pain/

7. pain\*.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]

8.6 or 7

9.5 and 8

10. limit 9 to (human and (adult <18 to 64 years> or aged <65+ years>))

Science Citation Index Expanded (http://apps.webofknowledge.com)(1900 to November 2013)(3759
hits)
#3 3,759 #2 AND #1
#2 385,187 TS=(pain\*)
#1 68,630 TS=(gaba\* or neurontin\* or neurotonin\* or horizant\*)

### Preliminary searches performed 30 June 2014

Total number of references identified: 16861 references Number of duplicates removed: 3592 references Number of references in final list: 13569 references Number of new references: 789 references

Batch name: 140701\_J Wetterslev\_GABA

Cochrane Central Register of Controlled Trials (CENTRAL) (Issue 6 of 12, 2014) in The Cochrane Library (2619 hits in CENTRAL) #1 MeSH descriptor: [Amines] explode all trees and with qualifiers: [Adverse effects - AE, Therapeutic use - TUl #2 MeSH descriptor: [gamma-Aminobutyric Acid] explode all trees and with qualifiers: [Adverse effects - AE, Therapeutic use - TU] #3 MeSH descriptor: [Cyclohexanecarboxylic Acids] explode all trees and with qualifiers: [Adverse effects - AE, Therapeutic use - TU] #4 (gaba\* or neurontin\* or neurotonin\* or horizant\*) #5 #1 or #2 or #3 or #4 #6 MeSH descriptor: [Pain] explode all trees #7 pain\* #8 #6 or #7 #9 #5 and #8 #10 adult\* or middle age\* or aged #11 #9 and #10

MEDLINE (Ovid SP)(1946 to July 2014)(6319 hits)

1. exp Amines/ae, tu [Adverse Effects, Therapeutic Use]

2. exp gamma-Aminobutyric Acid/ae, tu [Adverse Effects, Therapeutic Use]

3. exp Cyclohexanecarboxylic Acids/ae, tu [Adverse Effects, Therapeutic Use]

4. (gaba\* or neurontin\* or neurotonin\* or horizant\*).mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept, rare disease supplementary concept, unique identifier]

5.1 or 2 or 3 or 4

6. exp Pain/

7. pain\*.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept, rare disease supplementary concept, unique identifier]

8.6 or 7

9.5 and 8

10. limit 9 to (humans and ("all adult (19 plus years)" or "young adult (19 to 24 years)" or "adult (19 to 44 years)" or "young adult and adult (19-24 and 19-44)" or "middle age (45 to 64 years)" or "middle aged (45 plus years)" or "all aged (65 and over)" or "aged (80 and over)"))

#### EMBASE (1974 to July 2014)(3847 hits)

1. amine/ae, dt, th [Adverse Drug Reaction, Drug Therapy, Therapy]

2. 4 aminobutyric acid/ae, dt [Adverse Drug Reaction, Drug Therapy]

3. cyclohexanecarboxylic acid derivative/ae, dt [Adverse Drug Reaction, Drug Therapy]

4. (gaba\* or neurontin\* or neurotonin\* or horizant\*).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]

5. 1 or 2 or 3 or 4

6. exp pain/

7. pain\*.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]

8.6 or 7

9.5 and 8

10. limit 9 to (human and (adult <18 to 64 years> or aged <65+ years>))

Science Citation Index Expanded (http://apps.webofknowledge.com)(1900 to July 2014)(4076 hits)
#3 4,076 #2 AND #1
#2 417,945 TS=(pain\*)
#1 72,059 TS=(gaba\* or neurontin\* or neurotonin\* or horizant\*)

### Preliminary searches performed 14 November 2014

Total number of references identified: 17315 references Number of duplicates removed: 4105 references Number of references in final list: 13210 references Number of new references: 462 references

Batch name: 141114\_J Wetterslev\_GABA NEW

<u>Cochrane Central Register of Controlled Trials</u> (CENTRAL)(Issue 11 of 12, 2014) (2645 hits) #1 MeSH descriptor: [Amines] explode all trees and with qualifiers: [Adverse effects - AE, Therapeutic use - TU] #2 MeSH descriptor: [gamma-Aminobutyric Acid] explode all trees and with qualifiers: [Adverse effects - AE, Therapeutic use - TU] #3 MeSH descriptor: [Cyclohexanecarboxylic Acids] explode all trees and with qualifiers: [Adverse effects - AE, Therapeutic use - TU] #3 MeSH descriptor: [Cyclohexanecarboxylic Acids] explode all trees and with qualifiers: [Adverse effects - AE, Therapeutic use - TU] #4 (gaba\* or neurontin\* or neurotonin\* or horizant\*)

#5 #1 or #2 or #3 or #4

#6 MeSH descriptor: [Pain] explode all trees
#7 pain\*
#8 #6 or #7
#9 #5 and #8
#10 adult\* or middle age\* or aged
#11 #9 and #10

### MEDLINE (Ovid SP)(1946 to November 2014)(6549 hits)

1. exp Amines/ae, tu [Adverse Effects, Therapeutic Use]

2. exp gamma-Aminobutyric Acid/ae, tu [Adverse Effects, Therapeutic Use]

3. exp Cyclohexanecarboxylic Acids/ae, tu [Adverse Effects, Therapeutic Use]

4. (gaba\* or neurontin\* or neurotonin\* or horizant\*).mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept, rare disease supplementary concept, unique identifier]

5.1 or 2 or 3 or 4

6. exp Pain/

7. pain\*.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept, rare disease supplementary concept, unique identifier]

8.6 or 7

9. 5 and 8

10. limit 9 to (humans and ("all adult (19 plus years)" or "young adult (19 to 24 years)" or "adult (19 to 44 years)" or "young adult and adult (19-24 and 19-44)" or "middle age (45 to 64 years)" or "middle aged (45 plus years)" or "all aged (65 and over)" or "aged (80 and over)"))

### EMBASE (1974 to November 2014)(3962 hits)

1. amine/ae, dt, th [Adverse Drug Reaction, Drug Therapy, Therapy]

2. 4 aminobutyric acid/ae, dt [Adverse Drug Reaction, Drug Therapy]

3. cyclohexanecarboxylic acid derivative/ae, dt [Adverse Drug Reaction, Drug Therapy]

4. (gaba\* or neurontin\* or neurotonin\* or horizant\*).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]

5.1 or 2 or 3 or 4

6. exp pain/

7. pain\*.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]

8.6 or 7

9.5 and 8

10. limit 9 to (human and (adult <18 to 64 years> or aged <65+ years>))

### Science Citation Index Expanded (1900 to November 2014)(4159 hits)

#3 4,159 #2 AND #1

#2 417,588 TS=(pain\*)

#1 72,305 TS=(gaba\* or neurontin\* or neurotonin\* or horizant\*)

### Preliminary searches performed 9 April 2015

Total number of references identified: 17466 references Number of duplicates removed: 4042 references Number of references in final list: 13424 references Number of new references: 126 references Batch name: 150409\_J Wetterslev\_GABA

Cochrane Central Register of Controlled Trials (CENTRAL) (Issue 3 of 12, 2015) (2629 hits) #1 MeSH descriptor: [Amines] explode all trees and with qualifiers: [Adverse effects - AE, Therapeutic use - TU] #2 MeSH descriptor: [gamma-Aminobutyric Acid] explode all trees and with qualifiers: [Adverse effects - AE, Therapeutic use - TU] #3 MeSH descriptor: [Cyclohexanecarboxylic Acids] explode all trees and with qualifiers: [Adverse effects - AE, Therapeutic use - TU] #4 (gaba\* or neurontin\* or neurotonin\* or horizant\*) #5 #1 or #2 or #3 or #4 #6 MeSH descriptor: [Pain] explode all trees #7 pain\* #8 #6 or #7 #9 #5 and #8 #10 adult\* or middle age\* or aged #11 #9 and #10

### MEDLINE (Ovid SP)(1946 to April 2015) (6432 hits)

1. exp Amines/ae, tu [Adverse Effects, Therapeutic Use]

2. exp gamma-Aminobutyric Acid/ae, tu [Adverse Effects, Therapeutic Use]

3. exp Cyclohexanecarboxylic Acids/ae, tu [Adverse Effects, Therapeutic Use]

4. (gaba\* or neurontin\* or neurotonin\* or horizant\*).mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept, rare disease supplementary concept, unique identifier]

5. 1 or 2 or 3 or 4

6. exp Pain/

7. pain\*.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept, rare disease supplementary concept, unique identifier]

8.6 or 7

9. 5 and 8

10. limit 9 to (humans and ("all adult (19 plus years)" or "young adult (19 to 24 years)" or "adult (19 to 44 years)" or "young adult and adult (19-24 and 19-44)" or "middle age (45 to 64 years)" or "middle aged (45 plus years)" or "all aged (65 and over)" or "aged (80 and over)"))

### EMBASE (1974 to April 2015) (4081 hits)

1. amine/ae, dt, th [Adverse Drug Reaction, Drug Therapy]

2. 4 aminobutyric acid/ae, dt [Adverse Drug Reaction, Drug Therapy]

3. cyclohexanecarboxylic acid derivative/ae, dt [Adverse Drug Reaction, Drug Therapy]

4. (gaba\* or neurontin\* or neurotonin\* or horizant\*).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]

 $5.\,1\,or\,2\,or\,3\,or\,4$ 

6. exp pain/

7. pain\*.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]

8.6 or 7

9.5 and 8

10. limit 9 to (human and (adult <18 to 64 years> or aged <65+ years>))

### Science Citation Index Expanded (1900 to April 2015) (4324 hits)

#3 4,324 #2 AND #1 #2 430,421 TS=(pain\*) #1 73,791 TS=(gaba\* or neurontin\* or neurotonin\* or horizant\*)

### Preliminary searches performed 23<sup>rd</sup> September 2015

Total number of references identified: 18200 references Number of duplicates removed: 4184 references Number of references in final list: 14016 references Number of new references: 1188 references

Batch name: 150915\_J Wetterslev\_GABA

#### Cochrane Central Register of Controlled Trials (CENTRAL) (Issue 8 of 12, 2015) (2798 hits)

#1 MeSH descriptor: [Amines] explode all trees and with qualifiers: [Adverse effects - AE, Therapeutic use - TU]

#2 MeSH descriptor: [gamma-Aminobutyric Acid] explode all trees and with qualifiers: [Adverse effects - AE, Therapeutic use - TU]

#3 MeSH descriptor: [Cyclohexanecarboxylic Acids] explode all trees and with qualifiers: [Adverse effects - AE, Therapeutic use - TU]

- #4 (gaba\* or neurontin\* or neurotonin\* or horizant\*)
- #5 #1 or #2 or #3 or #4
- #6 MeSH descriptor: [Pain] explode all trees
- #7 pain\*
- #8 #6 or #7
- #9 #5 and #8
- #10 adult\* or middle age\* or aged
- #11 #9 and #10

### MEDLINE (Ovid SP) (1946 to September 2015) (6621 hits)

1. exp Amines/ae, tu [Adverse Effects, Therapeutic Use]

2. exp gamma-Aminobutyric Acid/ae, tu [Adverse Effects, Therapeutic Use]

3. exp Cyclohexanecarboxylic Acids/ae, tu [Adverse Effects, Therapeutic Use]

4. (gaba\* or neurontin\* or neurotonin\* or horizant\*).mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept, rare disease supplementary concept, unique identifier]

5.1 or 2 or 3 or 4

6. exp Pain/

7. pain\*.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept, rare disease supplementary concept, unique identifier]

8.6 or 7

9.5 and 8

10. limit 9 to (humans and ("all adult (19 plus years)" or "young adult (19 to 24 years)" or "adult (19 to 44 years)" or "young adult and adult (19-24 and 19-44)" or "middle age (45 to 64 years)" or "middle aged (45 plus years)" or "all aged (65 and over)" or "aged (80 and over)"))

### EMBASE (1974 to September 2015) (4289 hits)

1. amine/ae, dt, th [Adverse Drug Reaction, Drug Therapy]

2. 4 aminobutyric acid/ae, dt [Adverse Drug Reaction, Drug Therapy]

3. cyclohexanecarboxylic acid derivative/ae, dt [Adverse Drug Reaction, Drug Therapy]

4. (gaba\* or neurontin\* or neurotonin\* or horizant\*).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]

5. 1 or 2 or 3 or 4

6. exp pain/

7. pain\*.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]

- 8.6 or 7
- 9.5 and 8

10. limit 9 to (human and (adult <18 to 64 years> or aged <65+ years>))

Science Citation Index Expanded (1900 to September 2015) (4492 hits) #3 4,492 #2 AND #1 #2 445,898 TS=(pain\*) #1 75,431 TS=(gaba\* or neurontin\* or neurotonin\* or horizant\*)

### Preliminary searches performed 12<sup>th</sup> April 2016

Total number of references identified:	references
Number of duplicates removed:	references
Number of references in final list:	references
Number of new references:	references

Batch name: 160412\_J Wetterslev\_GABA

Cochrane Central Register of Controlled Trials (CENTRAL) (Issue 4 of 12, 2015) (2993 hits)

#1 MeSH descriptor: [Amines] explode all trees and with qualifiers: [Adverse effects - AE, Therapeutic use - TU]

#2 MeSH descriptor: [gamma-Aminobutyric Acid] explode all trees and with qualifiers: [Adverse effects - AE, Therapeutic use - TU]

#3 MeSH descriptor: [Cyclohexanecarboxylic Acids] explode all trees and with qualifiers: [Adverse effects - AE, Therapeutic use - TU]

- #4 (gaba\* or neurontin\* or neurotonin\* or horizant\*)
- #5 #1 or #2 or #3 or #4
- #6 MeSH descriptor: [Pain] explode all trees
- #7 pain\*
- #8 #6 or #7
- #9 #5 and #8
- #10 adult\* or middle age\* or aged
- #11 #9 and #10

### MEDLINE (Ovid SP) (1946 to April 2016) (6625 hits)

1. exp Amines/ae, tu [Adverse Effects, Therapeutic Use]

2. exp gamma-Aminobutyric Acid/ae, tu [Adverse Effects, Therapeutic Use]

3. exp Cyclohexanecarboxylic Acids/ae, tu [Adverse Effects, Therapeutic Use]

4. (gaba\* or neurontin\* or neurotonin\* or horizant\*).mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept, rare disease supplementary concept, unique identifier]

5. 1 or 2 or 3 or 4

6. exp Pain/

7. pain\*.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept, rare disease supplementary concept, unique identifier]

8.6 or 7

9.5 and 8

10. limit 9 to (humans and ("all adult (19 plus years)" or "young adult (19 to 24 years)" or "adult (19 to 44 years)" or "young adult and adult (19-24 and 19-44)" or "middle age (45 to 64 years)" or "middle aged (45 plus years)" or "all aged (65 and over)" or "aged (80 and over)"))

### EMBASE (1974 to April 2016) (4474 hits)

1. amine/ae, dt, th [Adverse Drug Reaction, Drug Therapy]

2. 4 aminobutyric acid/ae, dt [Adverse Drug Reaction, Drug Therapy]

3. cyclohexanecarboxylic acid derivative/ae, dt [Adverse Drug Reaction, Drug Therapy]

4. (gaba\* or neurontin\* or neurotonin\* or horizant\*).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]

5. 1 or 2 or 3 or 4

6. exp pain/

7. pain\*.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]

8.6 or 7

9.5 and 8

10. limit 9 to (human and (adult <18 to 64 years> or aged <65+ years>))

Science Citation Index Expanded (1900 to April 2016) (4717 hits) #3 #2 AND #1 #2 TS=(pain\*) #1 TS=(gaba\* or neurontin\* or neurotonin\* or horizant\*)

### **Google Scholar search**

After the 1st search, 13th November 2013 Gabapentin AND Postoperative pain Gabapentin AND Acute pain management Gabapentin AND Perioperative pain management

After the 2nd search, 30th June 2014 Gabapentin AND Postoperative pain Gabapentin AND Acute pain management Gabapentin AND Perioperative pain management

Limits: titles from  $1^{st}$  November 2013 and on

After the 3rd search, 14th November 2014 Gabapentin AND Postoperative pain Gabapentin AND Acute pain management Gabapentin AND Perioperative pain management

Limits: titles from 1st June 2014 and on

After the 4th search, 9th April 2015 Gabapentin AND Postoperative pain Gabapentin AND Acute pain management Gabapentin AND Perioperative pain management Limits: titles from 1st November 2014 and on

After the 5th search, 23rd September 2015 Gabapentin AND Postoperative pain Gabapentin AND Acute pain management Gabapentin AND Perioperative pain management

Limits: titles from 1st April 2015 and on

After the 6th search, 12<sup>th</sup> April 2016 Gabapentin AND Postoperative pain Gabapentin AND Acute pain management Gabapentin AND Perioperative pain management

Limits: titles from 1<sup>st</sup> September 2015 and on

# Supplemental Digital Content 2 Opioid conversion

Opioid	Administration	Opioid: Intravenous morphine
1 mg Fentanyl	i.v.	100 mg morphine
1 mg Hydromorphone	i.v.	5 mg morphine
1 mg Morphine oral	oral	0.33 mg morphine
1 mg Nalbuphine	i.v.	1 mg morphine
1 mg Pethidine/Meperidine	i.v.	0.13 mg morphine
1 mg Propoxyphene	i.v.	5 mg morphine
1 mg Tramadol oral	oral	0.07 mg morphine

# Supplemental Digital Content 3 Trial characteristics

Trial					<b>Total 24-hour morphine</b> <b>consumption</b> Intra venous morphine (mg)		
	No* of patients	Surgical Procedures	Dose mg/day (bolus mg)	<b>Treatment</b> Single / Multiple dose	Intervention (mg) (Mean SD)	<b>Control (mg)</b> (Mean SD)	
			300 mg/day	Multiple dose			
Amr 2009 <sup>32</sup>	100	Radical or partial mastectomy	(300 mg)		13.5 (0.5)	22.0 (2.1)	
Bang 2009 <sup>36</sup>	46	Arthroscopic shoulder surgery	300 mg/day	Single dose	32.1 (29.1)	30.1 (28.67)	
			300 mg/day				
Behdad 2012 <sup>39</sup>	61	Hysterectomy	(100 mg)	Multiple dose	-	-	
Chowdhury 2010 <sup>46</sup>	200	Gynecological surgery	300 mg/day	Single dose	-	-	
			200 mg /day				
Clarke 2014 <sup>48</sup>	179	Total knee arthroplasty	(600 mg)	Multiple dose	37 (1.5)	48 (1.3)	
		Abdominal hysterectomy and	300 mg/day				
Ghafari 2009 <sup>60</sup>	66	salphingooophrectomy	(300 mg)	Multiple dose	15.8 (1.2)	26.9 (2.3)	
Hassani 2014 <sup>67</sup>	60	Laparoscopic gastric by-pass	100 mg/day	Single dose	-	-	
			300 mg/day				
Khurana 2013 <sup>77</sup>	60	Lumbar discectomy	(300 mg)	Multiple dose	-	-	
Mohammadi 200895	70	Assisted reproductive techniques	300 mg/day	Single dose	-	-	
Mohammadi 200996	80	Abdominal surgery/gynecological surgery	300 mg/day	Single dose	-	-	
			300 mg/day				
Lichtinger 2011 <sup>84</sup>	40	Bilateral photorefractive keratectomy	(600 mg)	Multiple dose	-	-	
Pandey 2004c <sup>107</sup>	56	Single level lumbar disc surgery	300 mg/day	Single dose	90.9 (34.1)	92.5 (41.8)	
Ray 2015 <sup>118</sup>	60	Abdominal hysterectomy	300 mg/day	Single dose	-	-	
-		*	300 mg /day				
Sekhavet 2009 <sup>123</sup>	98	Abdominal hysterectomy	(600 mg)	Multiple dose	40.1 (14.5)	52.7 (21.1)	
			300mg/day				
Spence 2011 <sup>131</sup>	57	Shoulder arthroscopy	(300 mg)	Multiple dose	-	-	
Vahedi 2011 <sup>140</sup>	76	Lumbar laminectomy and discectomy	300 mg/day	Single dose	18.6 (9.0)	21.5 (11.3)	

			300 mg/day			
Vasigh 2016 <sup>141</sup>	76	Laminectomy	(600 mg)	Multiple dose	-	-
Verma 2008 <sup>142</sup>	50	Abdominal hysterectomy	300 mg/day	Single dose	-	-
			300 mg/day	Multiple dose		18 (15.5)
Waikakul 2011 <sup>144</sup>	48	Spine, major joint, tumor and major limb surgery	(400 mg)		15.5 (9.3)	
			300 mg/day			
Yoon 2001 <sup>145</sup>	32	Hysterectomy	(400 mg)	Multiple dose	24.1 (9.9)	32.7 (14.6)
Ajori 2011 <sup>30</sup>	138	Abdominal hysterectomy	600 mg/day	Single dose	-	-
		Mastectomy or quandrandectomy and axillary				
Azemati 2013 <sup>33</sup>	100	node dissection	600 mg/day	Single dose	-	-
Bafna 2014 <sup>143</sup>	60	Gynecological surgery	600 mg/day	Single dose	-	-
Bashir 2009 <sup>38</sup>	100	Laparoscopic cholecystectomy	600 mg/day	Single dose	-	-
			600 mg/day			
Bhandari 2014 <sup>41</sup>	40	Laparoscopic cholecystectomy	(600 mg)	Multiple dose	-	-
Bharti 2012 <sup>42</sup>	40	Total mastectomy with axillary node dissection	600 mg/day	Single dose	2.1 (2.2)	4.9 (3.4)
Celebi 2013 <sup>45</sup>	60	Gynecological laparoscopy	600 mg/day	Single dose	-	-
Clarke 2009b <sup>147</sup>	115	Total hip arthroplasty	600 mg/day	Single dose	37.0 (1.5)	48 (1.3)
Ercan 2014 <sup>54</sup>	34	Carotid Endartectomy	600 mg/day	Single dose	-	-
Gosai 2015 <sup>64</sup>	60	Mastectomy	600 mg/day	Single dose	-	-
Grover 2009 <sup>66</sup>	46	Total mastectomy with axillary node dissection	600 mg/day	Single dose	-	-
Hoseini 2015 <sup>68</sup>	44	Cholecystectomy	600 mg/day	Single dose	-	-
			600 mg/day			
loseph 2014 <sup>71</sup>	50	Abdominal hysterectomy	(600 mg)	Multiple dose	38.7 (18.0)	44.3 (16.0)
Kavitha 2013 <sup>72</sup>	56	Intraocular surgery/cataract	600 mg/day	Single dose	-	-
Kazak 2009 <sup>73</sup>	60	Nasal septal, nasal sinus surgery	600 mg/day	Single dose	-	-
Khademi 2009 <sup>74</sup>	87	Open cholecystectomy	600 mg/day	Single dose	2.8 (1.3)	3.5 (1.5)
Khezri 2013 <sup>76</sup>	80	Cataract surgery	600 mg/day	Single dose	-	-
		Thoratectomy; lobectomy; pneumonectomy;				
Kinney 2011 <sup>79</sup>	125	chest wall resection	600 mg/day	Single dose	-	-
Manhoori 2014 <sup>85</sup>	50	Unilateral herniorrhaphy	400 mg/day	Single dose	-	-
Maleh 2013 <sup>86</sup>	80	Laparoscopic surgery	600 mg/day	Single dose	2.5 (2.6)	2.7 (2.7)
Mardani-Kivi						3.7 (2.5)
2013 <sup>88</sup>	108	Anterior Collateral Ligament reconstruction	600 mg/day	Single dose	2.5 (2.3)	


Menda 2010 <sup>89</sup>	60	Coronary Artery Bypass Graft	600 mg/day	Single dose	6.0 (8.5)	15.1 (20)
		Unilateral radical mastectomy and axillary	600 mg/day			
Metry 2008 <sup>91</sup>	68	dissection	(1200 mg)	Single dose	16.1 (7.7)	29.2 (9.6)
Misra 2013 <sup>94</sup>	73	Craniotomy for intracranial tumor	600 mg/day	Single dose	24.6 (19.6)	29.2 (25.2)
			600 mg/day			10.0 (7.4)
Monks 2015 <sup>98</sup>	197	Cesarean section	(600 mg)	Multiple dose	10.0 (11.9)	
Moore 2010 <sup>99</sup>	44	Cesarean section	600 mg/day	Single dose	3.0 (3.0)	4.0 (5.0)
Özcan 2011 <sup>102</sup>	40	Supratentorial tumor surgery	600 mg/day	Single dose	15.0 (5.0)	19.0 (4.2)
Pandey 2005 <sup>108</sup>	60	Open donor nephrectomy	600 mg/day	Single dose	59.4 (23.2)	92.5 (41.8)
Pandey 2006 <sup>105</sup>	250	Laparoscopic cholecystectomy	600 mg/day	Single dose	39.2 (26.3)	67.7 (25.3)
Parikh 2010 <sup>109</sup>	60	Elective surgery	600 mg/day	Single dose	31.7 (20.3)	31.9 (19.8)
			600 mg/day			
Paul 2013111	101	Total knee arthroplasty	(200 mg)	Multiple dose	27.9 (23.0)	26.8 (19.0)
			600 mg/day			
Paul 2015 <sup>112</sup>	102	Total hip arthroplasty	(600 mg)	Multiple dose	19.7 (16.4)	25.1 (14.5)
Saeed 2013121	100	Laparoscopic cholecystectomy	600 mg/day	Single dose	-	-
Sava 2009122	50	Colorectal surgery	600 mg/day	Single dose	35.6 (14.1)	54.7 (13.0)
Semira 2013 <sup>124</sup>	60	Laparoscopic cholecystectomy	600 mg/day	Single dose	-	-
			600 mg/day			
Sharma 2015 <sup>127</sup>	40	Laparoscopic cholecystectomy	(600 mg)	Multiple dose	-	-
Short 2012 <sup>9</sup>	63	Cecaerean section	300 mg	Single dose	5.7 (5.3)	7.9 (3.8)
Siddiqui 2013 <sup>129</sup>	72	Major bowel surgery	600 mg/day	Single dose	-	-
Soltanzadeh			400 mg/day			
2011 <sup>130</sup>	60	Coronary Artery Bypass Grafting	(800 mg)	Multiple dose	2.5 (0.9)	4.0 (1.5)
Srivastava 2009132	120	Open cholecystectomy	600 mg/day	Single dose	25.4 (4.5)	37.6 (8.4)
Zaldivar-Ramirez			600 mg/day			
2011 <sup>146</sup>	34	Nissen laparoscopic fund_operation	(300 mg)	Multiple dose	-	-
Adam 2006 <sup>29</sup>	53	Arthroscopic shoulder surgery	800 mg/day	Single dose	-	-
Badawy 2014 <sup>34</sup>	40	Abdominal hysterectomy	800 mg/day	Single dose	11.5 (2.3)	13.0 (2.9)
Deniz 201249	51	Radical Retropubic Prostatectomy	900 mg/day	Single dose	22.2 (11.9)	25.6 (10.5)
Farzi 2015 <sup>55</sup>	103	Septorhinoplasty	900 mg/day	Single dose	-	-
Ghai 2011 <sup>61</sup>	60	Abdominal hysterectomy	900 mg/day	Single dose	5.4 (1.6)	4.3 (1.9)
Ghai 2012 <sup>62</sup>	60	Abdominal hysterectomy	900 mg/day	Single dose	-	-

			900 mg /day			
Kuhnle 2010 <sup>82</sup>	82	PRK Myopia surgery	(300 mg)	Multiple dose	-	-
Kim 2004 <sup>78</sup>	41	Mastectomy	900 mg/day	Single dose	35.8 (20.8)	33.5 (26.1)
Koc 2007 <sup>80</sup>	40	Varicocele	800 mg/day	Single dose	-	-
			900 mg/day			
Leung 2006 <sup>83</sup>	21	Spine surgery	(900 mg)	Multiple dose	-	-
Lunn 2015 <sup>5</sup>	140	Total knee arthroplasty	900 mg/day	Multiple dose	45.4 (35.7)	50.5 (41.4)
Marashi 2012 <sup>87</sup>	44	Thyroidectomy	900 mg/day	Single dose	18.3 (15.6)	65.7 (31.0)
Mishra 2016 <sup>93</sup>	60	Laparoscopic cholecystectomy	900 mg/day	Single dose	-	-
Neogi 2012 <sup>100</sup>	60	Laparoscopic cholecystectomy	900 mg/day	Single dose	-	-
			900 mg/day			
Pakravan 2012 <sup>104</sup>	100	Post photorefractive keratectomy surgery	(300 mg)	Multiple dose	-	-
Prabhakar 2007 <sup>113</sup>	20	Elective brachial plexus exploration	800 mg/day	Single dose	23.8 (5.0)	20.0 (2.1)
Radhakrishnan			800 mg/day			
2005 <sup>114</sup>	30	Lumbar laminectomy or lumbar discectomy	(400 mg)	Multiple dose	-	-
Rajendran 2014 <sup>116</sup>	60	Small gastrointestinal procedures	900 mg/day	Single dose	-	-
Ram 2015 <sup>115</sup>	60	Abdominal hysterectomy	900 mg/day	Single dose	-	-
Rimaz 2014 <sup>119</sup>	60	Dacryocystorhinostomy	900 mg/day	Single dose	-	-
Short 2012a <sup>9</sup>	63	Cesarean section	600 mg	Single dose	6.7 (3.6)	7.9 (3.8)
Abdelmageed				Single dose		12.2 (1.1)
2010 <sup>28</sup>	60	Tonsillectomy	1200 mg/day		6.6 (1.3)	
Al-Mujadi 2005 <sup>31</sup>	72	Elective thyroid surgery	1200 mg/day	Single dose	15.2 (7.6)	29.5 (9)
Bartholdy 2006 <sup>37</sup>	76	Sterilization laparoscopic with Filshie clips	1200 mg/day	Single dose	-	-
Bakry 2011 <sup>35</sup>	60	Cataract surgery	1200 mg/day	Single dose	-	-
			1200 mg/day			
Bekawi 2014 <sup>40</sup>	60	Laparoscopic cholecystectomy	(1200 mg)	Multiple dose	0 (2.2)	7.5 (0.7)
Brogly 200843	43	Total or partial thyroidectomy	1200 mg/day	Single dose	0 (1.48)	0 (4.4)
Butt 2010 <sup>44</sup>	100	Mastectomy	1200 mg/day	Single dose	-	-
Clarke 2013 <sup>47</sup>	44	General-, gynecological-, plastic and ENT surgery	1200 mg/day	Single dose	-	-
	1	Abdominal hysterectomy and	2400 mg/day	Ŭ		
Dierking 2003 <sup>50</sup>	80	salphingooophrectomy	(600 mg)	Multiple dose	43.0 (23.7)	63.0 (25.9)
<u> </u>		Unilateral radical mastectomy with axillary				
Dirks 2002 <sup>51</sup>	65	dissection	1200 mg/day	Single dose	-	-

Doha 2010 <sup>52</sup>	59	Radical Mastectomy	1200 mg/day	Single dose	39.9 (33.0)	42.7 (36.1)
Durmus 2006 <sup>53</sup>	50	Total abdominal hysterectomy	1200 mg/day	Single dose	40.0 (10.0)	66.0 (10.0)
		Radical mastectomy or lobectomy with axillary	1200 mg/day			
Fassoulaki 2002 <sup>57</sup>	50	node dissection	(1200 mg)	Multiple dose	23.8 (5.0)	23.2 (5.8)
			1600 mg/day			
Fassoulaki 2005 <sup>58</sup>	59	Abdominal hysterectomy	400 mg	Multiple dose	20.3 (7.9)	25.7 (11.2)
			1600 mg/day			
Fassoulaki 200656	60	Abdominal hysterectomy	800 mg	Multiple dose	22.0 (2.9)	35.0 (4.8)
Frouzanfard 2013 <sup>59</sup>	50	Abdominal hysterectomy	1200 mg/day	Single dose	1.2 (0.2)	5.2 (2.8)
			1800 mg/day			
Gilron 2004 <sup>63</sup>	47	Abdominal hysterectomy	600 mg	Multiple dose	56.8 (32.4)	82.1 (48.2)
			1200 mg/day			
Grosen 2014 <sup>65</sup>	104	Thoracotomy for malignancy	(1200 mg)	Multiple dose	11.2 (21.6)	17.9 (23.69)
		Exploratory thoracotomy, pneumonectomy,				
Hout 2007 <sup>69</sup>	51	lobectomy, segmentectomy, biopsy	1200 mg/day	Single dose	2.4 (2.5)	2.7 (3.2)
Jajeda 2014 <sup>70</sup>	50	Upper abdominal surgery	1200 mg/day	Single dose	-	-
Khan 2013 <sup>75</sup>	69	Abdominal hysterectomy	1200 mg/day	Single dose	13.1 (4.7)	24.3 (9.3)
Kosucu 2013 <sup>81</sup>	60	Posterolateral or lateral thoracotomy	1200 mg/day	Single dose	25.9 (8.3)	44.0 (11.0)
Lunn 2015a <sup>5</sup>	141	Total knee arthroplasty	1300 mg/day	Multiple dose	46.2 (41.0)	50.5 (41.4)
Ménigaux 2004 <sup>90</sup>	40	Arthroscopic anterior cruciate ligament	1200 mg/day	Single dose	21.0 (12.0)	20.0 (19.0)
			1800 mg/day			
Mikkelsen 200692	51	Tonsillectomy	(1200 mg)	Multiple dose	-	-
Mohammed 2012 <sup>97</sup>	80	Functional endoscopic sinus surgery	1200 mg/day	Single dose	-	-
			1200 mg/day			
Omran 2005 <sup>101</sup>	50	Posterolateral thoracotomy for lobectomy	(1200 mg)	Multiple dose	23.9 (2.6)	31.5 (2.8)
		Decompressive lumbar laminectomy and	1800 mg/day			
Özgenzil 2011 <sup>103</sup>	60	discectomy	600 mg	Multiple dose	29.5 (9.6)	37.3 (9.5)
Pathak 2014 <sup>110</sup>	80	Cholecystectomy	1200 mg/day	Single dose	-	-
Rapchuk 2009 <sup>117</sup>	54	Cardiac surgery	1200 mg/day	Single dose	-	-
Rorarius 2004 <sup>102</sup>	90	Vaginal hysterectomy	1200 mg/day	Single dose	-	-
		Abdominal hysterectomy and		_		
Sen 2009a <sup>125</sup>	40	salphingooophrectomy	1200 mg/day	Single dose	31.0 (12.0)	48.0 (17.0)
Sen 2009b126	59	Unilateral inguinal herniotomy	1200 mg/day	Single dose	20.0 (11.5)	28.0 (11.5)

Sheen 2008128	80	Orthopedic surgeries	1200 mg/day	Single dose	-	-
Syal 2010 <sup>133</sup>	60	Open cholecystectomy	1200 mg/day	Single dose	40.2 (35.2)	46.7 (35.8)
		Ear-nose and throat-, general-, orthopedic-, and				
Tirault 2010 <sup>134</sup>	135	gynecologic surgery	1200 mg/day	Single dose	-	-
		Abdominal hysterectomy and				
Turan 2003a <sup>12</sup>	50	salphingooophrectomy	1200 mg/day	Single dose	27.0 (14.4)	42.0 (8.4)
Turan 2003b135	50	Discectomy spinal fusion surgery	1200 mg/day	Single dose	16.3 (8.9)	42.8 (10.9)
Turan 2004 <sup>137</sup>	50	Ear Nose and Throat surgery	1200 mg/day	Single dose	-	-
			1200 mg/day			
Turan 2005 <sup>136</sup>	40	Lower limb surgery	(1200 mg)	Multiple dose	-	-
		Abdominal hysterectomy and	1200 mg/day			-
Turan 2006 <sup>138</sup>	50	salphingooophrectomy	(1200 mg)	Multiple dose	-	
			1200 mg/day			
Ucak 2011 <sup>139</sup>	40	Coronary Artery Bypass Graft	(1200 mg)	Multiple dose	9.9 (5.4)	14.9 (7.3)





# Supplemental Digital Content 5 Forest plot of VAS 6h rest from trials with low risk of bias

		apentin			ntrol			Mean Difference	Mean Difference
Study or Subgroup	Mean [VAS]	SD [VAS]	Total	Mean [VAS]	SD [VAS]	Total	Weight	IV, Random, 95% CI [VAS]	IV, Random, 95% CI [VAS]
3.7.1 0-350 mg									
Short 2012	14	7.4	42	20	10	21	12.1%	-6.00 [-10.83, -1.17]	ı <del>-</del>
Waikakul 2011	50	25	24	60	25	24	9.7%	-10.00 [-24.14, 4.14]	i —+
Subtotal (95% CI)			66			45	21.8%	-6.42 [-10.99, -1.85]	♦
Heterogeneity: Tau <sup>2</sup> :	= 0.00; Chi <sup>2</sup> =	0.28, df =	1 (P =	$0.60$ ; $I^2 = 0\%$					
Test for overall effect	t: Z = 2.75 (P =	= 0.006)							
3.7.2 351-700 mg									
Kinney 2011	27	25.2	57	28	26.2	68	11.2%	-1.00 [-10.03, 8.03]	Ⅰ
Moore 2010	19.5	15.5	21	40	20	23	10.8%	-20.50 [-31.02, -9.98]	
Short 2012a	15	6.7	42	20	10	21	12.1%	-5.00 [-9.73, -0.27	i 🚽
Srivastava 2010	23	3.17	60	49	3.33	60	12.5%	-26.00 [-27.16, -24.84]	
Subtotal (95% CI)			180			172	46.5%	-13.24 [-27.57, 1.08]	
3.7.4 701-1050 mg Subtotal (95% CI)			0			0		Not estimable	
		le							
Test for overall effect		le							
Test for overall effect 3.7.5 > 1050 mg		le 19.1	22	23.5	21.3	21	10.3%	-1.00 [-13.11, 11.11]	
Test for overall effect 3.7.5 > 1050 mg Brogly 2008 Fassoulaki 2005	t: Not applicab 22.5 17	19.1 28	29	23.5 20	31	30	10.3% 9.4%	-1.00 [-13.11, 11.11] -3.00 [-18.06, 12.06]	
Test for overall effect 3.7.5 > 1050 mg Brogly 2008 Fassoulaki 2005 Grosen 2014	t: Not applicab 22.5	19.1	29 52			30 52	9.4% 11.9%	-3.00 [-18.06, 12.06] -7.11 [-13.13, -1.09]	
Test for overall effect 3.7.5 > 1050 mg Brogly 2008 Fassoulaki 2005 Grosen 2014 Subtotal (95% CI)	t: Not applicab 22.5 17 6.84	19.1 28 12.97	29 52 103	20 13.95	31 17.94	30	9.4%	-3.00 [-18.06, 12.06]	
Heterogeneity: Not a Test for overall effect 3.7.5 > 1050 mg Brogly 2008 Fassoulaki 2005 Grosen 2014 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> Test for overall effect	t: Not applicab 22.5 17 6.84 = 0.00; Chi <sup>2</sup> =	19.1 28 12.97 0.91, df =	29 52 103	20 13.95	31 17.94	30 52	9.4% 11.9%	-3.00 [-18.06, 12.06] -7.11 [-13.13, -1.09]	
Test for overall effect 3.7.5 > 1050 mg Brogly 2008 Fassoulaki 2005 Grosen 2014 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup>	t: Not applicab 22.5 17 6.84 = 0.00; Chi <sup>2</sup> =	19.1 28 12.97 0.91, df =	29 52 103	20 13.95	31 17.94	30 52 <b>103</b>	9.4% 11.9%	-3.00 [-18.06, 12.06] -7.11 [-13.13, -1.09]	•
Test for overall effect 3.7.5 > 1050 mg Brogly 2008 Fassoulaki 2005 Grosen 2014 Substoal (95% CI) Heterogeneity: Tau <sup>2</sup> Test for overall effect Total (95% CI)	t: Not applicab 22.5 17 6.84 = 0.00; Chi <sup>2</sup> = t: Z = 2.15 (P =	19.1 28 12.97 0.91, df = = 0.03)	29 52 103 2 (P = 349	20 13.95 0.63); I <sup>2</sup> = 0%	31 17.94	30 52 103 320	9.4% 11.9% <b>31.7%</b>	-3.00 [-18.06, 12.06] -7.11 [-13.13, -1.09] -5.57 [-10.65, -0.50]	• •
Test for overall effect 3.7.5 > 1050 mg Brogly 2008 Fassoulaki 2005 Grosen 2014 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> Test for overall effect	t: Not applicab 22.5 17 6.84 = 0.00; Chi <sup>2</sup> = t: Z = 2.15 (P = = 183.29; Chi <sup>2</sup>	19.1 28 12.97 0.91, df = = 0.03) = 200.72,	29 52 103 2 (P = 349	20 13.95 0.63); I <sup>2</sup> = 0%	31 17.94	30 52 103 320	9.4% 11.9% <b>31.7%</b>	-3.00 [-18.06, 12.06] -7.11 [-13.13, -1.09] -5.57 [-10.65, -0.50]	•

# Supplemental Digital Content 6 Forest plot of VAS 6h rest from all trials estimates

Vahedi 2011         61.1           Vahedi 2011         61.1           Verma 2008         23           wakakui 2011         50           Yoon 2001         29           Subtotal (95% CI)         -           Heterogeneity: Tau <sup>2</sup> = 85.21; Chi <sup>2</sup> = 204.         Fest for overall effect: Z = 4.10 (P < 0.000           3.8.2 351-700 mg         Ajori 2011         40           Joirks 2002         14         Grover 2009         10           Gazak 2009         15         Stear 2014         30           Mahori 2014         30         MardaniKivi 2013         50           Menda 2010         20         Merna 2014         30           MardaniKivi 2013         50         Yenday 2005         29.5           Parikh 2010         29         Standay 2015         29.5           Agiendran 2014         42.7         Short 2012a         13           Stabtotal (95% CI)         -         292.5         Strivastava 2010         23           Gadiava 2012         23         Stibutotal (95% CI)         -           Heterogeneity: Tau <sup>2</sup> = 84.00; Chi <sup>2</sup> = 292.         Fest for overall effect: Z = 6.50 (P < 0.000         3.8           Subtotal (95% CI)         -         -         -	20 9.6 5.26	23						IV, Random, 95% CI [VAS]
kehad 2012         38           ichowdhury 2010         40.8           ichowdhury 2010         40.8           ichowdhury 2010         40.8           ichowdhury 2010         40.8           ichafari 2009         42.5           ekhavet 2009         37.9           hort 2012         14           fahedi 2011         61.1           ferma 2008         23           walkakul 2011         50           foon 2001         29           waltotal (95% CI)         elsterogeneity: Tau <sup>2</sup> = 85.21; Chi <sup>2</sup> = 204.           iest for overall effect: Z = 4.10 (P < 0.000	9.6	23	60	20	22	1 500	-15 00 (-26 56 - 2 44)	
chowdhury 2010       40.8         chafari 2009       37.9         chord 2012       14         fachari 2009       37.9         short 2012       14         fachadi 2011       61.1         fachedi 2011       61.1         fachedi 2011       61.1         fachedi 2011       61.1         feterogeneity: Tau <sup>2</sup> = 85.21; Chi <sup>2</sup> = 204.       feterogeneity: Tau <sup>2</sup> = 85.21; Chi <sup>2</sup> = 204.         fest for overall effect: Z = 4.10 (P < 0.000		30	66.2	20 13.7	23 31	1.5% 1.9%	-15.00 [-26.56, -3.44] -28.20 [-34.12, -22.28]	
hafari 2009 42.5 ekhavet 2009 37.9 hort 2012 14 'Ahedi 2011 61.1 'erma 2008 23 Vaikakul 2011 50 Gon 2001 29 <b>vuibtotal (95% CI)</b> leterogeneity: Tau <sup>2</sup> = 85.21; Chi <sup>2</sup> = 204. 'est for overall effect: Z = 4.10 (P < 0.000 'k.8.2 351-700 mg jori 2011 40 Dirks 2002 14 Grover 2009 10 (azak 2009 15 'hezri 2013 0 funey 2011 27 Aahoori 2014 30 Aardani-Kivi 2013 50 deta 2010 20 Atardani-Kivi 2013 50 Aardani-Kivi 2013 50 Aardani-Kivi 2013 20 Aardani-Kivi 2013 20 Aarday 2005 29.5 arikh 2010 20 Atery 2008 12.52 Anday 2005 29.5 arikh 2010 29 starka 2010 20 Atery 2013 30 Jozcan 2012 12 ubtotal (95% CI) eterogeneity: Tau <sup>2</sup> = 84.00; Chi <sup>2</sup> = 292. 'est for overall effect: Z = 6.50 (P < 0.000 .8.4 701-1050 mg iadawy 2014 40 Deniz 2012 23 im 2004 27 oic 2007 2.3 Aarashi 2012 48 trabhakar 2007 37.5 tadhakrishnan 2005 10 ubtotal (95% CI) eterogeneity: Tau <sup>2</sup> = 4.94; Chi <sup>2</sup> = 8.22, 'est for overall effect: Z = 3.59 (P = 0.000 .8.5 > 1050 mg bodelmageed 2010 32 Uhotal (95% CI) eterogeneity: Tau <sup>2</sup> = 4.94; Chi <sup>2</sup> = 8.22, 'est for overall effect: Z = 3.59 (P = 0.000 .8.5 > 1050 mg bodelmageed 2010 32 Uhotal (95% CI) eterogeneity: Tau <sup>2</sup> = 4.94; Chi <sup>2</sup> = 8.22, 'est for overall effect: Z = 3.59 (P = 0.000 .8.5 > 1050 mg bodelmageed 2010 32 Uhotal (95% CI) eterogeneity: Tau <sup>2</sup> = 4.94; Chi <sup>2</sup> = 8.22, 'est for overall effect: Z = 3.59 (P = 0.000 .8.5 > 1050 mg bodelmageed 2010 32 Uhotal (95% CI) eterogeneity: Tau <sup>2</sup> = 4.94; Chi <sup>2</sup> = 8.22, 'est for overall effect: Z = 3.59 (P = 0.000 .8.5 > 1050 mg bodelmageed 2010 32 .1.12 boha 2010 18 Durma 2007 45 assoulaki 2005 17 assoulaki 2005 17 assoulaki 2005 27 rouzanfard 2013 35.6 illon 2004 29 tiran 2003 14.12 boha 2014 18 Durnan 2006 35 en 2009b 15 tiran 2003 13 tiran 2004 15 tiran 2003 13 tiran 2005 34 tiran 2003 13 tiran 2005 34 tiran 2003 13 tiran 2004 35 en 2009b 15 tiran 2003 14 tiran 2003b 13 tiran 2004 34 tiran 2005 34 tir		100	45	3.37	100	2.0%	-4.20 [-5.42, -2.98]	
iekhavet 2009 37.9 ihort 2012 14 Vahedi 2011 61.1 Verma 2008 23 Vaikakul 2011 50 (foon 2001 29 Vaibtotal (95% CI) 29 Valtatione 2009 10 Cazak 2009 10 Cazak 2009 10 Cinney 2011 27 Valtada 2010 20 Vertry 2008 12.52 Valtada 2010 20 Vertry 2008 12.52 Valtada 2010 29 Valtada 2010 29 Vertry 2008 12.52 Valtada 2010 29 Vertry 2011 20 Vertry 2012 12 Valtada 2010 29 Vertry 2012 12 Valtada 2010 29 Vertry 2014 40 Vertry 2012 12 Vertry 2012 12 Vertry 2012 12 Vertry 2014 40 Vertry 2014 40 Vertry 2014 40 Vertry 2012 12 Vertry 2012 12 Vertry 2012 12 Vertry 2012 2012 12 Vertry 2012 40 Vertry 2014 40 Vertry 2015 10 Verter 2010 12 Vertry 2014 40 Vertry 2015 10 Verter 2010 12 Verter 2010 12 Verter 2012 12 Verter 2012 12 Verter 2014 51 Verter 2014 51 Verter 2014 52 Vertry 2008 22.5 Vertry 2003 14.12 Vertry 2008 42.5 Vertry 2003 14.12 Vertry 2003 13 Vertry 2003 13 Ver	3.5	33	58.1	4	33	2.0%	-15.60 [-17.41, -13.79]	•
short 2012         14           Vahedi 2011         61.1           Vahedi 2011         61.1           Verma 2008         23           Waikakul 2011         50           foon 2001         29           Subtotal (95% CI)         29           Subtotal (95% CI)         204           Fest for overall effect: Z = 4.10 (P < 0.007	20.8	49	76.6	22.4	49	1.7%	-38.70 [-47.26, -30.14]	-
/ahedi 2011         61.1           /erma 2008         23           wakakui 2011         50           /oon 2001         29           yubtotal (95% CI)         -           +eterogeneity: Tau <sup>2</sup> = 85.21; Chi <sup>2</sup> = 204.         Fest for overall effect: Z = 4.10 (P < 0.000	7.4	42	20	10	21	1.9%	-6.00 [-10.83, -1.17]	-
Waikakul 2011         50           (oon 2001         29           (jubtotal (95% CI)         29           Vaikakul 2011         29           Vaikakul 2013         29           Subtotal (95% CI)         29           Vaikakul 2013         20           Ska: 351-700 mg         200           Ska: 351-700 mg         10           Ska: 2002         14           Grover 2009         10           Cacak 2009         15           Khezri 2013         0           Ginney 2011         27           Wahoori 2014         30           Mardani-Kivi 2013         50           Wenda 2010         20           Wetry 2008         12.52           May 2005         29.5           Yarikh 2010         29           Yarakh 2010         23           Zaldwar Ramirez 2011         30           Zycan 2012         23           Zaldwar Ramirez 2011         30           Zycan 2012         23           Zaldwar 2010         23           Zadadwy 2014         40           Deniz 2012         23           Kadawy 2014         40           Den	20.9	36	56.8	24.4	40	1.6%	4.30 [-5.89, 14.49]	+
Yoon 2001         29           Subtotal (95% CI)         29           Subtotal (95% CI)         204           Fest for overall effect: Z = 4.10 (P < 0.000	14	25	32	16	25	1.7%	-9.00 [-17.33, -0.67]	
Subtotal (95% CI)         Image: Subtotal (95% CI)           Heterogeneity: Tau <sup>2</sup> = 85.21; Chi <sup>2</sup> = 204.           Test for overall effect: Z = 4.10 (P < 0.000	25	24	60	25	24	1.4%	-10.00 [-24.14, 4.14]	+
Heterogeneity: Tau <sup>2</sup> = 85.21; Chi <sup>2</sup> = 204.         Test for overall effect: Z = 4.10 (P < 0.000	72	16	41	59	16	0.3%	-12.00 [-57.61, 33.61]	
Fest for overall effect: Z = 4.10 ( $P < 0.000$ <b>3.8.2 351-700 mg</b> Ajori 2011       40         Dirks 2002       14         Grover 2009       10         Gazak 2009       15         Khezri 2013       0         Ginney 2011       27         Mahoori 2014       30         Mardani-Kivi 2013       50         Menda 2010       20         Metry 2008       12.52         Moore 2010       19.5         Yarikh 2010       29         Agiendran 2014       42.7         Schort 2012       12         Stadaw 2010       23         Stadaw 2012       12         Subtotal (95% CI)       23         Heterogeneity: Tau <sup>2</sup> = 84.00; Chi <sup>2</sup> = 292.         Fest for overall effect: Z = 6.50 ( $P < 0.000$ 3.8.4 701-1050 mg         Gadawy 2014       40         Deniz 2012       23         Matrishnan 2005       10         Subtotal (95% CI)       10         Heterogeneity: Tau <sup>2</sup> = 4.94; Chi <sup>2</sup> = 8.22,         Fest for overall effect: Z = 3.59 ( $P = 0.000$ S.8.5 > 1050 mg       32         Abdelmageed 2010       32         N-		378			362	16.0%	-13.65 [-20.17, -7.13]	◆
Ajori 2011         40           Dirks 2002         14           Dirks 2002         14           Irover 2009         10           Gazak 2009         15           (hezri 2013)         0           (inney 2011)         27           Aahoori 2014         30           Adradmi-Kivi 2013         50           Adradmi-Kivi 2013         50           Adradmi-Kivi 2013         50           Adradmi-Kivi 2013         50           Adradar 2010         29           Yagendra 2014         42.7           Abori 2010         29           Yagendra 2014         42.7           Abori 2010         23           Taldivar Ramirez 2011         30           Dyzcar 2012         12           Liubtotal (95% CI)         12           Viubtotal (95% CI)         14           Adrashi 2012         48           Yabhakar 2007         37.5           Tadhakrishnan 2005         10           Vatersopeneity: Tau <sup>2</sup> = 4.94; Chi <sup>2</sup> = 8.22,           Test for overall effect: Z = 3.59 (P = 0.000           8.8.5 > 1050 mg           Nbdelmageed 2010         32           Varmabkar 2007         45 <td></td> <td>9 (P &lt;</td> <td>0.00001); l<sup>2</sup> =</td> <td>96%</td> <td></td> <td></td> <td></td> <td></td>		9 (P <	0.00001); l <sup>2</sup> =	96%				
Dirks 2002         14           Grover 2009         10           Graver 2009         15           Kinney 2011         27           Mahoori 2014         30           Mardani-Kivi 2013         50           Wenda 2010         20           Wetry 2008         12.52           Mardani-Kivi 2013         50           Wenda 2010         20           Wetry 2008         12.52           Mardani-Kivi 2013         50           Woore 2010         19.5           Paraday 2005         29.5           Parakh 2010         23           Agjendran 2014         42.7           Short 2012         13           Dirks 2010         23           Zadidvar Ramirez 2011         30           Dacar 2012         12           Subtotal (95% CI)         -           Heterogeneity: Tau <sup>2</sup> = 84.00: Chi <sup>2</sup> = 292.           Test for overall effect: Z = 3.59 (P < 0.000								
Dirks 2002         14           Grover 2009         10           Graver 2009         15           Kinney 2011         27           Mahoori 2014         30           Mardani-Kivi 2013         50           Wenda 2010         20           Wetry 2008         12.52           Mardani-Kivi 2013         50           Wenda 2010         20           Wetry 2008         12.52           Mardani-Kivi 2013         50           Woore 2010         19.5           Paraday 2005         29.5           Parakh 2010         23           Agjendran 2014         42.7           Short 2012         13           Dirks 2010         23           Zadidvar Ramirez 2011         30           Dacar 2012         12           Subtotal (95% CI)         -           Heterogeneity: Tau <sup>2</sup> = 84.00: Chi <sup>2</sup> = 292.           Test for overall effect: Z = 3.59 (P < 0.000	30	69	63	28	69	1.6%	-23.00 [-32.68, -13.32]	
Kazak 2009         15           Khezri 2013         0           Khezri 2013         0           Kinney 2011         27           Mahoori 2014         30           Mardani-Kivi 2013         50           Metda 2010         20           Metry 2008         12.52           Mardani-Kivi 2013         50           Moore 2010         19.5           Panday 2005         29.5           Parikh 2010         29           Agjendran 2014         42.7           Short 2012a         15           Srivastava 2010         23           Zaldivar Ramirez 2011         30           Dzcan 2012         12           Subtotal (95% CI)         Heterogeneity: Tau <sup>2</sup> = 84.00; Chi <sup>2</sup> = 292.           Fest for overall effect: Z = 6.50 (P < 0.000	18	31	18	15	34	1.7%	-4.00 [-12.10, 4.10]	-+
Khezri 2013         0           Kinney 2011         27           Mahoori 2014         30           Mardani-Kivi 2013         50           Menda 2010         20           Metry 2008         12.52           Moore 2010         19.5           Panday 2005         29.5           Parkh 2010         29           Rajendran 2014         42.7           Short 2012         12           Zaldivar Ramirez 2011         30           Dozcan 2012         12           Subtotal (95% CI)         1           Heterogeneity: Tau <sup>2</sup> = 84.00: Chi <sup>2</sup> = 292.           Fest for overall effect: Z = 6.50 (P < 0.000	8.15	27	10	8.15	23	1.9%	0.00 [-4.53, 4.53]	+
Kinney 2011         27           Mahoori 2014         30           Mardani-Kivi 2013         50           Menda 2010         20           Menda 2010         20           Merny 2008         12.52           Moore 2010         19.5           Parikh 2010         29           Rajendran 2014         42.7           Short 2012a         12           Subtotal (95% CI)         23           Zaldivar Ramirez 2011         30           Ozcan 2012         12           Subtotal (95% CI)         12           Fest for overall effect: Z = 6.50 (P < 0.001	22.5	30	22	29.5	30	1.4%	-7.00 [-20.28, 6.28]	-+
Mahoʻni 2014         30           Mardani-Kivi 2013         50           Mardani-Kivi 2013         50           Merda 2010         20           Metry 2008         12.52           Moore 2010         19.5           Panday 2005         29.5           Parkh 2010         29           Panday 2005         29.5           Parkh 2010         29           Short 2012a         15           Strivastava 2010         23           Zaldivar Ramirez 2011         30           Dzcan 2012         12           Subtotal (95% CI)         40           Heterogeneity: Tau <sup>2</sup> = 84.00: Chi <sup>2</sup> = 292.           Test for overall effect: Z = 6.50 (P < 0.000	8	30	0	19	30	1.8%	0.00 [-7.38, 7.38]	+
MardaniKivi 2013         50           Menda 2010         20           Metry 2008         12.52           Moore 2010         19.5           anday 2005         29.5           Parikh 2010         29           Aglendran 2014         42.7           Short 2012a         15           Sirivastava 2010         23           Zaldivar Ramirez 2011         30           Zocan 2012         12           Subtotal (95% CI)         -           Heterogeneity: Tau <sup>2</sup> = 84.00: Chi <sup>2</sup> = 292.         Test for overall effect: Z = 6.50 (P < 0.000	25.2	57	28	26.2	68	1.7%	-1.00 [-10.03, 8.03]	+
Wenda 2010         20           Metry 2008         12.52           Moore 2010         19.5           Panday 2005         29.5           Parikh 2010         29           Rajendran 2014         42.7           Short 2012a         15           Srivastava 2010         23           Zaldivar Ramirez 2011         30           Dozcan 2012         12           Subtotal (95% CI)         200           Stadowy 2014         40           Deniz 2012         23           Sadawy 2014         40           Deniz 2012         23           Marashi 2012         48           Yarabhakar 2007         27.5           Sadhay 2014         40           Deniz 2012         23           Warashi 2012         48           Yarabhakar 2007         37.5           Sadhay 2014         40           Deniz 2012         23           Marashi 2012         48           Yarabhakar 2007         37.5           Sadhey SCI)         48           Vetterogeneity: Tau <sup>2</sup> = 4.94; Chl <sup>2</sup> = 8.22,           Fest for overall effect: Z = 3.59 (P = 0.000           3.5 > 1050 mg         32     <	15.8	25	56.8	11.4	25	1.8%	-26.80 [-34.44, -19.16]	
Metry 2008         12.52           Moore 2010         19.5           Anaday 2005         29.5           Parikh 2010         29           Parikh 2010         29           Short 2012a         15           Short 2012a         15           Short 2012a         13           Short 2012a         12           Subtotal (95% CI)         -           Heterogeneity: Tau <sup>2</sup> = 84.00; Chi <sup>2</sup> = 292.         Fest for overall effect: Z = 6.50 (P < 0.000	8	55	70	7	30	2.0%	-20.00 [-23.28, -16.72]	-
Moore 2010         19.5           Panday 2005         29.5           Parakh 2010         29.5           Parakh 2010         29.5           Parakh 2010         29           Sajendran 2014         42.7           Short 2012a         15           Sirivastava 2010         23           Zaldivar Ramirez 2011         30           Zocan 2012         12           Subtotal (95% CI)         -           Heterogeneity: Tau <sup>2</sup> = 84.00; Chi <sup>2</sup> = 292.         rest for overall effect: Z = 6.50 (P < 0.000	31	30	30	48	30	1.0%	-10.00 [-30.45, 10.45]	+
Panday 2005         29.5           Panday 2005         29.5           Parikh 2010         29           Parikh 2010         29           Short 2012a         15           Srivastava 2010         23           Zaldivar Ramirez 2011         30           Dzcan 2012         12           Subtotal (95% CI)         4           Heterogeneity: Tau <sup>2</sup> = 84.00; Chi <sup>2</sup> = 292,           Fest for overall effect: Z = 6.50 (P < 0.001	9.5	67	24.1	13	34	1.9%	-11.58 [-16.51, -6.65]	~
Parikh 2010       29         Rajendran 2014       42.7         Skajendran 2014       15         Srivastava 2010       23         Sirbitastava 2010       23         Zaldivar Ramirez 2011       30         Dzcan 2012       12         Subtotal (95% CI)       12         Fest for overall effect: Z = 6.50 (P < 0.000	15.5	21	40	20	23	1.6%	-20.50 [-31.02, -9.98]	
Rajendran 2014         42.7           short 2012a         15           short 2012a         15           short 2012a         12           Zaldivar Ramirez 2011         30           Zacan 2012         12           Subtotal (95% CI)         12           Subtotal (95% CI)         292.           Fest for overall effect: Z = 6.50 (P < 0.007	12.36	40	50	10	20	1.9%	-20.50 [-26.32, -14.68]	-
short 2012a         15           sirvastava 2010         23           sirvastava 2010         23           sirvastava 2010         30           Dzcan 2012         12           subtotal (95% CI)         -           Heterogeneity: Tau <sup>2</sup> = 84.00; Chi <sup>2</sup> = 292.         Fest for overall effect: Z = 6.50 (P < 0.000	7	30	55	6	30	2.0%	-26.00 [-29.30, -22.70]	~
Srivatava 2010 23 Zaldivar Ramirez 2011 30 Dzcara 2012 12 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 84.00: Chi <sup>2</sup> = 292. Test for overall effect: Z = 6.50 (P < 0.00/ 3.8.4 701-1050 mg Badawy 2014 40 Deniz 2012 23 Kim 2004 27 Koc 2007 2.3 Marashi 2012 48 Prabhakar 2007 37.5 Tadhakrishnan 2005 10 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 4.94; Chi <sup>2</sup> = 8.22, Test for overall effect: Z = 3.59 (P = 0.00/ 3.8.5 > 1050 mg Abdelmageed 2010 32 Ahdelmageed 2010 32 Ahdelmageed 2010 32 Dierking 2003 14.12 Doha 2010 18 Dorma 2007 45 Fassoulaki 2005 17 Fassoulaki 2006 25.7 Frouzanfard 2013 35.6 Cliron 2004 29 Srosen 2014 6.84 Hout 2007 0 Sins 36.17 Kosucu 2013 36.17 Kosucu 2013 36.17 Kosucu 2013 29 Ménigaux 2004 18 Dmran 2006 35 Ein 2009 15 Furan 2003 13 Sin 2014 31.6 Khan 2013 36.17 Kosucu 2013 29 Ménigaux 2004 18 Dmran 2005 34 Lica 2011 29.9	5.2	30	65	7.3	30	2.0%	-22.30 [-25.51, -19.09]	~
Zaldivar Ramirez 2011       30         Dzcara 2012       12         Subtotal (95% CI)       12         Heterogeneity: Tau <sup>2</sup> = 84.00; Chi <sup>2</sup> = 292.       Fest for overall effect: Z = 6.50 (P < 0.003	6.7	42	20	10	21	1.9%	-5.00 [-9.73, -0.27]	7
Dacan 2012         12           Subtotal (95% CI)         12           Subtotal (95% CI)         12           Feterogeneity: Tau <sup>2</sup> = 84.00; Chi <sup>2</sup> = 292.         Fest for overall effect: Z = 6.50 (P < 0.000	3.17	60	49	3.33	60	2.0%	-26.00 [-27.16, -24.84]	·
Subtotal (95% CI)           Heterogeneity: Tau <sup>2</sup> = 84.00; Chi <sup>2</sup> = 292.           Test for overall effect: Z = 6.50 (P < 0.00	13	18	55	9.8	16	1.8%	-25.00 [-32.69, -17.31]	<u> </u>
Heterogeneity: Tau <sup>2</sup> = 84.00; Chi <sup>2</sup> = 292.           Test for overall effect: Z = 6.50 (P < 0.00)	23	20 682	34	13	20 593	1.5% 31.4%	-22.00 [-33.58, -10.42]	
Fest for overall effect: Z = 6.50 (P < 0.001	30.46		- 0.000013-12	0.494	292	31.4%	-15.33 [-19.96, -10.71]	•
Badawy 2014         40           Deniz 2012         23           Sim 2004         27           Soc 2007         2.3           Marashi 2012         48           Trabhakar 2007         37.5           Radhakrishnan 2005         10           Subtotal (95% CI)         -           Heterogeneity: Tau <sup>2</sup> = 4.94; Chi <sup>2</sup> = 8.22,         Fest for overall effect: Z = 3.59 (P = 0.000           3.8.5 > 1050 mg         -           Abdelmageed 2010         32           Al-Mujadi 2005         14           Bartholdy 2006         4           Sarogly 2008         22.5           Dierking 2003         14.12           Doha 2010         18           Dormus 2007         45           Fassoulaki 2006         25.7           Frouzanfard 2013         35.6           Cilron 2004         29           Grosen 2014         6.84           40ut 2007         0           ajeda 2014         31.6           Khang 2004         18           Omran 2005         35           Sen 2009A         28           Sen 2009A         28           Sen 2009B         15           Turan 20		: 17 (P ·	< 0.00001); 1* =	= 94%				
Deniz 2012 23 (im 2004 27 (im 2004 27 (im 2004 27 (im 2004 48 Prabhakar 2007 2.3 Marashi 2012 48 Prabhakar 2007 37.5 Tadhakrishnan 2005 10 Subtotal (95% CI) 4eterogeneity: Tau <sup>2</sup> = 4.94; Chi <sup>2</sup> = 8.22, Fest for overall effect: Z = 3.59 (P = 0.000 3.8.5 > 1050 mg Abdelmageed 2010 32 Abdelmageed 2010 32 Abdelmageed 2010 32 Abdelmageed 2010 32 Abdelmageed 2010 32 Derking 2003 14.12 Doha 2010 14 Sartholdy 2006 4 Sarogly 2008 22.5 Dierking 2003 14.12 Doha 2010 18 Durmus 2007 45 Fassoulaki 2005 17 Fassoulaki 2005 17 Fassoulaki 2005 25.7 Frouzanfard 2013 35.6 Cilion 2004 29 Grosen 2014 6.84 Hout 2007 0 ajeda 2014 31.6 (han 2013 36.17 Kosucu 2013 29 Meinigaux 2004 18 Dmran 2005 35 Furan 2003b 13 Furan 2004 15 Furan 2003b 13 Furan 2005 34 Lak 2011 29.9								
Kim 2004         27           Kim 2004         23           Koc 2007         2.3           Marashi 2012         48           Prabhakar 2007         37.5           Radhakrishnan 2005         10           Subtotal (95% CI)         10           Heterogeneity: Tau <sup>2</sup> = 4.94; Chi <sup>2</sup> = 8.22, Fest for overall effect: Z = 3.59 (P = 0.001           3.8.5 > 1050 mg           Abdelmageed 2010         32           Al-Mujadi 2005         14           Bartholdy 2006         4           Strogly 2008         22.5           Dierking 2003         14.12           Doha 2010         18           Durmus 2007         45           Fassoulaki 2005         17           Fososoulaki 2005         29           Grosen 2014         6.84           Hout 2007         0           ajeda	5	19	45	5	19	2.0%	-5.00 [-8.18, -1.82]	~
Koc 2007         2.3           Marashi 2012         48           Prabhakar 2007         37.5           Radhakrishnan 2005         10           Subtotal (95% Cl)         10           Heterogeneity: Tau <sup>2</sup> = 4.94; Chi <sup>2</sup> = 8.22,         Test for overall effect: Z = 3.59 (P = 0.000           3.8.5 > 1050 mg         32           Ah-Mujadi 2005         14           Bartholdy 2006         4           Brogly 2008         22.5           Dierking 2003         14.12           Doha 2010         18           Durmus 2007         45           Fassoulaki 2006         25.7           Frouzanfard 2013         35.6           Giron 2004         29           Grosen 2014         6.84           Hout 2007         0           Aigeda 2014         31.6           Khan 2013         36.17           Kosucu 2013         29           Weinigaux 2004         18           Omran 2006         35           Sen 2009a         28           Sen 2009b         15           Turan 2003b         13           Turan 2003b         13           Turan 2003b         13	28	25	31	27	26	1.3%	-8.00 [-23.11, 7.11]	-+
Marashi 2012         48           Prabhakar 2007         37.5           sadhakrishnan 2005         10           Subtotal (95% CI)         10           Feterogeneity: Tau <sup>2</sup> = 4.94; Chi <sup>2</sup> = 8.22,         Feterogeneity: Tau <sup>2</sup> = 4.94; Chi <sup>2</sup> = 8.22,           Feterogeneity: Tau <sup>2</sup> = 4.94; Chi <sup>2</sup> = 8.22,         Feterogeneity: Tau <sup>2</sup> = 4.94; Chi <sup>2</sup> = 8.22,           Sathotal (95% CI)         32           Abdelmageed 2010         32           Abdelmageed 2010         32           Jork (2005)         14           Bartholdy 2006         4           Stroby 2008         22.5.           Derking 2003         14.12           Doha 2010         18           Dumus 2007         45           Fassoulaki 2005         17           Fassoulaki 2006         25.7           Frouzanfard 2013         35.6           Gilron 2004         29           Grosen 2014         6.84           Hout 2007         0           ajeda 2014         31.6           Khan 2013         36.17           Kosuu 2013         29           Weinigaux 2004         18           Dmran 2006         35           Sien 2009b         15	22.2	21	29	17.6	20	1.5%	-2.00 [-14.23, 10.23]	
Prabhakar 2007         37.5           kadhakrishnan 2005         10           Subtoral (95% CI)         10           Heterogeneity: Tau <sup>2</sup> = 4.94; Chi <sup>2</sup> = 8.22,         Fest for overall effect: Z = 3.59 (P = 0.004)           3.8.5 > 1050 mg         32           Ah-Mujadi 2005         14           Bartholdy 2006         4           Arogly 2008         22.5           Dierking 2003         14.12           Doha 2010         18           Durmus 2007         45           Fassoulaki 2005         17           Forsen 2014         6.84           Hout 2007         0           ajeda 2014         31.6           Khangu 2004         18           Omran 2005         35           Sen 2009b         15           Furan 2003b         13           Furan 2003b         13           Furan 2003b         13	9	20	12.5	27	20	1.5%	-10.20 [-22.67, 2.27]	
Radhakrishnan 2005         10           Subtotal (95% CI)         10           Fleterogeneity: Tau <sup>2</sup> = 4.94; Chl <sup>2</sup> = 8.22,         Test for overall effect: Z = 3.59 (P = 0.007           3.8.5 > 1050 mg         2           Abdelmageed 2010         32           Abdelmageed 2010         32           Bartholdy 2006         4           Bartholdy 2008         22.5           Dierking 2003         14.12           Doha 2010         18           Durmus 2007         45           Fassoulaki 2005         17           Fassoulaki 2006         25.7           Frouzanfard 2013         35.6           Gilron 2004         29           Grosen 2014         6.84           Hout 2007         0           Aigeda 2014         31.6           Khan 2013         36.17           Kosucu 2013         29           Grosen 2014         18           Omran 2006         35           Sen 2009b         15           Furan 2003a         18           Furan 2003b         13           Furan 2003b         13           Furan 2003b         13           Furan 2003b         13	10	22	59	9	22	1.9%	-11.00 [-16.62, -5.38]	-
Subtotal (95% CI)           Heterogeneity: Tau <sup>2</sup> = 4.94; Chi <sup>2</sup> = 8.22,           Test for overall effect: Z = 3.59 (P = 0.00           3.8.5 > 1050 mg           Abdelmageed 2010         32           Al-Mujadi 2005         14           Bartholdy 2006         4           Brogly 2008         22.5           Dierking 2003         14.12           Doha 2010         18           Durmus 2007         45           Fassoulaki 2005         17           Fassoulaki 2005         17           Fassoulaki 2005         17           Fassoulaki 2005         17           Forouzanfard 2013         35.6           Gilron 2004         29           Grosen 2014         6.84           Hout 2007         0           Aigeda 2014         31.6           Khan 2013         36.17           Kosucu 2013         29           Ménigaux 2004         18           Omran 2005         35           Sen 2009b         15           Turan 2003b         13           Turan 2003b         13           Turan 2003b         13           Turan 2004         15           Turan 2005	11.1	10	47.5	14.4	10	1.5%	-10.00 [-21.27, 1.27]	
Heterogeneity: Tau <sup>2</sup> = 4.94; Chi <sup>2</sup> = 8.22,           Test for overall effect: Z = 3.59 (P = 0.00/           3.8.5 > 1050 mg           Al-Mujadi 2005         14           Bartholdy 2006         4           Brogly 2008         22.5           Dierking 2003         14.12           Doha 2010         18           Durmus 2007         45           Fassoulaki 2006         25.7           Frouzanfard 2013         35.6           Gilron 2004         29           Grosen 2014         6.84           Hout 2007         0           Algieda 2014         31.6           Khan 2013         36.17           Kosucu 2013         29           Menigaux 2004         18           Omran 2005         35           Sen 2009a         28           Sen 2009b         15           Turan 2003b         13           Turan 2003b         13           Turan 2005         34           Ucak 2011         29.9	12.5	30	10	12.5	30	1.8%	0.00 [-6.33, 6.33]	,T
3.8.5 > 1050 mg           Abdelmageed 2010         32           Al-Mujadi 2005         14           Bartholdy 2006         4           Brogly 2008         22.5           Dierking 2003         14.12           Doha 2010         18           Durmus 2007         45           Fassoulaki 2005         17           Fassoulaki 2005         17           Fassoulaki 2005         17           Forexanfard 2013         35.6           Gilron 2004         29           Grosen 2014         6.84           Hout 2007         0           Jajeda 2014         31.6           Khan 2013         36.17           Kosucu 2013         29           Ménigaux 2004         18           Omran 2006         35           Sen 2009a         28           Sen 2009b         15           Turan 2003b         13           Turan 2003b         13           Turan 2005         34           Ucak 2011         29.9	df = 6 (	147 P = 0.2	2); I <sup>2</sup> = 27%		147	11.5%	-5.99 [-9.25, -2.72]	•
Abdelmageed 2010         32           Al-Mujail 2005         14           Bartholdy 2006         4           Brogly 2008         22.5           Dierking 2003         14.12           Doha 2010         18           Durmus 2007         45           Fassoulaki 2005         17           Fassoulaki 2005         17           Fassoulaki 2006         25.7           Frouzanfard 2013         35.6           Gifron 2004         29           Grosen 2014         6.84           Hout 2007         0           Jajeda 2014         31.6           Khan 2013         36.17           Kosucu 2013         29           Ménigaux 2004         18           Omran 2006         35           Sen 2009a         28           Sen 2009a         28           Sen 2009b         15           Turan 2003b         13           Turan 2003b         13           Turan 2003b         13           Turan 2005         34           Ucak 2011         29.9	)03)							
Al-Mujadi 2005         14           Bartholdy 2006         4           Bartholdy 2008         22.5           Dierking 2003         14.12           Doha 2010         18           Durmus 2007         45           Fassoulaki 2002         7           Fassoulaki 2005         17           Fassoulaki 2005         17           Fassoulaki 2005         29           Grosen 2014         6.84           Hout 2007         0           ajeda 2014         31.6           Khan 2013         36.17           Kosucu 2013         29           Ménigaux 2004         18           Omran 2006         35           Sen 2009a         28           Sen 2009b         15           Turan 2003b         13           Furan 2003b         13           Furan 2004         15           Furan 2005         34           Jucak 2011         29.9		30	21	6	30	1.0%	11 00 [7 42 14 58]	-
Bartholdy 2006         4           Brogly 2008         22.5           Dichking 2003         14.12           Doha 2010         18           Durmus 2007         45           Fassoulaki 2002         7           Fassoulaki 2005         17           Fassoulaki 2006         25.7           Frouzanfard 2013         35.6           Giron 2004         29           Grosen 2014         6.84           Hout 2007         0           ajgeda 2014         31.6           Khan 2013         29           Khan 2013         21.7           Kosucu 2013         29           Crosen 2014         6.84           Hout 2007         0           Jajeda 2014         31.6           Khan 2013         29           Crosen 2014         18           Omran 2006         35           Sen 2009b         15           Turan 2003b         13           Furan 2003b         13           Furan 2005         34           Ucak 2011         29.9	8 7	30 35	21 24.1	6 13	30 37	1.9% 1.9%	11.00 [7.42, 14.58] -10.10 [-14.89, -5.31]	
strogly 2008         22.5           Dierking 2003         14.12           Doha 2010         18           Durmus 2007         45           Fassoulaki 2005         17           rassoulaki 2005         17           rassoulaki 2006         25.7           rouzanfard 2013         35.6           Gilron 2004         29           Grosen 2014         6.84           Yout 2007         0           Oajeda 2014         31.6           Khan 2013         36.17           Kosucu 2013         29           Wénigaux 2004         18           Dmran 2006         35           Sen 2009a         28           Sen 2009a         18           Furan 2003b         13           Furan 2003b         13           Furan 2004         15           Furan 2005         34           Jcak 2011         29.9	7.4	35	24.1	6.6	37	2.0%		
Dierking 2003         14.12           Doha 2010         18           Doha 2010         18           Durmus 2007         45           Fassoulaki 2005         17           Fassoulaki 2005         17           Fassoulaki 2005         17           Fassoulaki 2005         25.7           Frouzanfard 2013         35.6           Cilron 2004         29           Grosen 2014         6.84           Hout 2007         0           ajeda 2014         31.6           Khan 2013         36.17           Kosucu 2013         29           Weinigaux 2004         18           Dmran 2006         35           Sien 2009a         28           Sien 2009b         15           Furan 2003b         13           Furan 2003b         13           Furan 2004         15           Furan 2005         34           Lock 2011         29.9	7.4	38 22	23.5		38 21	2.0%	-2.00 [-5.15, 1.15]	1
Doha 2010         18           Doha 2017         45           rassoulaki 2002         7           rassoulaki 2005         17           rassoulaki 2006         25.7           rouzanfard 2013         35.6           Gilron 2004         29           rossen 2014         6.84           Hout 2007         0           ajeda 2014         31.6           Khan 2013         29           Weinigaux 2004         18           Dmran 2006         35           Sei an 2003a         18           Furan 2003b         13           Furan 2003b         13           Furan 2004         5           Furan 2005         34           Lock 2011         29.9	15.23	40	23.5	21.3 18.59	40	1.5%	-1.00 [-13.11, 11.11]	
Durmus 2007         45           Fassoulaki 2005         17           Fassoulaki 2005         17           Fassoulaki 2006         25.7           Frouzanfard 2013         35.6           Gilron 2004         29           Grosen 2014         6.84           Hout 2007         0           Gajeda 2014         31.6           Khan 2013         36.17           Kosucu 2013         29           Ménigaux 2004         18           Dmran 2006         35           Sen 2009a         28           Sen 2009b         15           Furan 2003b         13           Furan 2003b         13           Furan 2004         5           Furan 2005         34           Jcak 2011         29.9	15.23	30	21.53	18.59	29	1.8%	-7.41 [-14.86, 0.04]	
Fassoulaki 2002         7           rassoulaki 2005         17           rassoulaki 2006         25.7           rrouzanfard 2013         35.6           Gilron 2004         29           Grosen 2014         6.84           Hout 2007         0           ajeda 2014         31.6           Khan 2013         36.17           Kosucu 2013         29           Keingaux 2004         18           Dmran 2006         35           Sen 2009a         28           Sen 2009b         15           Furan 2003b         13           Furan 2004         5           Furan 2005         34           Lock 2011         29.9	51	25	52	61	29	0.6%	-15.00 [-22.28, -7.72]	
Fassoulaki 2005         17           Fassoulaki 2006         25.7           Forouzanfard 2013         35.6           Gilron 2004         29           Grosen 2014         6.84           Jout 2007         0           ajeda 2014         31.6           Khan 2013         36.17           Kosucu 2013         29           Wénigaux 2004         18           Dmran 2006         35           Sen 2009A         28           Sen 2009A         18           Furan 2003B         13           Furan 2003B         13           Furan 2005         34           Joak 2011         29.9	20	25	9	19	25	1.6%	-7.00 [-38.17, 24.17] -2.00 [-12.81, 8.81]	
Fassoulaki 2006         25.7           rrouzanfard 2013         35.6           Siltron 2004         29           Grosen 2014         6.84           Hout 2007         0           ajeda 2014         31.6           Khan 2013         36.17           Kosucu 2013         29           Ménigaux 2004         18           Dmran 2006         35           Sen 2009b         15           Furan 2003b         13           Furan 2003b         13           Furan 2004         15           Furan 2005         34           Loak 2011         29.9	20	29	20	31	30	1.3%	-3.00 [-12.81, 8.81]	_ <u>_</u>
rouzanfard 2013         35.6           cilron 2004         29           crosen 2014         6.84           dout 2007         0           ajeda 2014         31.6           Khan 2013         36.17           Kosucu 2013         29           Weinigaux 2004         18           Dmran 2006         35           sien 2009a         28           sien 2009b         15           Furan 2003b         13           Furan 2003b         13           Furan 2005         34           Loak 2011         29.9	16.1	30	26.8	19.6	30	1.7%	-1.10 [-10.18, 7.98]	1
Gliron 2004         29           Grosen 2014         6.84           Hout 2007         0           ajeda 2014         31.6           Khan 2013         36.17           Kosucu 2013         29           Wénigaux 2004         18           Dmran 2006         35           sen 2009a         28           sen 2009b         15           Furan 2003b         13           Furan 2003b         13           Furan 2004         5           Joach 2011         29.9	15	25	65.6	19.6	25	1.7%	-30.00 [-39.18, -20.82]	<u> </u>
incsen 2014         6.84           hout 2007         0           ajeda 2014         31.6           (chan 2013         36.17           (cosucu 2013)         29           #denigaux 2004         18           Dmran 2006         35           sien 2009b         15           furan 2003b         13           furan 2003b         13           furan 2005         34           jcak 2011         29.9	4	23	39	3	24	2.0%	-10.00 [-12.03, -7.97]	•
Hout 2007         0           ajeda 2014         31.6           (shan 2013)         36.17           Kosucu 2013         29           Wénigaux 2004         18           Durran 2006         35           sen 2009a         28           Sen 2009b         15           Furan 2003a         18           Furan 2003b         13           Furan 2004         55           Furan 2005         34           Jcak 2011         29.9	12.97	52	13.95	د 17.94	52	1.8%	-7.11 [-13.13, -1.09]	
ajeda 2014         31.6           (han 2013         36.17           Ossucu 2013         29           Ménigaux 2004         18           Dmran 2006         35           sen 2009a         28           sen 2009a         18           Furan 2003a         18           Furan 2003b         13           Furan 2005         34           Jock 2011         29.9	5.93	23	15.95	3.7	28	2.0%		· 1
xhan 2013         36.17           Xosucu 2013         29           Weinigaux 2004         18           Dmran 2006         35           sen 2009a         28           sen 2009b         15           Furan 2003b         13           Furan 2004         55           Furan 2003b         13           Furan 2004         15           Furan 2005         34           Jeak 2011         29.9	5.93 4.7	23	52.4	10.5	28	2.0%	0.00 [-2.78, 2.78]	- I
Kosucu 2013         29           Ménigaux 2004         18           Durran 2006         35           sen 2009a         28           sen 2009b         15           Furan 2003a         18           Furan 2003b         13           Furan 2004         15           Furan 2005         34           Jcak 2011         29.9	4.7	34	52.4	10.51	35	1.9%	-20.80 [-25.31, -16.29] -15.83 [-21.52, -10.14]	· · · · · · · · · · · · · · · · · · ·
Ménigaux 2004         18           Dmran 2006         35           en 2009ba         28           ien 2009ba         15           Furan 2003a         18           Turan 2003b         13           Turan 2003b         15           Furan 2003b         13           Turan 2004         15           Furan 2005         34           Leak 2011         29.9	13.4	29	42	21	31	1.9%	-13.00 [-21.52, -10.14]	
Dmran 2006         35           Sen 2009a         28           Sen 2009b         15           Furan 2003a         18           Furan 2003b         13           Furan 2004         15           Furan 2005         34           Jucak 2011         29.9	7	29	42	34	20	1.7%	-3.00 [-21.39, -4.41]	
ien 2009a 28 ien 2009b 15 furan 2003a 18 furan 2003b 13 furan 2004 15 furan 2005 34 izak 2011 29.9	45.59	20	61	45.69	20	0.8%	-26.00 [-51.30, -0.70]	
sen 2009b         15           Furan 2003a         18           Turan 2003b         13           Furan 2004         15           Furan 2005         34           Jizak 2011         29.9	45.59	20	41	45.69	20	0.8%	-13.00 [-36.13, 10.13]	
Furan 2003a         18           Furan 2003b         13           Furan 2004         15           Furan 2005         34           Jcak 2011         29.9	12	30	20	25	20	1.6%	-5.00 [-15.06, 5.06]	
Furan 2003b         13           Furan 2004         15           Furan 2005         34           Jcak 2011         29.9	12	25	42	10	29	1.6%	-24.00 [-31.40, -16.60]	_
Γuran 2004 15 Γuran 2005 34 Ucak 2011 29.9		25	42 24		25			
Furan 2005 34 Jeak 2011 29.9	15 31	25	24	18 53	25	1.7% 0.9%	-11.00 [-20.18, -1.82] -16.00 [-40.07, 8.07]	
Jcak 2011 29.9								
	11	20	57	83	20	0.5%	-23.00 [-59.69, 13.69]	
Uzgenčil 2011 24	2	20	50	65	20	0.7%	-20.10 [-48.60, 8.40]	
Subtotal (95% CI)	6.7	30	33.3	10.9	30 764	1.9%	-9.30 [-13.88, -4.72]	T I
Heterogeneity: Tau <sup>2</sup> = 73.68; Chi <sup>2</sup> = 247.		755 26 (P ·	< 0.00001); I <sup>2</sup> =	- 89%	764	41.1%	-9.43 [-13.29, -5.56]	•
Test for overall effect: Z = 4.78 (P < 0.00)	)001)							
'otal (95% CI) leterogeneity: Tau <sup>2</sup> = 112.12; Chi <sup>2</sup> = 140	0261 -	1962	(P < 0.00001)	2 - 069	1866	100.0%	-11.67 [-14.61, -8.73]	+

# Supplemental Digital Content 7 Forest plot of VAS 6h mobilization from trials with low risk of

# <u>bias</u>

		apentin			ntrol			Mean Difference	Mean Difference
Study or Subgroup	Mean [VAS]	SD [VAS]	Total	Mean [VAS]	SD [VAS]	Total	Weight	IV, Random, 95% CI [VAS	] IV, Random, 95% CI [VAS]
3.9.1 0-350 mg									
Short 2012	29	10.4		40	10	21	18.8%	-11.00 [-16.31, -5.69	
Subtotal (95% CI)			42			21	18.8%	-11.00 [-16.31, -5.69]	◆
Heterogeneity: Not a									
Test for overall effec	t: $Z = 4.06 (P < $	< 0.0001)							
3.9.2 351-700 mg									
Moore 2010	20	13.25	21	40	14.5	23	11.3%	-20.00 [-28.20, -11.80]	1
Short 2012a	31	14	42	40	10	21	16.5%	-9.00 [-15.02, -2.98	i -
Srivastava 2010	59	3.33	60	70.5	3.5	60	34.1%		
Subtotal (95% CI)			123			104	61.9%	-12.43 [-16.81, -8.04]	◆
Heterogeneity: Tau <sup>2</sup>	= 8.91; Chi <sup>2</sup> =	4.77, df =	2 (P =	0.09); I <sup>2</sup> = 58%	6				
Test for overall effec	t: Z = 5.56 (P <	< 0.00001)							
3.9.5 701-1050 mg	1								
Subtotal (95% CI)			0			0		Not estimable	.
Heterogeneity: Not a	pplicable								
Test for overall effec	t: Not applicabl	le							
3.9.6 > 1050 mg									
Brogly 2008	45.6	24.8	22	39.4	20.1	21	5.3%	6.20 [-7.26, 19.66	1 +
Fassoulaki 2005	40	67	29	53	78	30	0.8%	-13.00 [-50.06, 24.06	i —
Grosen 2014	12.42	18.55	52	21.29	19.28	52	13.3%	-8.87 [-16.14, -1.60	
Subtotal (95% CI)			103			103	19.3%	-3.77 [-15.42, 7.89]	↓ ◆
Heterogeneity: Tau <sup>2</sup>			= 2 (P =	: 0.14); I <sup>2</sup> = 48	%				
Test for overall effec	t: $Z = 0.63$ (P =	= 0.53)							
restron overall ence			268			228	100.0%	-10.69 [-14.03, -7.35]	
Total (95% CI)									
	= 8.15; Chi <sup>2</sup> =	11.92, df :	= 6 (P =	$= 0.06$ ; $I^2 = 50$	1%				
Total (95% CI)				$= 0.06$ ; $I^2 = 50$	1%				-100 -50 0 50 1 Favours Gabapentin Favours Control

# Supplemental Digital Content 8 Forest plot of VAS 6h mobilization from all trials estimates

study or Subgroup 3.10.1 0-350 mg short 2012 (oon 2001 Subtotal (95% Cl) Heterogeneity: Tau <sup>2</sup> = 0 Fest for overall effect: Z 3.10.2 351-700 mg Grover 2009 Menda 2010 Metry 2008 Moore 2010 short 2012a Sirivastava 2010 Subtotal (95% Cl)	29 41 0.00; Chi <sup>2</sup> = 0.	10.4 60 06, df = 1	42 16 58 . (P = 0 27 30 67	40 58	10 74 7.41	21 16 37	Weight 7.2% 0.3% 7.5%	IV, Random, 95% CI [VAS] -11.00 [-16.31, -5.69] -17.00 [-63.68, 29.68] -11.08 [-16.35, -5.80]	
Short 2012 Yoon 2001 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0 Fest for overall effect: Z 3.10.2 351-700 mg Grover 2009 Menda 2010 Metry 2008 Moore 2010 Short 2012a Srivastava 2010	41 0.00; Chi <sup>2</sup> = 0. = 4.12 (P < 0) 30 43.5 20.52 20 31	60 06, df = 1 0.0001) 14.81 57 14.48 13.25	16 58 (P = 0 27 30 67	58 .80); I <sup>2</sup> = 0% 30	74	16 37	0.3%	-17.00 [-63.68, 29.68]	
Yoon 2001 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0 Fest for overall effect: Z <b>3.10.2 351-700 mg</b> Grover 2009 Menda 2010 Metry 2008 Moore 2010 Short 2012a Srivastava 2010	41 0.00; Chi <sup>2</sup> = 0. = 4.12 (P < 0) 30 43.5 20.52 20 31	60 06, df = 1 0.0001) 14.81 57 14.48 13.25	16 58 (P = 0 27 30 67	58 .80); I <sup>2</sup> = 0% 30	74	16 37	0.3%	-17.00 [-63.68, 29.68]	
Subtotal (95% Cl) Heterogeneity: Tau <sup>2</sup> = 0 Fest for overall effect: Z <b>3.10.2 351-700 mg</b> Grover 2009 Menda 2010 Metry 2008 Moore 2010 Short 2012a Srivastava 2010	0.00; Chi <sup>2</sup> = 0. = 4.12 (P < 0 30 43.5 20.52 20 31	06, df = 1 0.0001) 14.81 57 14.48 13.25	58 (P = 0 27 30 67	.80); I <sup>2</sup> = 0%	7.41	37			
Heterogeneity: Tau <sup>2</sup> = 0 Fest for overall effect: Z 3.10.2 351-700 mg Grover 2009 Menda 2010 Metry 2008 Moore 2010 Short 2012a Grivastava 2010	30 43.5 20.52 20 31	14.81 57 14.48 13.25	(P = 0 27 30 67	30			7.5%	-11.08 [-16.35, -5.80]	•
Fest for overall effect: Z 3.10.2 351-700 mg Grover 2009 Menda 2010 Metry 2008 Moore 2010 Short 2012a Srivastava 2010	30 43.5 20.52 20 31	14.81 57 14.48 13.25	27 30 67	30					
3.10.2 351-700 mg Grover 2009 Menda 2010 Metry 2008 Moore 2010 Short 2012a Srivastava 2010	30 43.5 20.52 20 31	14.81 57 14.48 13.25	30 67						
Grover 2009 Menda 2010 Metry 2008 Moore 2010 Short 2012a Grivastava 2010	43.5 20.52 20 31	57 14.48 13.25	30 67						
Menda 2010 Metry 2008 Moore 2010 Short 2012a Srivastava 2010	43.5 20.52 20 31	57 14.48 13.25	30 67						
Metry 2008 Moore 2010 Short 2012a Srivastava 2010	20.52 20 31	14.48 13.25	67	65		23	6.4%	0.00 [-6.35, 6.35]	↓ +
Moore 2010 Short 2012a Srivastava 2010	20 31	13.25			78	30	0.5%	-21.50 [-56.07, 13.07]	
short 2012a Srivastava 2010	31			31.3	15	34	6.5%	-10.78 [-16.90, -4.66]	-
Frivastava 2010		14	21	40	14.5	23	5.1%	-20.00 [-28.20, -11.80]	
Frivastava 2010			42	40	10	21	6.6%	-9.00 [-15.02, -2.98]	
	22	3.33	60	70.5	3.5	60	10.1%	-11.50 [-12.72, -10.28]	·
		2.200	247		210	191	35.2%	-10.21 [-14.72, -5.70]	
Heterogeneity: Tau <sup>2</sup> = 1	8.56; Chi <sup>2</sup> = 1	17.46, df =	= 5 (P =	= 0.004); I <sup>2</sup> =	71%				
Fest for overall effect: Z	= 4.44 (P < 0)	0.00001)							
3.10.5 701-1050 mg									
Kim 2004	42	25.2	21	37	15.8	20	2.9%	5.00 [-7.81, 17.81]	↓ <del>↓</del> -
rabhakar 2007	52.5	10.9	10	65	19.6	10	2.6%	-12.50 [-26.40, 1.40]	
Radhakrishnan 2005	20	15	30	30	20	30	4.6%	-10.00 [-18.95, -1.05]	
Subtotal (95% CI)			61			60	10.1%	-6.11 [-16.15, 3.94]	•
Test for overall effect: Z 3.10.6 > 1050 mg	= 1.19 (P = 0	).23)							
Al-Mujadi 2005	23	12	35	31.3	15	37	6.4%	-8.30 [-14.56, -2.04]	·
Bartholdy 2006	3	7.4	38	51.5	9.6	38	8.4%	-2.00 [-5.85, 1.85]	
Brogly 2008	45.6	24.8	22	39.4	20.1	21	2.7%	6.20 [-7.26, 19.66]	
Dierking 2003	42.53	25.9	40	51.09	28.27	40	3.2%	-8.56 [-20.44, 3.32]	
Dirks 2002	42.33	23.9	31	31.09	28.27	34	3.2%	-12.00 [-22.70, -1.30]	
Durmus 2007	67	77	25	76	83	25	0.3%	-9.00 [-53.38, 35.38]	
assoulaki 2002	21	35	25	29	52	25	1.0%		
assoulaki 2002	40	67	29	53	78	30	0.5%	-8.00 [-32.57, 16.57]	
								-13.00 [-50.06, 24.06]	
assoulaki 2006	47.8	19.7	30	45.1	24.6	30	3.5%	2.70 [-8.58, 13.98]	
Grosen 2014	12.42	18.55	52	21.29	19.28	52	5.7%	-8.87 [-16.14, -1.60]	
Omran 2006	60	35.16	25	80	35.16	25	1.5%	-20.00 [-39.49, -0.51]	
Sen 2009a	32	34	20	56	54	20	0.8%	-24.00 [-51.97, 3.97]	
Sen 2009b	19	15	30	21	25	29	3.8%	-2.00 [-12.56, 8.56]	· · · · · · · · · · · · · · · · · · ·
Furan 2003a	31.2	17	25	43	12	25	5.1%	-11.80 [-19.96, -3.64]	
Jcak 2011	39	20	20	55	68	20	0.6%	-16.00 [-47.06, 15.06]	
Subtotal (95% CI)			447			451	47.2%	-6.34 [-9.60, -3.08]	•
Heterogeneity: Tau <sup>2</sup> = 8 Fest for overall effect: Z			14 (P =	$= 0.18$ ; $I^2 = 2$	5%				
			013			730	100.0%	917 1074 5 601	
Fotal (95% CI)	C CD CL 12		813	0.00011 -2	5.004	/39	100.0%	-8.17 [-10.74, -5.60]	· · · ·
Heterogeneity: Tau <sup>2</sup> = 1 Fest for overall effect: Z			= 25 (P	$= 0.0001$ ; $ ^2$	= 58%				-100 -50 0 50

Test for subgroup differences:  $Chi^2 = 3.32$ , df = 3 (P = 0.34),  $l^2 = 9.7\%$ 

abaper

# Supplemental Digital Content 9 Forest plot of VAS 24h rest from trials with low risk of bias

		apentin			ntrol			Mean Difference	Mean Difference
Study or Subgroup	Mean [VAS]	SD [VAS]	Total	Mean [VAS]	SD [VAS]	Total	Weight	IV, Random, 95% CI [VAS	] IV, Random, 95% CI [VAS]
3.11.1 0-350 mg									
Spence 2011	4	7	28	4	8	31	11.9%	0.00 [-3.83, 3.83]	1 +
Waikakul 2011	30	20	24	35	17.5	24	5.1%	-5.00 [-15.63, 5.63	i <del>-+</del>
Subtotal (95% CI)			52			55	17.0%	-0.57 [-4.18, 3.03]	1 🔶
Heterogeneity: Tau <sup>2</sup>	= 0.00; Chi <sup>2</sup> =	0.75, df =	1 (P =	$0.39$ ; $I^2 = 0\%$					
Test for overall effect	t: Z = 0.31 (P =	= 0.75)							
3.11.2 351-700 mg									
Monks 2015	11	4.4	100	19	5.9	97	14.2%	-8.00 [-9.46, -6.54	ı •
Moore 2010	7	5.5	21	20	22.5	23	5.9%	-13.00 [-22.49, -3.51	
Paul 2015	24.5	16.1	48	23.6	20.8	54	8.0%	0.90 [-6.28, 8.08	
Short 2012a	17	5.9	42	10	10	21	10.9%	7.00 [2.37, 11.63	
Srivastava 2010	21	3.25	60	28	3.33	60	14.4%	-7.00 [-8.18, -5.82	
Subtotal (95% CI)			271			255	53.5%	-3.92 [-7.91, 0.07]	
Heterogeneity: Tau <sup>2</sup>	= 14.81; Chi <sup>2</sup> :	= 42.84, df	= 4 (P	< 0.00001);	$^{2} = 91\%$				
Test for overall effec	t: Z = 1.93 (P =	= 0.05)							
3.11.4 701-1050 m	g								
Subtotal (95% CI)			0			0		Not estimable	2
Heterogeneity: Not a	pplicable								
Test for overall effec	t: Not applicab	le							
3.11.5 > 1050 mg									
Brogly 2008	12.4	10.4	22	15.5	17.9	21	6.5%	-3.10 [-11.90, 5.70]	1 +
Fassoulaki 2005	16	27	29	7	14	30	4.9%	9.00 [-2.03, 20.03]	1 -
Grosen 2014	6.58	13.61	52	12.43	16.4	52	9.5%	-5.85 [-11.64, -0.06	ı <del>~</del>
GIOSEII 2014	29	18.2	57	31	18.9	68	8.7%	-2.00 [-8.52, 4.52]	
Kinney 2011			160			171	29.5%	-1.76 [-6.95, 3.43]	1 🔶
Kinney 2011 Subtotal (95% CI)		= 5.50, df =	= 3 (P =	• 0.14); I <sup>2</sup> = 4	5%				
Kinney 2011	= 12.53; Chi <sup>2</sup> =		= 3 (P =	= 0.14); I <sup>2</sup> = 4	5%				
Kinney 2011 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup>	= 12.53; Chi <sup>2</sup> =		= 3 (P =	: 0.14); I <sup>2</sup> = 4	5%	481	100.0%	-2.83 [-5.82, 0.16]	1 •
Kinney 2011 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> Test for overall effec Total (95% CI)	= 12.53; Chi <sup>2</sup> = t: Z = 0.66 (P =	= 0.51)	483			481	100.0%	-2.83 [-5.82, 0.16]	
Kinney 2011 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> Test for overall effec	= 12.53; Chi <sup>2</sup> = t: Z = 0.66 (P = = 15.76; Chi <sup>2</sup> =	= 0.51) = 64.04, df	483			481	100.0%	-2.83 [-5.82, 0.16]	J + -100 -50 0 50 1 Favours Gabapentin Favours Contro

# Supplemental Digital Content 10 Forest plot of VAS 24h rest from all trials estimates

		entin D [VAS]	Total	Cont Mean (VAS) S		Total	Weight	Mean Difference IV, Random, 95% CI [VAS]	Mean Difference IV, Random, 95% CI [VAS]
tudy or Subgroup .12.1 0-350 mg			· otur			. oran	Acigin	,	
ang 2009	32	20	23	38	20	23	1.3%	-6.00 [-17.56, 5.56]	
ehdad 2012	25.3	5	30	42.7	14.2	31	1.9%	-17.40 [-22.71, -12.09]	-
ihafari 2009	18.1	3	33	34.8	4	33	2.2%	-16.70 [-18.41, -14.99]	
azak 2009	10.5	12.5	30	17.5	19	30	1.7%	-7.00 [-15.14, 1.14]	-
ichtinger 2011	49	30	20	69.5	30	20	0.8%	-20.50 [-39.09, -1.91]	
aul 2015	24.5	16.1	48	23.6	20.8	54	1.8%	0.90 [-6.28, 8.08]	+
ekhavet 2009	40.1	14.5	49	52.7	21.1	49	1.8%		
hort 2012		2.7	49	10		21		-12.60 [-19.77, -5.43]	·L
	13				10		2.0%	3.00 [-1.35, 7.35]	1
pence 2011	4	7	28	4	8	31	2.1%	0.00 [-3.83, 3.83]	
ahedi 2011	25.8	19.5	36	34	27.2	40	1.4%	-8.20 [-18.77, 2.37]	
erma 2008	12	13	25	21	12	25	1.8%	-9.00 [-15.94, -2.06]	
aikakul 2011/	30	20	24	35	17.5	24	1.4%	-5.00 [-15.63, 5.63]	-
oon 2001	17	32	16	11	30	16	0.6%	6.00 [-15.49, 27.49]	
<b>ubtotal (95% CI)</b> leterogeneity: Tau <sup>2</sup> = 8 'est for overall effect: Z			<b>404</b> 12 (P	< 0.00001); l <sup>2</sup> =	= 91%	397	20.7%	-7.26 [-12.82, -1.70]	•
.12.2 351-700 mg									
jori 2011	2	8	69	9	13	69	2.1%	-7.00 [-10.60, -3.40]	-
larke 2009b	13	3.97	76	14	4	39	2.1%	-1.00 [-2.54, 0.54]	1
									$\downarrow$
inney 2011 Inhaari 2014	29	18.2	57	31	18.9	68	1.8%	-2.00 [-8.52, 4.52]	
lahoori 2014	4	7	25	11.2	12.3	25	1.9%	-7.20 [-12.75, -1.65]	_ ~1
lardani-Kivi 2013	40	7	55	69	10	53	2.1%	-29.00 [-32.27, -25.73]	- T
lenda 2010	23	35	30	38	60	30	0.5%	-15.00 [-39.86, 9.86]	
letry 2008	18.49	14.94	67	23	13	34	1.9%	-4.51 [-10.16, 1.14]	7
lonks 2015	11	4.4	100	19	5.9	97	2.2%	-8.00 [-9.46, -6.54]	•
loore 2010	7	5.5	21	20	22.5	23	1.5%	-13.00 [-22.49, -3.51]	
anday 2005	32.5	18.11	40	30	20	20	1.4%	2.50 [-7.91, 12.91]	+-
arikh 2010	37	7	30	46	6	30	2.1%	-9.00 [-12.30, -5.70]	-
hort 2012a	17	5.9	42	10	10	21	2.0%	7.00 [2.37, 11.63]	<del>~</del>
rivastava 2010	21	3.25	60	28	3.33	60	2.2%	-7.00 [-8.18, -5.82]	•
aldivar Ramirez 2011	10	10	18	37	6	16	1.9%	-27.00 [-32.48, -21.52]	-
zcan 2012	9	25	20	27	9	20	1.3%	-18.00 [-29.64, -6.36]	
ubtotal (95% CI)	-		710		-	605	27.3%	-8.87 [-12.88, -4.85]	•
eterogeneity: Tau <sup>2</sup> = 5	$1.50^{\circ}$ Chi <sup>2</sup> = 33 <sup>2</sup>	8 62 df =		< 0.00001)· l <sup>2</sup> =	- 96%				•
est for overall effect: Z			140	( 0.00001), 1	- 50%				
.12.4 701-1050 mg									
adawy 2014	20	2.5	19	25	2.5	19	2.2%	-5.00 [-6.59, -3.41]	•
eniz 2012	12	19	25	8	15	26	1.5%	4.00 [-5.42, 13.42]	+-
im 2004	23	19	21	20	10.3	20	1.5%	3.00 [-6.30, 12.30]	+-
oc 2007	2	4	20	3	6	20	2.1%	-1.00 [-4.16, 2.16]	+
eung 2006	60	20	9	50	20	12	0.9%	10.00 [-7.29, 27.29]	+
arashi 2012	33	6	22	35	7	22	2.1%	-2.00 [-5.85, 1.85]	+
rabhakar 2007	38.5	10	10	54	13.5	10	1.4%	-15.50 [-25.91, -5.09]	
ubtotal (95% CI) leterogeneity: Tau <sup>2</sup> = 1	0.02: Chi <sup>2</sup> - 18	02 df - 6	126	0.006) 12 - 679	,	129	11.7%	-2.24 [-5.59, 1.10]	•
est for overall effect: Z			, (r – t		2				
	= 1.51 (r = 0.1								
.12.5 > 1050 mg									
bdelmageed 2010	21	4	30	10	7	30	2.1%	11.00 [8.12, 13.88]	-
bdelmageed 2010 dam 2006	21 30	4 60	27	30	60	26	0.3%	0.00 [-32.31, 32.31]	
bdelmageed 2010 dam 2006 Il-Mujadi 2005	21 30 18	4 60 16	27 35						
bdelmageed 2010 dam 2006 I-Mujadi 2005	21 30	4 60	27	30	60	26	0.3%	0.00 [-32.31, 32.31]	
bdelmageed 2010 dam 2006 I-Mujadi 2005 ekawi 2014	21 30 18	4 60 16	27 35	30 23	60 13	26 37	0.3% 1.8%	0.00 [-32.31, 32.31] -5.00 [-11.76, 1.76]	
bdelmageed 2010 dam 2006 I-Mujadi 2005 ekawi 2014 rogly 2008	21 30 18 9.7	4 60 16 5.6	27 35 30	30 23 6	60 13 6.2	26 37 32	0.3% 1.8% 2.1%	0.00 [-32.31, 32.31] -5.00 [-11.76, 1.76] 3.70 [0.76, 6.64]	
bdelmageed 2010 dam 2006 I-Mujadi 2005 ekawi 2014 rogly 2008 ierking 2003	21 30 18 9.7 12.4	4 60 16 5.6 10.4	27 35 30 22	30 23 6 15.5	60 13 6.2 17.9	26 37 32 21	0.3% 1.8% 2.1% 1.6%	0.00 [-32.31, 32.31] -5.00 [-11.76, 1.76] 3.70 [0.76, 6.64] -3.10 [-11.90, 5.70]	
bdelmageed 2010 dam 2006 I-Mujadi 2005 ekawi 2014 orogly 2008 ierking 2003 urmus 2007	21 30 18 9.7 12.4 13.64	4 60 16 5.6 10.4 19.19 40	27 35 30 22 40 25	30 23 6 15.5 15.21 39	60 13 6.2 17.9 18.93 49	26 37 32 21 40 25	0.3% 1.8% 2.1% 1.6% 1.6% 0.5%	0.00 [-32.31, 32.31] -5.00 [-11.76, 1.76] 3.70 [0.76, 66] -3.10 [-11.90, 5.70] -1.57 [-9.92, 6.78] -12.00 [-36.79, 12.79]	
bdelmageed 2010 dam 2006 I-Mujadi 2005 ekawi 2014 rogly 2008 ierking 2003 urmus 2007 assoulaki 2002	21 30 18 9.7 12.4 13.64 27 4	4 60 16 5.6 10.4 19.19 40 12	27 35 30 22 40 25 25	30 23 6 15.5 15.21 39 7	60 13 6.2 17.9 18.93 49 14	26 37 32 21 40 25 25	0.3% 1.8% 2.1% 1.6% 1.6% 0.5% 1.7%	0.00 [-32.31, 32.31] -5.00 [-11.76, 1.76] 3.70 [0.76, 6.64] -3.10 [-11.90, 5.70] -1.57 [-9.92, 6.78] -12.00 [-36.79, 12.79] -3.00 [-10.23, 4.23]	
bdelmageed 2010 dam 2006 I-Mujadi 2005 ekawi 2014 rogly 2008 ierking 2003 urmus 2007 assoulaki 2002	21 30 18 9.7 12.4 13.64 27 4 16	4 60 16 5.6 10.4 19.19 40 12 27	27 35 30 22 40 25 25 29	30 23 6 15.5 15.21 39 7 7	60 13 6.2 17.9 18.93 49 14 14	26 37 21 40 25 25 30	0.3% 1.8% 2.1% 1.6% 1.6% 0.5% 1.7% 1.4%	0.00 [-32.31, 32.31] -5.00 [-11.76, 1.76] 3.70 [0.76, 6.64] -3.10 [-11.90, 5.70] -1.57 [-9.92, 6.78] -12.00 [-36.79, 12.79] -3.00 [-10.23, 4.23] 9.00 [-2.03, 20.03]	
bdelmageed 2010 dam 2006 I-Mujadi 2005 ekawi 2014 rogly 2008 ierking 2003 urmus 2007 assoulaki 2002 assoulaki 2005 rouzanfard 2013	21 30 18 9.7 12.4 13.64 27 4 16 5.6	4 60 16 5.6 10.4 19.19 40 12 27 5.8	27 35 30 22 40 25 25 29 25	30 23 6 15.5 15.21 39 7 7 7	60 13 6.2 17.9 18.93 49 14 14 12.7	26 37 21 40 25 25 30 25	0.3% 1.8% 2.1% 1.6% 1.6% 0.5% 1.7% 1.4% 1.9%	0.00 [-32.31, 32.31] -5.00 [-11.76, 1.76] 3.70 [0.76, 6.64] -3.10 [-11.90, 5.70] -1.57 [-9.92, 6.78] -12.00 [-36.79, 12.79] -3.00 [-10.23, 4.23] 9.00 [-2.03, 20.03] -11.60 [-17.07, -6.13]	
bdelmageed 2010 dam 2006 I-Mujadi 2005 ekawi 2014 rogly 2008 urmus 2007 assoulaki 2002 assoulaki 2005 rouzanfard 2013 ilron 2004	21 30 18 9,7 12.4 13.64 27 4 16 5.6 13.82	4 60 16 5.6 10.4 19.19 40 12 27 5.8 12.5	27 35 30 22 40 25 25 29 25 23	30 23 6 15.5 15.21 39 7 7 7 17.2 23.63	60 13 6.2 17.9 18.93 49 14 14 12.7 16.52	26 37 32 21 40 25 25 30 25 24	0.3% 1.8% 2.1% 1.6% 0.5% 1.7% 1.4% 1.9% 1.6%	0.00 [-32.31, 32.31] -5.00 [-11.76, 1.76] 3.70 [0.76, 6.64] -3.10 [-11.90, 5.70] -1.57 [-9.29, 6.78] -2.00 [-36.79, 12.79] -3.00 [-10.23, 4.23] 9.00 [-2.03, 20.03] -11.60 [-17.07, -6.13] -9.81 [-18.16, -1.46]	
bdelmageed 2010 dam 2006 I-Mujadi 2005 ekawi 2014 rogly 2008 urmus 2007 assoulaki 2002 assoulaki 2005 rouzanfard 2013 ilron 2004	21 30 18 9.7 12.4 13.64 27 4 16 5.6 13.82 6.58	4 60 16 5.6 10.4 19.19 40 12 27 5.8 12.5 13.61	27 35 30 22 40 25 25 29 25 23 52	30 23 6 15.5 15.21 39 7 7 17.2 23.63 12.43	60 13 6.2 17.9 18.93 49 14 14 12.7 16.52 16.4	26 37 32 21 40 25 25 30 25 24 52	0.3% 1.8% 2.1% 1.6% 1.6% 1.7% 1.4% 1.9% 1.6% 1.9%	0.00 [-32.31, 32.31] -5.00 [-11.76, 1.76] 3.70 [0.76, 6.64] -3.10 [-11.90, 5.70] -1.57 [-9.92, 6.78] -12.00 [-36.79, 12.79] -3.00 [-10.23, 4.23] 9.00 [-2.03, 20.03] -11.60 [-17.07, -6.13] -9.81 [-18.16, -1.46] -5.85 [-11.64, -0.66]	
bdelmageed 2010 dam 2006 I-Mujadi 2005 ekawi 2014 rogly 2008 ierking 2003 urmus 2007 assoulaki 2002 assoulaki 2005 rouzanfard 2013 ilron 2004 rosen 2014 out 2007	21 30 9,7 12,4 13,64 27 4 16 5,6 13,82 6,58 5	4 60 16 5.6 10.4 19.19 40 12 27 5.8 12.5 13.61 59.3	27 35 30 22 40 25 25 29 25 23 52 23	30 23 6 15.5 15.21 39 7 7 17.2 23.63 12.43 0	60 13 6.2 17.9 18.93 49 14 12.7 16.52 16.4 14.8	26 37 21 40 25 25 30 25 24 52 28	0.3% 1.8% 2.1% 1.6% 0.5% 1.7% 1.4% 1.9% 1.6% 1.9% 0.5%	0.00 [-32.31, 32.31] -5.00 [-11.76, 1.76] 3.70 [0.76, 6.64] -3.10 [-11.90, 5.70] -1.57 [-9.92, 6.78] -12.00 [-36.79, 12.79] -3.00 [-10.23, 4.23] 9.00 [-2.03, 20.03] -11.60 [-17.07, -6.13] -9.81 [-18.16, -1.46] -5.85 [-11.64, -0.06] 5.00 [-19.85, 29.85]	* * * * * *
bdelmageed 2010 dam 2006 I-Mujadi 2005 ekawi 2014 rogly 2008 ierking 2003 urmus 2007 assoulaki 2002 assoulaki 2005 rouzanfard 2013 ilron 2004 rosen 2014 out 2007 ijeda 2014	21 30 9,7 12.4 13.64 27 4 16 5.6 13.82 6.58 5 30	4 60 16 5.6 10.4 19.19 40 12 27 5.8 12.5 13.61 59.3 1	27 35 30 22 40 25 25 29 25 23 52 23 25	30 23 6 15.5 15.21 39 7 7 7 17.2 23.63 12.43 0 39.2	60 13 6.2 17.9 18.93 49 14 14 12.7 16.52 16.4 14.8 8.1	26 37 21 40 25 30 25 24 52 28 25	0.3% 1.8% 2.1% 1.6% 1.5% 1.7% 1.4% 1.9% 1.6% 1.9% 0.5% 2.1%	0.00 [-32.31, 32.31] -5.00 [-11.76, 1.76] 3.70 [0.76, 6.64] -3.10 [-11.90, 5.70] -1.57 [-9.92, 6.78] -3.00 [-10.23, 4.23] 9.00 [-2.03, 20.03] -11.60 [-17.07, -6.13] -9.81 [-18.16, -1.46] -5.85 [-11.64, -0.06] 5.00 [-19.85, 29.85] -9.20 [-12.40, -6.00]	
bdelmageed 2010 dam 2006 I-Mujadi 2005 ekawi 2014 rogly 2008 urmus 2007 assoulaki 2002 assoulaki 2005 rouzanfard 2013 ifron 2004 rosen 2014 out 2007 jeda 2014 han 2013	21 30 18 9.7 12.4 13.64 27 4 16 5.6 13.82 6.58 5 30 8.52	4 60 16 5.6 10.4 19.19 40 12 27 5.8 12.5 13.61 59.3 1 7.43	27 35 30 22 40 25 29 25 23 52 23 25 23 34	30 23 6 15.5 15.21 39 7 7 7 17.2 23.63 12.43 0 39.2 24.28	60 13 6.2 17.9 18.93 49 14 12.7 16.52 16.4 14.8 8.1 11.18	26 37 32 21 40 25 30 25 24 52 28 25 35	0.3% 1.8% 2.1% 1.6% 1.6% 1.7% 1.4% 1.9% 0.5% 2.1% 2.0%	$\begin{array}{c} 0.00 \left[-32.31, 32.31\right]\\ -5.00 \left[-11.76, 1.76\right]\\ 3.70 \left[0.76, 6.64\right]\\ -3.10 \left[-11.90, 5.70\right]\\ -1.57 \left[-9.92, 6.78\right]\\ -12.00 \left[-36.79, 12.79\right]\\ -3.00 \left[-10.23, 4.23\right]\\ 9.00 \left[-2.03, 20.03\right]\\ -11.60 \left[-17.07, -6.13\right]\\ -9.81 \left[-18.16, -1.46\right]\\ -5.85 \left[-11.64, -0.06\right]\\ 5.00 \left[-19.85, 29.85\right]\\ -9.20 \left[-12.40, -6.00\right]\\ -15.76 \left[-20.23, -11.29\right]\end{array}$	
bdelmageed 2010 dam 2006 I-Mujadi 2005 ekawi 2014 rogly 2008 ierking 2003 urmus 2007 assoulaki 2002 assoulaki 2005 rouzanfard 2013 ilron 2004 rosen 2014 out 2007 jeda 2014 han 2013 osucu 2013	21 30 9,7 12,4 13,64 27 4 16 5,6 13,82 6,58 5 30 8,52 13	4 60 16 5.6 10.4 19.19 40 12 27 5.8 12.5 13.61 59.3 1 7.43 8	27 35 30 22 40 25 25 23 52 23 25 34 29	30 23 6 15.5 15.21 39 7 7 7 7 7 23.63 12.43 0 39.2 24.28 32	60 13 6.2 17.9 18.93 14 14 12.7 16.52 16.4 14.8 8.1 11.18 11	26 37 21 40 25 25 20 25 24 52 28 25 35 35	0.3% 1.8% 2.1% 1.6% 1.6% 1.7% 1.4% 1.9% 1.6% 1.9% 0.5% 2.1% 2.0% 2.0%	0.00 [-32.31, 32.31] -5.00 [-11.76, 1.76] 3.70 [0.76, 6.64] -3.10 [-11.90, 5.70] -1.57 [-9.92, 6.78] -1.2.00 [-36.79, 12.79] -3.00 [-10.23, 4.23] 9.00 [-2.03, 20.03] -11.60 [-17.07, -6.13] -9.81 [-18.16, -1.46] -5.85 [-11.64, -0.66] 5.00 [-19.85, 29.85] -9.20 [-12.40, -6.00] -15.76 [-20.23, -11.29] -19.00 [-2.384, -14.16]	
bdelmageed 2010 dam 2006 I-Mujadi 2005 ekawi 2014 rogly 2008 ierking 2003 urmus 2007 assoulaki 2002 assoulaki 2005 rouzanfard 2013 ilron 2004 rosen 2014 out 2007 njeda 2014 han 2013 osucu 2013	21 30 9,7 12.4 13.64 27 4 16 5.6 13.82 6.58 30 8.52 13 21	4 60 16 5.6 10.4 19.19 40 12 27 5.8 12.5 13.61 59.3 1 7.43 8 17	27 35 30 22 40 25 29 25 23 52 23 25 34 29 20	30 23 6 15.5 15.21 39 7 7 7 7 7 23.63 12.43 0 39.2 24.28 32 24.28 32 21	60 13 6.2 17.9 18.93 49 14 14 14 12.52 16.4 14.8 8.1 11.18 23	26 37 32 21 40 25 30 25 24 52 28 25 35 31 20	0.3% 1.8% 2.1% 1.6% 0.5% 1.4% 1.9% 0.5% 2.1% 2.0% 1.2%	$\begin{array}{c} 0.00 \left[-32.31, 32.31\right]\\ -5.00 \left[-11.76, 1.76\right]\\ 3.70 \left[0.76, 6.64\right]\\ -3.10 \left[-11.90, 5.70\right]\\ -1.57 \left[-9.29, 6.78\right]\\ 9.00 \left[-2.03, 20.03\right]\\ 9.00 \left[-2.03, 20.03\right]\\ -9.81 \left[-18.16, -1.46\right]\\ -5.85 \left[-11.64, -0.06\right]\\ 5.00 \left[-19.85, 29.85\right]\\ -9.20 \left[-12.40, -6.00\right]\\ -15.76 \left[-20.23, +1.29\right]\\ -19.00 \left[-2.384, -14.16\right]\\ 0.00 \left[-12.53, 12.53\right]\end{array}$	
bdelmageed 2010 dam 2006 I-Mujadi 2005 ekawi 2014 rogly 2008 ierking 2003 urmus 2007 assoulaki 2002 assoulaki 2005 rouzanfard 2013 ilron 2004 rosen 2014 out 2007 njeda 2014 han 2013 osucu 2013	21 30 18 9,7 12.4 13.64 27 4 16 5.6 13.82 6.58 5 30 8.52 13 30 8.52 13 32	4 60 16 5.6 10.4 19.19 40 12 27 5.8 12.5 13.61 59.3 1 7.43 8	27 35 30 22 40 25 29 25 23 25 23 25 34 29 20 25	30 23 6 15.5 15.21 39 7 7 7 23.63 12.43 0 39.2 24.28 32 24.28 32 21 54	60 13 6.2 17.9 18.93 14 14 12.7 16.52 16.4 14.8 8.1 11.18 11	26 37 32 21 40 25 25 24 52 25 24 52 25 35 31 20 25	0.3% 1.8% 2.1% 1.6% 1.6% 1.7% 1.4% 1.9% 1.6% 1.9% 0.5% 2.1% 2.0% 2.0%	$\begin{array}{c} 0.00 \left[-32.31, 32.31\right]\\ -5.00 \left[-11.76, 1.76\right]\\ 3.70 \left[0.76, 6.64\right]\\ -3.10 \left[-11.90, 5.70\right]\\ -1.57 \left[-9.29, 6.78\right]\\ 9.00 \left[-36.79, 12.79\right]\\ -3.00 \left[-10.23, 4.23\right]\\ 9.00 \left[-2.03, 20.03\right]\\ -11.60 \left[-17.07, -6.13\right]\\ -9.81 \left[-18.16, -1.46\right]\\ -5.85 \left[-11.64, -0.06\right]\\ 5.00 \left[-12.80, -6.00\right]\\ -9.20 \left[-12.40, -6.00\right]\\ -15.76 \left[-20.23, -11.29\right]\\ -19.00 \left[-23.84, -14.16\right]\\ 0.00 \left[-12.53, 12.53\right]\\ -22.00 \left[-3.43, -0.57\right]\end{array}$	· · · · · · · ·
bdelmageed 2010 dam 2006 I-Mujadi 2005 ekawi 2014 rogly 2008 ierking 2003 urmus 2007 assoulaki 2002 assoulaki 2002 assoulaki 2003 ilron 2004 rosen 2014 out 2007 jeda 2014 han 2013 osucu 2013 lénigaux 2004 mran 2006	21 30 9,7 12.4 13.64 27 4 16 5.6 13.82 6.58 30 8.52 13 21	4 60 16 5.6 10.4 19.19 40 12 27 5.8 12.5 13.61 59.3 1 7.43 8 17	27 35 30 22 40 25 29 25 23 52 23 25 34 29 20	30 23 6 15.5 15.21 39 7 7 7 7 7 23.63 12.43 0 39.2 24.28 32 24.28 32 21	60 13 6.2 17.9 18.93 49 14 14 14 12.52 16.4 14.8 8.1 11.18 23	26 37 32 21 40 25 30 25 24 52 28 25 35 31 20	0.3% 1.8% 2.1% 1.6% 0.5% 1.4% 1.9% 0.5% 2.1% 2.0% 1.2%	$\begin{array}{c} 0.00 \left[-32.31, 32.31\right]\\ -5.00 \left[-11.76, 1.76\right]\\ 3.70 \left[0.76, 6.64\right]\\ -3.10 \left[-11.90, 5.70\right]\\ -1.57 \left[-9.29, 6.78\right]\\ 9.00 \left[-2.03, 20.03\right]\\ 9.00 \left[-2.03, 20.03\right]\\ -9.81 \left[-18.16, -1.46\right]\\ -5.85 \left[-11.64, -0.06\right]\\ 5.00 \left[-19.85, 29.85\right]\\ -9.20 \left[-12.40, -6.00\right]\\ -15.76 \left[-20.23, +11.29\right]\\ -19.00 \left[-2.384, -14.16\right]\\ 0.00 \left[-12.53, 12.53\right]\end{array}$	
bdelmageed 2010 dam 2006 I-Mujadi 2005 ekawi 2014 rogly 2008 ierking 2003 urmus 2007 assoulaki 2002 assoulaki 2002 assoulaki 2005 roozanfard 2013 iiron 2004 rosen 2014 out 2007 ijeda 2014 han 2013 osucu 2013 lénigaux 2004 imran 2006 apchuk 2010	21 30 18 9,7 12.4 13.64 27 4 16 5.6 13.82 6.58 5 30 8.52 13 30 8.52 13 32	4 60 16 5.6 10.4 19.19 40 12 27 5.8 12.5 13.61 59.3 1 7.43 8 17 38.66	27 35 30 22 40 25 29 25 23 25 23 25 34 29 20 25	30 23 6 15.5 15.21 39 7 7 7 23.63 12.43 0 39.2 24.28 32 24.28 32 21 54	60 13 6.2 17.9 18.93 49 14 14 12.7 16.52 16.4 14.8 8.1 11.18 11.18 123 38.66	26 37 32 21 40 25 25 24 52 25 24 52 25 35 31 20 25	0.3% 1.8% 2.1% 1.6% 0.5% 1.7% 1.4% 1.9% 0.5% 2.1% 2.0% 2.0% 2.0% 2.0%	$\begin{array}{c} 0.00 \left[-32.31, 32.31\right]\\ -5.00 \left[-11.76, 1.76\right]\\ 3.70 \left[0.76, 6.64\right]\\ -3.10 \left[-11.90, 5.70\right]\\ -1.57 \left[-9.29, 6.78\right]\\ 9.00 \left[-36.79, 12.79\right]\\ -3.00 \left[-10.23, 4.23\right]\\ 9.00 \left[-2.03, 20.03\right]\\ -11.60 \left[-17.07, -6.13\right]\\ -9.81 \left[-18.16, -1.46\right]\\ -5.85 \left[-11.64, -0.06\right]\\ 5.00 \left[-12.80, -6.00\right]\\ -9.20 \left[-12.40, -6.00\right]\\ -15.76 \left[-20.23, -11.29\right]\\ -19.00 \left[-23.84, -14.16\right]\\ 0.00 \left[-12.53, 12.53\right]\\ -22.00 \left[-3.43, -0.57\right]\end{array}$	
bdelmageed 2010 dam 2006 I-Mujadi 2005 ekawi 2014 rogly 2008 ierking 2003 urmus 2007 assoulaki 2002 assoulaki 2005 rouzanfard 2013 ilron 2004 rosen 2014 out 2007 njeda 2014 han 2013 osucu 2013 lénigaux 2004 mman 2006 apchuk 2010 en 2009a	21 30 18 9,7 12,4 13,64 27 4 16 5,6 13,82 6,58 5 30 8,52 13 21 32 18	4 60 16 5.6 10.4 19.19 40 12 27 5.8 12.5 13.61 59.3 1 7.43 8 17 38.66 33	27 35 30 22 40 25 29 25 23 25 23 25 34 29 20 25 27	30 23 6 15.5 15.21 39 7 7 7 7 23.63 12.43 0 39.2 24.28 32 24.28 32 21 54 21	60 13 6.2 17.9 18.93 49 14 14 12.7 16.52 16.4 14.8 8.1 11.18 23 38.66 34	26 37 32 21 40 25 25 24 52 25 30 25 35 31 20 25 27	0.3% 1.8% 2.1% 1.6% 1.6% 1.7% 1.9% 1.6% 1.9% 2.1% 2.0% 2.0% 2.0% 0.6% 0.8%	$\begin{array}{c} 0.00 \left[-32.31, 32.31\right]\\ -5.00 \left[-11.76, 1.76\right]\\ 3.70 \left[0.76, 6.64\right]\\ -3.10 \left[-11.90, 5.70\right]\\ -1.57 \left[-9.92, 6.78\right]\\ -12.00 \left[-36.79, 12.79\right]\\ -3.00 \left[-10.23, 4.23\right]\\ 9.00 \left[-2.03, 20.03\right]\\ -11.60 \left[-17.07, -6.13\right]\\ -9.81 \left[-18.16, -1.46\right]\\ -5.85 \left[-11.64, -0.06\right]\\ 5.00 \left[-12.82, 29.85\right]\\ -9.20 \left[-12.40, -6.00\right]\\ -15.76 \left[-20.23, -11.29\right]\\ -19.00 \left[-2.33, 4, -14.16\right]\\ 0.00 \left[-12.53, 12.53\right]\\ -22.00 \left[-43.43, -0.57\right]\\ -3.00 \left[-2.08, 7, 14.87\right]\\ \end{array}$	
bdelmageed 2010 dam 2006 I-Mujadi 2005 ekawi 2014 rogly 2008 ierking 2003 urmus 2007 assoulaki 2005 rouzanfard 2013 ilron 2004 rosen 2014 out 2007 jeda 2014 han 2013 osucu 2013 Iénigaux 2004 umran 2006 apchuk 2010 en 2009a en 2009a	21 30 18 9,7 12.4 13.64 27 4 16 5.6 13.82 6.58 30 8.52 13 8.52 13 21 32 21 82 2	4 60 16 5.6 10.4 19.19 40 12 27 5.8 12.5 13.61 59.3 1 7.43 8 17 38.66 33 35	27 35 30 22 40 25 29 25 23 52 23 52 23 52 23 52 23 25 34 29 20 25 27 20	30 23 6 15.5 15.21 39 7 7 7 7 7 23.63 12.43 0 39.2 24.28 32 24.28 32 21 54 21 16	60 13 6.2 17.9 18.93 49 14 14 12.7 16.52 16.4 14.8 8.1 11.18 11 23 38.66 34 28	26 37 32 21 40 25 30 25 24 52 28 25 35 31 20 25 27 20	0.3% 1.8% 2.1% 1.6% 0.5% 1.7% 1.9% 1.6% 1.9% 0.5% 2.0% 2.0% 2.0% 1.2% 0.6% 0.8%	$\begin{array}{c} 0.00 \left[-32.31, 32.31\right]\\ -5.00 \left[-11.76, 1.76\right]\\ 3.70 \left[10.76, 6.64\right]\\ -3.10 \left[-11.90, 5.70\right]\\ -1.57 \left[-9.92, 6.78\right]\\ 9.00 \left[-2.03, 20.03\right]\\ 9.00 \left[-2.03, 20.03\right]\\ -11.60 \left[-17.07, -6.13\right]\\ -9.81 \left[-18.16, -1.46\right]\\ -5.85 \left[-11.64, -0.06\right]\\ -5.85 \left[-11.64, -0.06\right]\\ -9.20 \left[-12.40, -6.00\right]\\ -15.76 \left[-20.23, -11.29\right]\\ -19.00 \left[-2.384, -14.16\right]\\ 0.00 \left[-12.53, 12.53\right]\\ -22.00 \left[-43.43, -0.57\right]\\ -3.00 \left[-20.87, 14.87\right]\\ -14.00 \left[-26.47, -1.53\right]\\ -9.00 \left[-10.61, -7.39\right]\\ -9.00 \left[-10.61, -7.39\right]\end{array}$	
bdelmageed 2010 dam 2006 I-Mujadi 2005 ekawi 2014 rogly 2008 ierking 2003 urmus 2007 assoulaki 2002 assoulaki 2002 assoulaki 2005 roozanfard 2013 ifron 2004 rosen 2014 out 2007 ijeda 2014 han 2013 osucu 2013 lénigaux 2004 imran 2006 apchuk 2010 en 2009a en 2009b uran 2003a	21 30 18 9,7 12,4 13,64 27 4 16 5,6 13,82 6,58 5 30 8,52 13 21 32 18 22 5	4 60 16 5.6 10.4 19.19 40 12 2.7 5.8 12.5 13.61 59.3 1 7.43 8 17 38.66 333 5 4 7	27 35 30 22 40 25 29 25 23 25 23 25 23 25 23 25 24 29 20 25 27 20 30 25	30 23 6 15.5 15.21 39 7 7 7 17.2 23.63 12.43 0 39.2 24.28 32 21 54 21 54 21 16 11 16	60 13 6.2 17.9 18.93 14 14 14 14 14 14 14 14 14 14 14 14 14	26 37 32 21 40 25 25 24 52 25 30 25 24 52 25 31 20 25 27 20 29 25	0.3% 1.8% 2.1% 1.6% 1.6% 1.6% 1.7% 1.4% 1.9% 0.5% 2.1% 2.0% 2.0% 2.0% 2.0% 2.0% 2.0% 1.2% 2.8% 1.2% 2.2%	$\begin{array}{c} 0.00 \left[-32.31, 32.31\right]\\ -5.00 \left[-11.76, 1.76\right]\\ 3.70 \left[0.76, 6.64\right]\\ -3.10 \left[-11.90, 5.70\right]\\ -1.57 \left[-9.92, 6.78\right]\\ -2.00 \left[-36.79, 12.79\right]\\ -3.00 \left[-10.23, 4.23\right]\\ 9.00 \left[-2.03, 20.03\right]\\ -9.01 \left[-2.03, 20.03\right]\\ -9.81 \left[-18.16, -1.46\right]\\ -5.85 \left[-11.64, -0.66\right]\\ 5.00 \left[-12.82, 29.85\right]\\ -9.20 \left[-12.40, -6.00\right]\\ -15.76 \left[-20.23, -11.29\right]\\ -19.00 \left[-2.33, 4, -14.16\right]\\ 0.00 \left[-12.53, 12.53\right]\\ -22.00 \left[-43.43, -0.57\right]\\ -3.00 \left[-20.87, 14.87\right]\\ -41.00 \left[-26.47, -1.53\right]\\ -9.00 \left[-10.61, -7.39\right]\\ -9.00 \left[-10.61, -7.39\right]\\ -11.00 \left[-16.45, -5.55\right] \end{array}$	
bdelmageed 2010 dam 2006 I-Mujadi 2005 ekawi 2014 rogly 2008 ierking 2003 urmus 2007 assoulaki 2002 assoulaki 2005 rouzanfard 2013 ilron 2004 rosen 2014 out 2007 tjeda 2014 han 2013 osucu 2013 lénigaux 2004 mran 2006 apchuk 2010 en 2009b uran 2003a uran 2003b	21 30 18 9,7 12.4 13.64 27 4 16 5.6 13.82 6.58 30 8.52 13 21 32 8 13 21 32 8 2 2 5 7	4 60 16 5.6 10.4 19.19 40 12 27 59.3 12.5 13.61 59.3 1 7.43 8 17 38.66 33 5 4 7 8	27 35 30 22 40 25 23 23 52 23 52 23 52 23 52 23 34 29 20 25 27 20 30 30 25 25 25 25	30 23 6 15.5 15.21 39 7 7 7 7 7 23.63 12.43 0 39.2 24.28 32 21 54 21 16 11 16 11	60 13 6.2 17.9 18.93 49 14 14 12.7 16.52 16.52 16.52 14.8 8.1 11.18 38.66 34 28 2 2 12 14	26 37 32 21 40 25 25 30 25 24 52 28 35 31 20 25 27 20 20 25 27 20 29 25 25	0.3% 1.8% 2.1% 1.6% 1.6% 1.6% 1.7% 1.4% 1.9% 2.1% 2.0% 1.2% 2.0% 1.2% 0.6% 2.2% 1.2% 1.8%	$\begin{array}{c} 0.00 \left[-32.31, 32.31\right]\\ -5.00 \left[-11.76, 1.76\right]\\ 3.70 \left[10.76, 6.64\right]\\ -3.10 \left[-11.90, 5.70\right]\\ -1.57 \left[-9.92, 6.78\right]\\ 9.00 \left[-2.03, 20.03\right]\\ 9.00 \left[-2.03, 20.03\right]\\ 9.00 \left[-2.03, 20.03\right]\\ -9.81 \left[-18.16, -1.46\right]\\ -5.85 \left[-11.64, -0.06\right]\\ 5.00 \left[-19.85, 29.85\right]\\ -9.20 \left[-12.40, -6.00\right]\\ -15.76 \left[-20.23, -11.29\right]\\ -19.00 \left[-2.3.84, -14.16\right]\\ 0.00 \left[-2.3.84, -14.16\right]\\ 0.00 \left[-2.3.84, -14.16\right]\\ 0.00 \left[-20.37, 14.87\right]\\ -3.00 \left[-20.87, 14.87\right]\\ -14.00 \left[-26.47, -1.53\right]\\ -9.00 \left[-10.61, -7.39\right]\\ -10.00 \left[-16.45, -5.55\right]\\ -4.00 \left[-10.32, 2.32\right] \end{array}$	
bdelmageed 2010 dam 2006 I-Mujadi 2005 ekawi 2014 rogly 2008 bierking 2003 uurmus 2007 assoulaki 2002 assoulaki 2005 rouzanfard 2013 iilron 2004 rosen 2014 han 2013 osucu 2013 ténigaux 2004 wmran 2006 apchuk 2010 en 2009a en 2009b uran 2003b uran 2003b	21 30 18 9,7 12,4 13.64 27 4 16 5.6 13.82 6.58 5 30 8.52 13 21 32 18 22 5 7 3	4 60 16 5.6 10.4 19.19 40 12 27 59.3 12.5 13.61 59.3 1 7.43 8 8 17 38.66 33 5 5 4 7 8 8.10 5 9 3 8.10 5 9 3 1 7 7 5 9 3 8 5 6 1 9 9 1 7 7 5 9 3 1 7 7 5 9 3 1 7 7 5 9 3 1 7 7 5 9 3 1 7 7 5 9 3 1 7 7 5 9 3 1 7 7 5 9 3 1 7 7 5 9 3 1 7 7 5 9 3 1 7 7 5 9 3 1 7 7 8 5 9 3 1 7 7 8 5 9 3 1 7 7 8 5 9 3 1 7 7 8 5 9 1 8 1 7 9 1 8 1 9 1 9 1 7 7 1 8 1 2 1 7 1 9 1 9 1 1 7 1 8 1 1 1 1 1 1 1 1 2 1 1 1 1 1 1 1 1 1	27 35 30 22 25 25 22 23 25 22 23 25 22 23 25 22 23 25 24 29 20 20 25 27 20 20 25 27 20 25 27 20 25 27 20 25 27 20 25 20 25 20 22 25 25 20 22 25 20 22 25 20 22 20 25 20 22 20 25 20 20 20 20 20 20 20 20 20 20 20 20 20	30 23 6 15.5 15.21 39 7 7 7 7 17.2 23.63 12.43 0 39.2 24.28 32 24.28 32 21 54 21 16 11 16 11	60 13 6.2 17.9 18.93 49 14 14 14 14 14 14 14 14 14 14 14 14 14	26 37 32 21 40 25 25 30 25 25 25 25 31 20 25 27 20 29 25 25 25 27 20 25 25 25 25 25 25 25 25 25 25	0.3% 1.8% 2.1% 1.6% 1.6% 1.6% 1.4% 1.9% 0.5% 2.0% 2.0% 1.2% 2.0% 1.2% 2.2% 1.2% 1.2% 1.2%	$\begin{array}{c} 0.00 \left[-32.31, 32.31\right]\\ -5.00 \left[-11.76, 1.76\right]\\ 3.70 \left[10.76, 6.64\right]\\ -3.10 \left[-11.90, 5.70\right]\\ -1.57 \left[-9.92, 6.78\right]\\ 9.00 \left[-2.03, 20.03\right]\\ 9.00 \left[-2.03, 20.03\right]\\ -11.60 \left[-17.07, -6.13\right]\\ -9.81 \left[-18.16, -1.46\right]\\ -5.85 \left[-11.64, -0.06\right]\\ -5.85 \left[-11.64, -0.06\right]\\ -9.20 \left[-12.40, -6.00\right]\\ -19.85, 29.85\right]\\ -9.20 \left[-12.40, -6.00\right]\\ -15.76 \left[-20.23, -11.29\right]\\ -19.00 \left[-23.84, -14.16\right]\\ 0.00 \left[-12.53, 12.53\right]\\ -22.00 \left[-43.43, -0.57\right]\\ -3.00 \left[-20.87, 14.87\right]\\ -14.00 \left[-26.47, -1.53\right]\\ -9.00 \left[-10.61, -7.39\right]\\ -11.00 \left[-10.64, -5.35\right]\\ -4.00 \left[-10.32, 2.32\right]\\ -11.00 \left[-21.09, -0.91\right] \end{array}$	
bdelmageed 2010 dam 2006 I-Mujadi 2005 ekawi 2014 rogjy 2008 ierking 2003 uurmus 2007 assoulaki 2002 assoulaki 2005 rouzanfard 2013 iitron 2004 irosen 2014 lout 2007 njeda 2014 han 2013 osucu 2013 ténigaux 2004 Jomran 2006 apchuk 2010 en 2009a en 2009b uran 2003a uran 2003b uran 2004	21 30 18 9,7 12,4 13,64 27 4 16 5,6 13,82 6,58 5 30 8,52 13 21 32 18 22 2 5 7 7 3 20	4 60 16 5.6 10.4 19.19 40 12 2.7 5.8 12.5 13.61 59.3 1 7.43 8 17 38.66 333 5 4 7 8 10.5 5 1	27 35 30 22 25 25 25 23 25 23 25 23 25 23 25 23 25 20 20 25 25 20 30 25 25 20 30 25 25 20 30 25 25 20 20 20 20 20 20 20 20 20 20 20 20 20	30 23 6 15.5 15.21 39 7 7 7 7 7 7 7 7 7 7 7 23.63 12.43 12.43 0 39.2 24.28 32 21 54 21 16 11 16 11 16 11	60 13 6.2 17.9 18.93 49 14 14 12.7 16.52 16.4 14.8 8.1 11.18 23 38.66 34 28 2 2 2 12 14 23.5 46	26 37 32 21 40 25 25 25 25 25 25 25 24 52 28 25 24 52 28 30 25 27 20 29 25 25 25 20	0.3% 1.8% 2.1% 1.6% 1.6% 1.7% 1.4% 1.9% 0.5% 2.1% 2.0% 2.0% 2.0% 1.2% 2.0% 2.0% 2.0% 1.2% 2.9% 1.8% 1.2% 2.1% 2.1% 2.1% 1.6% 1.6% 1.6% 1.6% 1.6% 1.6% 1.6% 1	$\begin{array}{c} 0.00 \left[-32.31, 32.31\right]\\ -5.00 \left[-11.76, 1.76\right]\\ 3.70 \left[0.76, 6.64\right]\\ -3.10 \left[-11.90, 5.70\right]\\ -1.57 \left[-9.92, 6.78\right]\\ -2.00 \left[-36.79, 12.79\right]\\ -3.00 \left[-10.23, 4.23\right]\\ 9.00 \left[-2.03, 20.03\right]\\ 9.00 \left[-2.03, 20.03\right]\\ -9.81 \left[-18.16, -1.46\right]\\ -5.85 \left[-11.64, -0.66\right]\\ 5.00 \left[-19.85, 29.85\right]\\ -9.20 \left[-12.40, -6.00\right]\\ -15.76 \left[-20.23, -11.29\right]\\ -15.76 \left[-20.23, -11.29\right]\\ -22.00 \left[-43.43, -0.57\right]\\ -22.00 \left[-23.84, -14.16\right]\\ 0.00 \left[-26.87, 14.87\right]\\ -41.00 \left[-26.47, -1.53\right]\\ -9.00 \left[-10.61, -7.39\right]\\ -9.00 \left[-10.61, -7.39\right]\\ -11.00 \left[-12.09, -0.91\right]\\ -6.00 \left[-26.16, 14.16\right] \end{array}$	
bbdelmageed 2010 dam 2006 J-Mujadi 2005 ekawi 2014 rogly 2008 bierking 2003 urmus 2007 assoulaki 2002 assoulaki 2005 rouzanfard 2013 iliron 2004 irosen 2014 bot 2007 ajeda 2014 han 2013 ossucu 2013 ténigaux 2004 mran 2006 apchuk 2010 en 2009b uran 2003a uran 2004 uran 2005 (ak 2011	21 30 18 9,7 12.4 13.64 27 4 16 5.6 13.82 6.58 30 8.52 13 21 32 8 2 2 2 5 7 3 20 12	4 60 16 5.6 10.4 19.19 40 12 27 59.3 12.5 13.61 59.3 12.5 13.61 59.3 1 7 38.66 33 5 4 7 8 10.5 10.5 10.5 10.5 10.5 10.5 10.5 10.5	27 35 30 22 40 25 25 25 23 25 23 25 23 25 23 25 20 20 25 25 25 25 25 20 20 20 20 20 20 20 20 20 20 20 20 20	30 23 6 15.5 15.21 39 7 7 7 7 7 23.63 12.43 0 39.2 24.28 32 21 54 21 16 11 16 11 16 11 16 11 14 26 30	60 13 6.2 17.9 18.93 14 14 12.7 16.52 16.4 14.8 8.1 11.18 38.66 34 28 28 28 2 2 12 14 23.5 48	26 37 32 21 40 25 25 25 25 24 52 28 25 27 20 20 25 25 25 27 20 20 25 25 25 25 26 20 20 25 25 25 25 25 25 25 25 25 25	0.3% 1.8% 2.1% 1.6% 1.6% 1.4% 1.9% 0.5% 2.0% 2.0% 2.0% 2.0% 2.0% 2.0% 2.0% 2.2% 1.2% 1.2% 1.2% 1.2% 1.2% 1.5% 0.7%	$\begin{array}{c} 0.00 \left[-32.31, 32.31\right]\\ -5.00 \left[-11.76, 1.76\right]\\ 3.70 \left[10.76, 6.64\right]\\ -3.10 \left[-11.90, 5.70\right]\\ -1.57 \left[-9.92, 6.78\right]\\ 9.00 \left[-2.03, 20.03\right]\\ 9.00 \left[-2.03, 20.03\right]\\ 9.00 \left[-2.03, 20.03\right]\\ 9.00 \left[-2.03, 20.03\right]\\ -9.81 \left[-18.16, -1.46\right]\\ -5.85 \left[-11.64, -0.06\right]\\ 5.00 \left[-19.85, 29.85\right]\\ -9.20 \left[-12.40, -6.00\right]\\ -15.76 \left[-20.23, -11.29\right]\\ -9.20 \left[-23.84, -14.16\right]\\ 0.00 \left[-23.84, -14.16\right]\\ 0.00 \left[-23.84, -14.16\right]\\ 0.00 \left[-20.87, 14.87\right]\\ -14.00 \left[-20.47, -1.53\right]\\ -9.00 \left[-10.61, -7.39\right]\\ -11.00 \left[-16.45, -5.55\right]\\ -4.00 \left[-10.32, 2.32\right]\\ -11.00 \left[-26.16, 14.16\right]\\ -8.00 \left[-39.04, 3.04\right] \end{array}$	
bdelmageed 2010 dam 2006 I-Mujadi 2005 ekawi 2014 rogjy 2008 ierking 2003 burmus 2007 assoulaki 2002 assoulaki 2005 rouzanfard 2013 iifron 2004 rosen 2014 lout 2007 ajeda 2014 han 2013 osucu 2013 iefnigaux 2004 mran 2006 apchuk 2010 en 2009a en 2009b uran 2003b uran 2003b uran 2004 uran 2004 uran 2004 uran 2004 uran 2005 lcak 2011 Izgencil 2011	21 30 18 9,7 12,4 13,64 27 4 16 5,6 13,82 6,58 5 30 8,52 13 21 32 18 22 2 5 7 7 3 20	4 60 16 5.6 10.4 19.19 40 12 2.7 5.8 12.5 13.61 59.3 1 7.43 8 17 38.66 333 5 4 7 8 10.5 5 1	27 35 300 25 25 25 23 35 25 25 23 35 25 25 27 20 300 25 25 25 25 20 20 30 30 30	30 23 6 15.5 15.21 39 7 7 7 7 7 7 7 7 7 7 7 23.63 12.43 12.43 0 39.2 24.28 32 21 54 21 16 11 16 11 16 11	60 13 6.2 17.9 18.93 49 14 14 12.7 16.52 16.4 14.8 8.1 11.18 23 38.66 34 28 2 2 2 12 14 23.5 46	26 37 32 21 40 25 25 30 25 24 52 25 35 31 20 25 27 20 29 25 25 27 20 25 25 27 20 25 25 26 25 25 25 26 25 25 25 25 25 25 25 25 25 25	0.3% 1.8% 2.1% 1.6% 1.6% 1.6% 1.7% 1.4% 1.9% 2.0% 2.0% 2.0% 1.2% 0.6% 0.8% 1.2% 0.6% 0.8% 1.2% 0.7% 0.7% 0.7%	$\begin{array}{c} 0.00 \left[-32.31, 32.31\right]\\ -5.00 \left[-11.76, 1.76\right]\\ 3.70 \left[10.76, 6.64\right]\\ -3.10 \left[-11.90, 5.70\right]\\ -1.57 \left[-9.92, 6.78\right]\\ 9.00 \left[-2.03, 20.03\right]\\ 9.00 \left[-2.03, 20.03\right]\\ 9.00 \left[-2.03, 20.03\right]\\ -11.60 \left[-17.07, -6.13\right]\\ -9.81 \left[-18.16, -1.46\right]\\ -5.85 \left[-11.64, -0.06\right]\\ -5.85 \left[-11.64, -0.06\right]\\ -9.20 \left[-12.40, -6.00\right]\\ -19.85, 29.85\right]\\ -9.20 \left[-12.40, -6.00\right]\\ -15.76 \left[-20.23, -11.29\right]\\ -19.00 \left[-23.84, -14.16\right]\\ 0.00 \left[-12.53, 12.53\right]\\ -22.00 \left[-43.43, -0.57\right]\\ -3.00 \left[-20.87, 14.87\right]\\ -3.00 \left[-20.87, 14.87\right]\\ -9.00 \left[-10.61, -7.39\right]\\ -11.00 \left[-16.45, -5.55\right]\\ -4.00 \left[-10.32, 2.32\right]\\ -11.00 \left[-21.09, -0.91\right]\\ -6.00 \left[-21.09, -0.91\right]\\ -6.00 \left[-20.87, -0.75\right] \end{array}$	·
bdelmageed 2010 dam 2006 I-Mujadi 2005 ekawi 2014 rogjy 2008 bierking 2003 uurmus 2007 assoulaki 2002 assoulaki 2002 assoulaki 2003 roouzanfard 2013 iliron 2004 irosen 2014 loot 2007 ijeda 2014 han 2013 osucu 2013 ténigaux 2004 Dmran 2006 apchuk 2010 en 2009b uran 2003a uran 2003 uran 2004 uran 2005 cak 2011 bzgencil 2011 ubiotal (95% CI)	21 30 18 9,7 12.4 13.64 27 4 16 5.6 13.82 6.58 5 30 8.52 13 21 32 2 18 2 2 2 5 7 7 3 0 20 12 11	4 60 16 5.6 10.4 19.19 40 12 27 58 12.5 13.61 59.3 1 7.43 8 17 38.66 333 5 4 4 7 8 10.5 1 0.1 4.8	27 35 300 25 25 23 52 23 52 23 52 23 24 29 200 25 27 20 300 25 27 20 300 25 27 20 302 27 20 20 20 20 20 20 20 20 20 20	30 23 6 15.5 15.21 39 7 7 7 7 7 23.63 12.43 12.43 0 39.2 24.28 32 21 54 21 16 11 16 11 16 11 16 30 15	60 13 6.2 17.9 18.93 49 14 14 12.7 16.52 16.4 14.8 8.1 11.18 11.18 11.18 11.18 11.18 338.66 34 28 2 12 14 23.5 46 48 7.7	26 37 32 21 40 25 25 25 25 24 52 28 25 27 20 20 25 25 25 27 20 20 25 25 25 25 26 20 20 25 25 25 25 25 25 25 25 25 25	0.3% 1.8% 2.1% 1.6% 1.6% 1.4% 1.9% 0.5% 2.0% 2.0% 2.0% 2.0% 2.0% 2.0% 2.0% 2.2% 1.2% 1.2% 1.2% 1.2% 1.2% 1.5% 0.7%	$\begin{array}{c} 0.00 \left[-32.31, 32.31\right]\\ -5.00 \left[-11.76, 1.76\right]\\ 3.70 \left[10.76, 6.64\right]\\ -3.10 \left[-11.90, 5.70\right]\\ -1.57 \left[-9.92, 6.78\right]\\ 9.00 \left[-2.03, 20.03\right]\\ 9.00 \left[-2.03, 20.03\right]\\ 9.00 \left[-2.03, 20.03\right]\\ 9.00 \left[-2.03, 20.03\right]\\ -9.81 \left[-18.16, -1.46\right]\\ -5.85 \left[-11.64, -0.06\right]\\ 5.00 \left[-19.85, 29.85\right]\\ -9.20 \left[-12.40, -6.00\right]\\ -15.76 \left[-20.23, -11.29\right]\\ -9.20 \left[-23.84, -14.16\right]\\ 0.00 \left[-23.84, -14.16\right]\\ 0.00 \left[-23.84, -14.16\right]\\ 0.00 \left[-20.87, 14.87\right]\\ -14.00 \left[-20.47, -1.53\right]\\ -9.00 \left[-10.61, -7.39\right]\\ -11.00 \left[-16.45, -5.55\right]\\ -4.00 \left[-10.32, 2.32\right]\\ -11.00 \left[-26.16, 14.16\right]\\ -8.00 \left[-39.04, 3.04\right] \end{array}$	
bdelmageed 2010 dam 2006 I-Mujadi 2005 ekawi 2014 rogly 2008 ierking 2003 urmus 2007 assoulaki 2002 assoulaki 2005 rouzanfard 2013 ilron 2004 out 2007 ijeda 2014 han 2013 osucu 2013 iénigaux 2004 urman 2006 apchuk 2010 en 2009a en 2009b uran 2003b uran 2004 uran 2004 uran 2004 uran 2004 uran 2005 cak 2011 zgencil 2011	21 30 18 9,7 12.4 13.64 27 4 16 5,6 13.82 6,58 5 30 8,52 13 21 32 18 2 2 2 5 7 3 20 12 11 3.25; Chi <sup>2</sup> = 264	4 60 16 5.6 10.4 19.19 40 12 27 59.3 12.5 13.61 59.3 1 7 38.66 33 3 5 4 7 7 8 8 10.5 1 0.1 4.8 4.23, df =	27 35 300 25 25 23 52 23 52 23 52 23 24 29 200 25 27 20 300 25 27 20 300 25 27 20 302 27 20 20 20 20 20 20 20 20 20 20	30 23 6 15.5 15.21 39 7 7 7 7 7 23.63 12.43 12.43 0 39.2 24.28 32 21 54 21 16 11 16 11 16 11 16 30 15	60 13 6.2 17.9 18.93 49 14 14 12.7 16.52 16.4 14.8 8.1 11.18 11.18 11.18 11.18 11.18 338.66 34 28 2 12 14 23.5 46 48 7.7	26 37 32 21 40 25 25 30 25 24 52 25 35 31 20 25 27 20 29 25 25 27 20 25 25 27 20 25 25 26 25 25 25 26 25 25 25 25 25 25 25 25 25 25	0.3% 1.8% 2.1% 1.6% 1.6% 1.6% 1.7% 1.4% 1.9% 2.0% 2.0% 2.0% 1.2% 0.6% 0.8% 1.2% 0.6% 0.8% 1.2% 0.7% 0.7% 0.7%	$\begin{array}{c} 0.00 \left[-32.31, 32.31\right]\\ -5.00 \left[-11.76, 1.76\right]\\ 3.70 \left[10.76, 6.64\right]\\ -3.10 \left[-11.90, 5.70\right]\\ -1.57 \left[-9.92, 6.78\right]\\ 9.00 \left[-2.03, 20.03\right]\\ 9.00 \left[-2.03, 20.03\right]\\ 9.00 \left[-2.03, 20.03\right]\\ -11.60 \left[-17.07, -6.13\right]\\ -9.81 \left[-18.16, -1.46\right]\\ -5.85 \left[-11.64, -0.06\right]\\ -5.85 \left[-11.64, -0.06\right]\\ -9.20 \left[-12.40, -6.00\right]\\ -19.85, 29.85\right]\\ -9.20 \left[-12.40, -6.00\right]\\ -15.76 \left[-20.23, -11.29\right]\\ -19.00 \left[-23.84, -14.16\right]\\ 0.00 \left[-12.53, 12.53\right]\\ -22.00 \left[-43.43, -0.57\right]\\ -3.00 \left[-20.87, 14.87\right]\\ -3.00 \left[-20.87, 14.87\right]\\ -9.00 \left[-10.61, -7.39\right]\\ -11.00 \left[-16.45, -5.55\right]\\ -4.00 \left[-10.32, 2.32\right]\\ -11.00 \left[-21.09, -0.91\right]\\ -6.00 \left[-26.16, 14.16\right]\\ -8.00 \left[-3.04, 3.04\right]\\ -4.00 \left[-7.25, -0.75\right] \end{array}$	
bdelmageed 2010 dam 2006 I-Mujadi 2005 ekawi 2014 rogly 2008 ierking 2003 urmus 2007 assoulaki 2002 assoulaki 2002 assoulaki 2003 roozanfard 2013 ilron 2004 out 2007 jeda 2014 out 2007 jeda 2014 out 2007 jeda 2014 out 2007 jeda 2014 out 2007 apchuk 2010 en 2009a en 2009b uran 2004 uran 2004 uran 2005 cak 2011 zgencil 2011 ubtotal (95% CI) eterogeneity: Tau <sup>2</sup> = 6 est for overall effect: Z	21 30 18 9,7 12.4 13.64 27 4 16 5,6 13.82 6,58 5 30 8,52 13 21 32 18 2 2 2 5 7 3 20 12 11 3.25; Chi <sup>2</sup> = 264	4 60 16 5.6 10.4 19.19 40 12 27 5.8 12.5 13.61 59.3 1 7.43 8 17 38.66 33 3 5 4 4 7 8 10.5 1 0.1 4.8 4.23, df = 009)	27 35 30 22 40 25 25 23 25 23 25 23 25 23 25 20 20 25 27 20 30 25 25 25 20 30 25 25 26 20 20 26 27 20 20 27 20 20 20 20 20 20 20 20 20 20 20 20 20	30 23 6 15.5 15.21 39 7 7 7 7 7 23.63 12.43 12.43 0 39.2 24.28 32 21 54 21 16 11 16 11 16 11 16 30 15	60 13 6.2 17.9 18.93 49 14 14 12.7 16.52 16.4 14.8 8.1 11.18 11.18 11.18 11.18 11.18 338.66 34 28 2 12 14 23.5 46 48 7.7	26 37 32 21 40 25 25 24 25 26 27 20 29 25 27 20 29 25 25 20 20 29 25 20 20 20 25 27 20 20 25 20 20 20 20 20 20 20 20 20 20	0.3% 1.8% 2.1% 1.6% 1.6% 1.4% 1.9% 0.5% 2.0% 2.0% 2.0% 2.0% 2.0% 1.2% 2.0% 1.2% 1.2% 1.2% 1.2% 1.2% 1.8% 1.5% 0.7% 2.1% 40.2%	$\begin{array}{c} 0.00 \left[-32.31, 32.31\right]\\ -5.00 \left[-11.76, 1.76\right]\\ 3.70 \left[10.76, 6.64\right]\\ -3.10 \left[-11.90, 5.70\right]\\ -1.57 \left[-9.92, 6.78\right]\\ 9.00 \left[-2.03, 20.03\right]\\ 9.00 \left[-2.03, 20.03\right]\\ 9.00 \left[-2.03, 20.03\right]\\ 9.00 \left[-2.03, 20.03\right]\\ -9.81 \left[-18.16, -1.46\right]\\ -5.85 \left[-11.64, -0.66\right]\\ 5.00 \left[-19.85, 29.85\right]\\ -9.20 \left[-12.40, -6.00\right]\\ -15.76 \left[-20.23, -11.29\right]\\ -9.20 \left[-12.40, -6.00\right]\\ -15.76 \left[-20.23, -11.29\right]\\ -3.00 \left[-20.384, -14.16\right]\\ 0.00 \left[-22.384, -14.16\right]\\ 0.00 \left[-22.384, -14.16\right]\\ 0.00 \left[-20.87, 14.87\right]\\ -3.00 \left[-20.87, 14.87\right]\\ -3.00 \left[-20.87, 14.87\right]\\ -14.00 \left[-26.47, -1.53\right]\\ -9.00 \left[-10.61, -7.39\right]\\ -9.00 \left[-10.61, -7.39\right]\\ -11.00 \left[-21.09, -0.91\right]\\ -6.00 \left[-22.616, 14.16\right]\\ -18.00 \left[-3.04, 3.04\right]\\ -4.00 \left[-7.25, -0.75\right]\\ -6.08 \left[-9.65, -2.51\right]\\ \end{array}$	
bdelmageed 2010 dam 2006 -Mujadi 2005 skawi 2014 ogly 2008 ierking 2003 urmus 2007 issoulaki 2002 issoulaki 2005 ouzanfard 2013 iron 2004 rosen 2014 out 2007 jeda 2014 den 2013 secu 2013 énigaux 2004 mran 2005 uran 2005 tak 2011 uran 2005 tak 2015 tak 2015	21 30 18 9.7 12.4 13.64 27 4 16 5.6 13.82 6.58 30 8.52 13 21 32 18 2 2 5 7 3 20 13 21 32 18 32 13 21 32 13 32 13 32 13 32 13 32 13 32 13 32 13 32 13 32 13 32 13 32 13 32 13 32 13 32 18 32 12 32 32 12 32 13 32 13 32 13 32 13 32 13 32 13 32 13 32 13 32 13 32 13 32 13 32 13 32 13 32 13 32 13 32 13 32 13 32 13 32 12 13 32 12 13 32 12 13 32 13 32 12 13 32 13 32 12 13 32 12 13 32 32 33 (P = 0.00	4 60 16 5.6 10.4 19.19 40 12 27 5.8 12.5 13.61 59.3 12.5 13.61 59.3 1 7 38.66 33 3 5 4 7 7 8 10.5 1 0.1 4.8 4.23, df = 009)	27 35 30 22 40 25 25 23 23 25 23 34 29 20 25 27 20 30 25 25 27 20 00 30 25 25 27 20 00 30 25 25 27 20 20 20 21 21 23 23 24 20 25 25 29 20 20 20 20 20 20 20 20 20 20 20 20 20	30 23 6 15.5 15.21 39 7 7 7 7 23.63 12.43 0 39.2 24.28 32 21 54 21 16 11 16 11 16 11 16 11 16 11 54 < 0.00001); I <sup>2</sup> =	60 13 6.2 17.9 18.93 49 14 14 14 14 14 14 14 14 14 14 14 14 12.7 16.52 16.4 11.18 38.66 34 28 2 2 12 14 23.5 48 7.7 = 90%	26 37 32 21 40 25 25 24 25 26 27 20 29 25 27 20 29 25 25 20 20 29 25 20 20 20 25 27 20 20 25 20 20 20 20 20 20 20 20 20 20	0.3% 1.8% 2.1% 1.6% 1.6% 1.6% 1.7% 1.4% 1.9% 2.0% 2.0% 2.0% 1.2% 0.6% 0.8% 1.2% 0.6% 0.8% 1.2% 0.7% 0.7% 0.7%	$\begin{array}{c} 0.00 \left[-32.31, 32.31\right]\\ -5.00 \left[-11.76, 1.76\right]\\ 3.70 \left[10.76, 6.64\right]\\ -3.10 \left[-11.90, 5.70\right]\\ -1.57 \left[-9.92, 6.78\right]\\ 9.00 \left[-2.03, 20.03\right]\\ 9.00 \left[-2.03, 20.03\right]\\ 9.00 \left[-2.03, 20.03\right]\\ -11.60 \left[-17.07, -6.13\right]\\ -9.81 \left[-18.16, -1.46\right]\\ -5.85 \left[-11.64, -0.06\right]\\ -5.85 \left[-11.64, -0.06\right]\\ -9.20 \left[-12.40, -6.00\right]\\ -19.85, 29.85\right]\\ -9.20 \left[-12.40, -6.00\right]\\ -15.76 \left[-20.23, -11.29\right]\\ -19.00 \left[-23.84, -14.16\right]\\ 0.00 \left[-12.53, 12.53\right]\\ -22.00 \left[-43.43, -0.57\right]\\ -3.00 \left[-20.87, 14.87\right]\\ -3.00 \left[-20.87, 14.87\right]\\ -9.00 \left[-10.61, -7.39\right]\\ -11.00 \left[-16.45, -5.55\right]\\ -4.00 \left[-10.32, 2.32\right]\\ -11.00 \left[-21.09, -0.91\right]\\ -6.00 \left[-26.16, 14.16\right]\\ -8.00 \left[-3.04, 3.04\right]\\ -4.00 \left[-7.25, -0.75\right] \end{array}$	

# Supplemental Digital Content 11 Forest plot of VAS 24h mobilization from trials with low risk

# <u>of bias</u>

		apentin			ntrol			Mean Difference	Mean Difference
Study or Subgroup	Mean [VAS]	SD [VAS]	Total	Mean [VAS]	SD [VAS]	Total	Weight	IV, Random, 95% CI [VAS	] IV, Random, 95% CI [VAS]
3.13.1 0-350 mg									
Short 2012	32	11.1	42	30	20		8.9%		
Subtotal (95% CI)			42			21	8.9%	2.00 [-7.19, 11.19]	↓ ◆
Heterogeneity: Not ap	plicable								
Test for overall effect	Z = 0.43 (P =	= 0.67)							
3.13.2 351-700 mg									
Monks 2015	40	6.7	100	47	8.15	97	11.7%	-7.00 [-9.09, -4.91	1 •
Moore 2010	10	5.5	21	18	15	23	10.1%	-8.00 [-14.57, -1.43	i -
Paul 2015	94.9	29.8	48	94.4	30.8	54	7.7%	0.50 [-11.27, 12.27	1 +
Short 2012a	37	10.4	42	30	20	21	8.9%	7.00 [-2.11, 16.11	1 +
Srivastava 2010	30	2.5	60	46	2.5	60	11.8%	-16.00 [-16.89, -15.11	•
Subtotal (95% CI)			271			255	50.3%	-5.94 [-12.78, 0.90]	◆
3.13.4 701-1050 mg Lunn 2015 Subtotal (95% CI)	41	14.5	92 <b>92</b>	42	8.7	29 <b>29</b>	11.1% <b>11.1%</b>		
Heterogeneity: Not ap Test for overall effect		= 0.65)							
3.13.5 > 1050 mg									
Brogly 2008	26	22	22	27	17	21	7.7%	-1.00 [-12.72, 10.72	1 +
Fassoulaki 2005	41	69	29	40.5	68	30	2.0%	0.50 [-34.47, 35.47	1
Grosen 2014	23.13	25.71	52	23.03	20.99	52	9.0%	0.10 [-8.92, 9.12	1 +
Lunn 2015a	41	14.5	91	42	8.7	29	11.1%		
Subtotal (95% CI)			194			132	29.8%	-0.80 [-4.49, 2.89]	∳
Heterogeneity: Tau <sup>2</sup> =			3 (P =	1.00); $I^2 = 0\%$					
Test for overall effect	Z = 0.42 (P =	= 0.67)							
Total (95% CI)			599			437	100.0%	-2.96 [-8.43, 2.51]	Ⅰ ♦
Heterogeneity: Tau <sup>2</sup> =	65.60: Chi <sup>2</sup>	= 182 25 0	f = 10	(P < 0.00001	$1^{2} = 95\%$				
neterogeneity. rau =									-100 -50 0 50
Test for overall effect:			- 10	(1 < 0.00001	,,, = 55%				-100 -50 0 50 Favours Gabapentin Favours Contr

# Supplemental Digital Content 12 Forest plot of VAS 24h mobilization from all trials estimates

	Gaba	pentin		Cor	ntrol			Mean Difference	Mean Difference
tudy or Subgroup	Mean [VAS]	SD [VAS]	Total	Mean [VAS]	SD [VAS]	Total	Weight	IV, Random, 95% CI [VAS]	IV, Random, 95% CI [VAS]
.14.1 0-350 mg									
hort 2012	32	11.1	42	30	20	21	4.3%	2.00 [-7.19, 11.19]	+-
roon 2001	23	41	16	37	58	16	1.4%	-14.00 [-48.80, 20.80]	
Subtotal (95% CI)			58			37	5.7%	0.96 [-7.93, 9.84]	◆
Heterogeneity: Tau <sup>2</sup> = Fest for overall effect			1 (P =	0.38); $I^2 = 0\%$					
		0.00)							
3.14.2 351-700 mg	26	2.07	76	20		20	5.00/		
Clarke 2009b	36	3.97	76	29	4	39	5.0%	7.00 [5.46, 8.54]	
Kim 2004	46	26.8	21	34	16	20	3.7%	12.00 [-1.44, 25.44]	_
Menda 2010	51	61	30	54	63	30	1.7%	-3.00 [-34.38, 28.38]	
Metry 2008	23.99	12.46	67	35	11	34	4.8%	-11.01 [-15.76, -6.26]	-
Monks 2015	40	6.7	100	47	8.15	97	5.0%	-7.00 [-9.09, -4.91]	-
Moore 2010	10	5.5	21	18	15	23	4.6%	-8.00 [-14.57, -1.43]	
Paul 2015	94.9	29.8	48	94.4	30.8	54	3.9%	0.50 [-11.27, 12.27]	+
Short 2012a	37	10.4	42	30	20	21	4.3%	7.00 [-2.11, 16.11]	
Srivastava 2010	30	2.5	60	46	2.5	60	5.1%	-16.00 [-16.89, -15.11]	•
Subtotal (95% CI)			465			378	38.2%	-2.50 [-11.38, 6.37]	+
Heterogeneity: Tau <sup>2</sup> = Test for overall effect			df = 8	(P < 0.00001);	; I <sup>2</sup> = 99%				
		0.36)							
3.14.4 701-1050 mg									
unn 2015	41	14.5	92	42	8.7	29	4.9%	-1.00 [-5.34, 3.34]	+
Prabhakar 2007	54.5	10.1	10	66.5	16.3	10	3.9%	-12.00 [-23.88, -0.12]	
	54.5	10.1		00.5	10.5				•
Subtotal (95% CI)			102			39	8.8%	-5.05 [-15.45, 5.35]	•
Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = Test for overall effect	= 39.67; Chi <sup>2</sup> =	2.90, df =	102						•
Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = Test for overall effect 3.14.5 > 1050 mg	= 39.67; Chi <sup>2</sup> = : Z = 0.95 (P =	2.90, df = 0.34)	<b>102</b> = 1 (P =	0.09); I <sup>2</sup> = 66	%	39	8.8%	-5.05 [-15.45, 5.35]	•
Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = Test for overall effect 3.14.5 > 1050 mg Al-Mujadi 2005	= 39.67; Chi <sup>2</sup> = : Z = 0.95 (P = 23	2.90, df = 0.34) 12	<b>102</b> = 1 (P = 35	0.09); I <sup>2</sup> = 66	%	<b>39</b> 37	<b>8.8%</b> 4.8%	- <b>5.05</b> [- <b>15.45</b> , <b>5.35</b> ] -12.00 [-17.33, -6.67]	-
Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = Fest for overall effect 3.14.5 > 1050 mg Al-Mujadi 2005 Brogly 2008	= 39.67; Chi <sup>2</sup> = : Z = 0.95 (P = 23 26	2.90, df = 0.34) 12 22	102 = 1 (P = 35 22	0.09); I <sup>2</sup> = 66 35 27	% 11 17	39 37 21	<b>8.8%</b> 4.8% 3.9%	-5.05 [-15.45, 5.35] -12.00 [-17.33, -6.67] -1.00 [-12.72, 10.72]	<b>●</b> 
Subtotal (95% Cl) Heterogeneity: Tau <sup>2</sup> = Test for overall effect 3.14.5 > 1050 mg Al-Mujadi 2005 Brogly 2008 Dierking 2003	= 39.67; Chi <sup>2</sup> = : Z = 0.95 (P = 23 26 37.48	2.90, df = 0.34) 12 22 27.03	102 = 1 (P = 35 22 40	0.09); I <sup>2</sup> = 66 35 27 34.12	11 17 20.96	39 37 21 40	<b>8.8%</b> 4.8% 3.9% 4.1%	- <b>5.05</b> [- <b>15.45</b> , <b>5.35</b> ] -12.00 [-17.33, -6.67]	• 
Subtotal (95% Cl) Heterogeneity: Tau <sup>2</sup> = Test for overall effect 3.14.5 > 1050 mg Al-Mujadi 2005 Brogly 2008 Dierking 2003 Durmus 2007	= 39.67; Chi <sup>2</sup> = : Z = 0.95 (P = 23 26 37.48 51	2.90, df = 0.34) 12 22 27.03 68	102 = 1 (P = 35 22 40 25	0.09); I <sup>2</sup> = 66 35 27 34.12 68	11 17 20.96 79	39 37 21 40 25	<b>8.8%</b> 4.8% 3.9% 4.1% 1.1%	-5.05 [-15.45, 5.35] -12.00 [-17.33, -6.67] -1.00 [-12.72, 10.72]	
Subtotal (95% Cl) Heterogeneity: Tau <sup>2</sup> = Test for overall effect 3.14.5 > 1050 mg Al-Mujadi 2005 Brogly 2008 Dierking 2003	= 39.67; Chi <sup>2</sup> = : Z = 0.95 (P = 23 26 37.48	2.90, df = 0.34) 12 22 27.03 68 31	102 = 1 (P = 35 22 40 25 25	0.09); I <sup>2</sup> = 66 35 27 34.12	11 17 20.96	39 37 21 40 25 25	<b>8.8%</b> 4.8% 3.9% 4.1%	-5.05 [-15.45, 5.35] -12.00 [-17.33, -6.67] -1.00 [-12.72, 10.72] 3.36 [-7.24, 13.96]	
Subtotal (95% Cl) Heterogeneity: Tau <sup>2</sup> = Test for overall effect 3.14.5 > 1050 mg Al-Mujadi 2005 Brogly 2008 Dierking 2003 Durmus 2007	= 39.67; Chi <sup>2</sup> = : Z = 0.95 (P = 23 26 37.48 51	2.90, df = 0.34) 12 22 27.03 68	102 = 1 (P = 35 22 40 25	0.09); I <sup>2</sup> = 66 35 27 34.12 68	11 17 20.96 79	39 37 21 40 25	<b>8.8%</b> 4.8% 3.9% 4.1% 1.1%	-5.05 [-15.45, 5.35] -12.00 [-17.33, -6.67] -1.00 [-12.72, 10.72] 3.36 [-7.24, 13.96] -17.00 [-57.86, 23.86]	
Subtotal (95% Cl) Heterogeneity: Tau <sup>2</sup> = Test for overall effect 3.14.5 > 1050 mg Al-Mujadi 2005 Brogly 2008 Dierking 2003 Durmus 2007 Fassoulaki 2002	= 39.67; Chi <sup>2</sup> = : Z = 0.95 (P = 23 26 37.48 51 20	2.90, df = 0.34) 12 22 27.03 68 31	102 = 1 (P = 35 22 40 25 25	0.09); l <sup>2</sup> = 66 35 27 34.12 68 31	11 17 20.96 79 54	39 37 21 40 25 25	<b>8.8%</b> 4.8% 3.9% 4.1% 1.1% 2.3%	-5.05 [-15.45, 5.35] -12.00 [-17.33, -6.67] -1.00 [-12.72, 10.72] 3.36 [-7.24, 13.96] -17.00 [-57.86, 23.86] -11.00 [-35.41, 13.41]	
Subtotal (95% Cl) Heterogeneity: Tau <sup>2</sup> = Test for overall effect 3.14.5 > 1050 mg Al-Mujadi 2005 Brogly 2008 Dierking 2003 Durmus 2007 Fassoulaki 2002 Fassoulaki 2005	= 39.67; Chi <sup>2</sup> = : Z = 0.95 (P = 23 26 37.48 51 20 41	2.90, df = 0.34) 12 22 27.03 68 31 69	102 = 1 (P = 35 22 40 25 25 29	$\begin{array}{c} 0.09); \  ^2 = 66\\ 35\\ 27\\ 34.12\\ 68\\ 31\\ 40.5 \end{array}$	11 17 20.96 79 54 68	39 37 21 40 25 25 30	<b>8.8%</b> 4.8% 3.9% 4.1% 1.1% 2.3% 1.4%	-5.05 [-15.45, 5.35] -12.00 [-17.33, -6.67] -1.00 [-12.72, 10.72] 3.36 [-7.24, 13.96] -17.00 [-35.41, 13.41] 0.50 [-34.47, 35.47]	
Subtotal (95% Cl) Heterogeneity: Tau <sup>2</sup> = Test for overall effect 3.14.5 > 1050 mg Al-Mujadi 2005 Brogly 2008 Dierking 2003 Durmus 2007 Fassoulaki 2002 Fassoulaki 2005 Grosen 2014	= 39.67; Chi <sup>2</sup> = : Z = 0.95 (P = 23 26 37.48 51 20 41 23.13	2.90, df 0.34) 12 22 27.03 68 31 69 25.71	102 = 1 (P = 35 22 40 25 25 29 52	0.09); l <sup>2</sup> = 66 35 27 34.12 68 31 40.5 23.03	11 17 20.96 79 54 68 20.99	39 37 21 40 25 25 30 52	4.8% 3.9% 4.1% 1.1% 2.3% 1.4% 4.3%	-5.05 [-15.45, 5.35] -12.00 [-17.33, -6.67] -1.00 [-12.72, 10.72] 3.36 [-7.24, 13.96] -17.00 [-57.86, 23.86] -11.00 [-35.41, 13.41] 0.50 [-34.47, 35.47] 0.10 [-8.92, 9.12]	
Subtotal (95% Cl) Heterogeneity: Tau <sup>2</sup> = Test for overall effect 3.14.5 > 1050 mg Al-Mujadi 2005 Brogly 2008 Dierking 2003 Dierking 2003 Dierking 2007 Fassoulaki 2002 Fassoulaki 2005 Grosen 2014 Hout 2007	= 39.67; Chi <sup>2</sup> = : Z = 0.95 (P = 23 26 37.48 51 20 41 23.13 30	2.90, df 0.34) 12 22 27.03 68 31 69 25.71 74.1	102 = 1 (P = 35 22 40 25 25 29 52 23	0.09); l <sup>2</sup> = 66 35 27 34.12 68 31 40.5 23.03 15	11 17 20.96 79 54 68 20.99 59.3	39 37 21 40 25 25 30 52 28	<ul> <li>8.8%</li> <li>4.8%</li> <li>3.9%</li> <li>4.1%</li> <li>2.3%</li> <li>1.4%</li> <li>4.3%</li> <li>1.3%</li> </ul>	-5.05 [-15.45, 5.35] -12.00 [-17.33, -6.67] -1.00 [-12.72, 10.72] 3.36 [-7.24, 13.96] -17.00 [-57.86, 23.86] -11.00 [-35.41, 13.41] 0.50 [-34.47, 35.47] 0.10 [-8.92, 9.12] 15.00 [-22.41, 52.41] -1.00 [-5.35, 3.35]	
Subtotal (95% Cl) Heterogeneity: Tau <sup>2</sup> = Test for overall effect 3.14.5 > 1050 mg Al-Mujadi 2005 3rogly 2008 Dierking 2003 Durmus 2007 Fassoulaki 2002 Grosen 2014 Hout 2007 Lunn 2015a Dmran 2006	= 39.67; Chi <sup>2</sup> = : Z = 0.95 (P = 23 26 37.48 51 20 41 23.13 30 41 54	2.90, df = 0.34) 12 22 27.03 68 31 69 25.71 7.41 14.5 38.66	102 = 1 (P = 35 22 40 25 25 29 52 23 91 25	0.09); l <sup>2</sup> = 66 35 27 34.12 68 31 40.5 23.03 15 42 76	% 11 17 20.96 79 54 68 20.99 59.3 8.7 38.66	39 37 21 40 25 25 30 52 28 29 25	8.8% 4.8% 3.9% 4.1% 2.3% 1.4% 4.3% 1.3% 4.9% 2.6%	-5.05 [-15.45, 5.35] -12.00 [-17.33, -6.67] -1.00 [-12.72, 10.72] 3.36 [-7.24, 13.96] -17.00 [-57.86, 23.86] -11.00 [-35.41, 13.41] 0.50 [-34.47, 35.47] 0.10 [-8.92, 9.12] 15.00 [-22.41, 52.41] -1.00 [-5.35, 3.35] -22.00 [-43.43, -0.57]	
Subtotal (95% Cl) Heterogeneity: Tau <sup>2</sup> = Test for overall effect 3.14.5 > 1050 mg Al-Mujadi 2005 Brogly 2008 Dierking 2003 Durmus 2007 Fassoulaki 2002 Grosen 2014 Hout 2007 Lunn 2015 Durnan 2006 Rapchuk 2010	= 39.67; Chi <sup>2</sup> = : Z = 0.95 (P = 23 26 37.48 51 20 41 23.13 30 41 54 45	2.90, df = 0.34) 12 22 27.03 68 31 69 25.71 74.1 14.5 38.66 65	102 = 1 (P = 35 22 40 25 25 29 52 23 91 25 27	$\begin{array}{l} 0.09); \ l^2 = 66\\ 35\\ 27\\ 34.12\\ 68\\ 31\\ 40.5\\ 23.03\\ 15\\ 42\\ 76\\ 45\end{array}$	% 11 17 20.96 79 54 68 20.99 59.3 8.7 38.66 63	37 21 40 25 25 30 52 28 29 25 27	8.8% 4.8% 3.9% 4.1% 1.1% 2.3% 1.4% 4.3% 4.3% 4.9% 2.6% 1.5%	-5.05 [-15.45, 5.35] -12.00 [-17.33, -6.67] -1.00 [-12.72, 10.72] 3.36 [-7.24, 13.96] -17.00 [-57.86, 23.86] -11.00 [-35.41, 13.41] 0.50 [-34.47, 35.47] 0.10 [-8.92, 9.12] 15.00 [-22.41, 52.41] -1.00 [-5.35, 3.35] -22.00 [-43.43, -0.57] 0.00 [-34.14, 34.14]	
Subtotal (95% Cl) Heterogeneity: Tau <sup>2</sup> = Test for overall effect 3.14.5 > 1050 mg Al-Mujadi 2005 Brogly 2008 Dierking 2003 Durmus 2007 Fassoulaki 2002 Fassoulaki 2002 Grosen 2014 Hout 2007 Lunn 2015a Dmran 2016 Rapchuk 2010 Sen 2009a	= 39.67; Chi <sup>2</sup> = : Z = 0.95 (P = 23 26 37.48 51 20 41 23.13 30 41 54 45 9	2.90, df = 0.34) 12 27.03 68 31 69 25.71 74.1 14.5 38.66 65 4	102 = 1 (P = 35 22 40 25 25 29 52 23 91 25 27 20	0.09); l <sup>2</sup> = 66 35 27 34.12 68 31 40.5 23.03 15 42 76 45 29	% 11 17 20.96 79 54 68 20.99 59.3 8.7 38.66 63 30	37 21 40 25 30 52 28 29 25 27 20	8.8% 4.8% 3.9% 4.1% 1.1% 2.3% 1.4% 4.3% 1.3% 4.9% 2.66% 1.5% 3.7%	-5.05 [-15.45, 5.35] -12.00 [-17.33, -6.67] -1.00 [-12.72, 10.72] 3.36 [-7.24, 13.96] -17.00 [-57.86, 23.86] -11.00 [-35.41, 13.41] 0.50 [-34.47, 35.47] 0.10 [-8.92, 9.12] 15.00 [-22.41, 52.41] -1.00 [-5.35, 3.35] -22.00 [-34.14, 34.14] -20.00 [-34.24, 36, -6.74]	
Subtotal (95% Cl) Heterogeneity: Tau <sup>2</sup> = Test for overall effect 3.14.5 > 1050 mg Al-Mujadi 2005 Brogly 2008 Dierking 2003 Durmus 2007 Fassoulaki 2002 Fassoulaki 2002 Grosen 2014 Hout 2007 Junn 2015a Dmran 2006 Gapchuk 2010 Sen 2009a Sen 2009b	= 39.67; Chi <sup>2</sup> = : Z = 0.95 (P = 23 26 37.48 51 20 41 23.13 30 41 54 45 9 2	2.90, df = 0.34) 12 27.03 68 31 69 25.71 74.1 14.5 38.66 65 4 3	102 = 1 (P = 35 22 40 25 25 29 52 23 91 25 27 20 30	0.09); l <sup>2</sup> = 66 35 27 34.12 68 31 40.5 23.03 15 42 76 45 29 15	% 11 17 20.96 79 54 68 20.99 59.3 8.7 38.66 63 30 15	39 37 21 40 25 30 52 28 29 25 27 20 29	8.8% 4.8% 3.9% 4.1% 2.3% 1.4% 4.3% 1.3% 2.6% 1.5% 3.7% 4.8%	-5.05 [-15.45, 5.35] -12.00 [-17.33, -6.67] -1.00 [-12.72, 10.72] 3.36 [-7.24, 13.96] -11.00 [-35.41, 13.41] 0.50 [-34.47, 35.47] 0.10 [-8.92, 9.12] 15.00 [-22.41, 52.41] -1.00 [-5.35, 3.35] -22.00 [-43.43, -0.57] 0.00 [-33.26, -6.74] -13.00 [-18.56, -7.44]	
Subtotal (95% Cl) Heterogeneity: Tau <sup>2</sup> = Test for overall effect 3.14.5 > 1050 mg Al-Mujadi 2005 Brogly 2008 Dierking 2003 Durmus 2007 Fassoulaki 2002 Grosen 2014 Hout 2007 Lunn 2015a Dmran 2006 Rapchuk 2010 Sen 2009b Furan 2003a	= 39.67; Chi <sup>2</sup> = : Z = 0.95 (P = 23 26 37.48 51 20 41 23.13 30 41 54 45 9 2 15.4	2.90, df = 0.34) 12 22 27.03 68 31 69 25.71 74.1 14.5 38.66 65 4 3 3 7	102 = 1 (P = 35 22 40 25 29 52 23 91 25 27 20 30 25	0.09); l <sup>2</sup> = 66 35 27 34.12 68 31 40.5 23.03 15 42 76 45 29 15 16	% 111 17 20.96 79 54 68 20.99 59.3 8.77 38.66 63 30 15 7	39 37 21 40 25 25 30 52 28 29 25 27 20 29 25	8.8% 4.8% 3.9% 4.1% 1.1% 2.3% 1.4% 4.3% 1.5% 3.7% 4.8% 4.9%	-5.05 [-15.45, 5.35] -12.00 [-17.33, -6.67] -1.00 [-12.72, 10.72] 3.36 [-7.24, 13.96] -17.00 [-57.86, 23.86] -11.00 [-53.41, 13.41] 0.50 [-34.47, 35.47] 0.10 [-8.92, 9.12] 15.00 [-22.41, 52.41] -1.00 [-5.35, 3.35] -22.00 [-43.43, -0.57] 0.00 [-34.14, 34.14] -20.00 [-33.26, -6.74] -13.00 [-18.56, -7.44] -0.60 [-4.48, 3.28]	
Subtotal (95% Cl) Heterogeneity: Tau <sup>2</sup> = Test for overall effect 3.14.5 > 1050 mg Al-Mujadi 2005 Brogly 2008 Dierking 2003 Durmus 2007 Fassoulaki 2002 Fassoulaki 2002 Fassoulaki 2005 Grosen 2014 Hout 2007 Lunn 2015a Dmran 2006 Kapchuk 2010 Sen 2009a Sen 2009b Furan 2003a Jcak 2011	= 39.67; Chi <sup>2</sup> = : Z = 0.95 (P = 23 26 37.48 51 20 41 23.13 30 41 54 45 9 2	2.90, df = 0.34) 12 27.03 68 31 69 25.71 74.1 14.5 38.66 65 4 3	102 = 1 (P = 35 22 40 25 25 29 52 23 91 25 27 20 30 25 20	0.09); l <sup>2</sup> = 66 35 27 34.12 68 31 40.5 23.03 15 42 76 45 29 15	% 11 17 20.96 79 54 68 20.99 59.3 8.7 38.66 63 30 15	39 37 21 40 25 25 30 52 28 29 25 27 20 29 25 20	8.8% 4.8% 3.9% 4.1% 1.1% 2.3% 1.4% 4.3% 2.6% 1.5% 3.7% 4.8% 4.9% 2.6% 1.7%	$\begin{array}{c} -5.05 \left[-15.45, 5.35\right] \\ \hline \\ -12.00 \left[-17.33, -6.67\right] \\ -1.00 \left[-12.72, 10.72\right] \\ 3.36 \left[-7.24, 13.96\right] \\ -17.00 \left[-57.86, 23.86\right] \\ -11.00 \left[-35.41, 13.41\right] \\ 0.50 \left[-34.47, 35.47\right] \\ 0.10 \left[-8.92, 9.12\right] \\ 15.00 \left[-22.41, 52.41\right] \\ -1.00 \left[-5.35, 3.35\right] \\ -22.00 \left[-43.43, -0.57\right] \\ 0.00 \left[-33.26, -6.74\right] \\ -3.00 \left[-33.26, -6.74\right] \\ -3.00 \left[-44.83, 3.28\right] \\ -14.00 \left[-44.93, 16.93\right] \end{array}$	
Subtotal (95% Cl) Heterogeneity: Tau <sup>2</sup> = Test for overall effect 3.14.5 > 1050 mg Al-Mujadi 2005 3rogly 2008 Dierking 2003 Durmus 2007 Fassoulaki 2002 Grosen 2014 Hout 2007 Lunn 2015a Dirran 2006 Kapchuk 2010 Sen 2009a Sen 2009b Furan 2003a Jcak 2011 Subtotal (95% Cl) Heterogeneity: Tau <sup>2</sup> =	= 39.67; Chi <sup>2</sup> = : Z = 0.95 (P = 23 26 37.48 51 20 41 23.13 30 41 54 45 9 2 15.4 37 = 31.21; Chi <sup>2</sup> =	2.90, df = 0.34) 12 22 27.03 68 31 69 25.71 74.1 14.5 38.66 65 4 3 3. 7 25 36.30, df	102 = 1 (P = 35 22 40 25 25 29 52 29 52 29 52 29 52 20 30 25 20 489	$\begin{array}{l} 0.09); \ l^2 = 66\\ 35\\ 27\\ 34.12\\ 68\\ 31\\ 40.5\\ 23.03\\ 15\\ 42\\ 76\\ 45\\ 29\\ 15\\ 16\\ 51\end{array}$	% 11 17 20.96 79 54 68 20.99 59.3 8.7 38.66 63 30 0 15 7 66	39 37 21 40 25 25 30 52 28 29 25 27 20 29 25	8.8% 4.8% 3.9% 4.1% 1.1% 2.3% 1.4% 4.3% 1.5% 3.7% 4.8% 4.9%	-5.05 [-15.45, 5.35] -12.00 [-17.33, -6.67] -1.00 [-12.72, 10.72] 3.36 [-7.24, 13.96] -17.00 [-57.86, 23.86] -11.00 [-53.41, 13.41] 0.50 [-34.47, 35.47] 0.10 [-8.92, 9.12] 15.00 [-22.41, 52.41] -1.00 [-5.35, 3.35] -22.00 [-43.43, -0.57] 0.00 [-34.14, 34.14] -20.00 [-33.26, -6.74] -13.00 [-18.56, -7.44] -0.60 [-4.48, 3.28]	
Subtotal (95% Cl) Heterogeneity: Tau <sup>2</sup> = Test for overall effect 3.14.5 > 1050 mg Al-Mujadi 2005 Brogly 2008 Dierking 2003 Dierking 2003 Durmus 2007 Fassoulaki 2002 Fassoulaki 2002 Grosen 2014 Hout 2007 Lunn 2015a Dmran 2006 Rapchuk 2010 Sen 2009a Sen 2009b Furan 2005a Jcak 2011 Subtotal (95% Cl)	= 39.67; Chi <sup>2</sup> = : Z = 0.95 (P = 23 26 37.48 51 20 41 23.13 30 41 54 45 9 2 15.4 37 = 31.21; Chi <sup>2</sup> =	2.90, df = 0.34) 12 22 27.03 68 31 69 25.71 74.1 14.5 38.66 65 4 3 3. 7 25 36.30, df	102 = 1 (P = 35 22 40 25 25 29 52 29 52 29 52 29 52 20 30 25 20 489	$\begin{array}{l} 0.09); \ l^2 = 66\\ 35\\ 27\\ 34.12\\ 68\\ 31\\ 40.5\\ 23.03\\ 15\\ 42\\ 76\\ 45\\ 29\\ 15\\ 16\\ 51\end{array}$	% 11 17 20.96 79 54 68 20.99 59.3 8.7 38.66 63 30 0 15 7 66	39 37 21 40 25 25 30 52 28 29 25 27 20 29 25 20	8.8% 4.8% 3.9% 4.1% 1.1% 2.3% 1.4% 4.3% 2.6% 1.5% 3.7% 4.8% 4.9% 2.6% 1.7%	$\begin{array}{c} -5.05 \left[-15.45, 5.35\right] \\ \hline \\ -12.00 \left[-17.33, -6.67\right] \\ -1.00 \left[-12.72, 10.72\right] \\ 3.36 \left[-7.24, 13.96\right] \\ -17.00 \left[-57.86, 23.86\right] \\ -11.00 \left[-35.41, 13.41\right] \\ 0.50 \left[-34.47, 35.47\right] \\ 0.10 \left[-8.92, 9.12\right] \\ 15.00 \left[-22.41, 52.41\right] \\ -1.00 \left[-5.35, 3.35\right] \\ -22.00 \left[-43.43, -0.57\right] \\ 0.00 \left[-33.26, -6.74\right] \\ -3.00 \left[-33.26, -6.74\right] \\ -3.00 \left[-44.83, 3.28\right] \\ -14.00 \left[-44.93, 16.93\right] \end{array}$	
Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = Test for overall effect 3.14.5 > 1050 mg Al-Mujadi 2005 Brogly 2008 Dierking 2003 Durmus 2007 Fassoulaki 2002 Grosen 2014 Hout 2007 Lunn 2015a Dmran 2006 Kapchuk 2010 Sen 2009a Sen 2009b Furan 2003a Jcak 2011 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = Test for overall effect Total (95% CI)	= 39.67; Chi <sup>2</sup> = : Z = 0.95 (P = 23 26 37.48 51 20 41 23.13 30 41 54 45 9 2 15.4 37 = 31.21; Chi <sup>2</sup> = : Z = 2.60 (P =	2.90, df = 0.34) 12 22 27.03 68 31 69 25.71 74.1 14.5 38.66 65 4 3 36.60 65 4 3 7 25 36.30, df 0.009)	102 = 1 (P = 35 22 40 25 25 23 91 25 27 20 30 25 27 20 30 25 = 14 (I = 1114	$\begin{array}{c} 0.09); \ l^2 = 66\\ 35\\ 27\\ 34.12\\ 68\\ 31\\ 40.5\\ 23.03\\ 15\\ 42\\ 76\\ 45\\ 29\\ 15\\ 16\\ 51\\ P = 0.0009); \ l^2\end{array}$	% 11 17 20.96 79 54 68 20.99 59.3 8.7 38.66 63 300 15 7 66 = 61%	39 37 21 40 25 25 30 25 22 8 29 25 27 20 29 25 20 29 25 20 433 887	8.8% 4.8% 3.9% 4.1% 1.1% 2.3% 1.4% 4.3% 2.6% 1.5% 3.7% 4.8% 4.9% 2.6% 1.7%	$\begin{array}{c} -5.05 \left[-15.45, 5.35\right] \\ \hline \\ -12.00 \left[-17.33, -6.67\right] \\ -1.00 \left[-12.72, 10.72\right] \\ 3.36 \left[-7.24, 13.96\right] \\ -17.00 \left[-57.86, 23.86\right] \\ -11.00 \left[-35.41, 13.41\right] \\ 0.50 \left[-34.47, 35.47\right] \\ 0.10 \left[-8.92, 9.12\right] \\ 15.00 \left[-22.41, 52.41\right] \\ -1.00 \left[-5.35, 3.35\right] \\ -22.00 \left[-43.43, -0.57\right] \\ 0.00 \left[-33.26, -6.74\right] \\ -3.00 \left[-33.26, -6.74\right] \\ -3.00 \left[-44.83, 3.28\right] \\ -14.00 \left[-44.93, 16.93\right] \end{array}$	
Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = Fest for overall effect 3.14.5 > 1050 mg Al-Mujadi 2005 Brogly 2008 Dierking 2003 Durmus 2007 Fassoulaki 2002 Fassoulaki 2002 Fassoulaki 2005 Grosen 2014 Hout 2007 Lunn 2015a Dmran 2006 Kapchuk 2010 Sen 2009a Sen 2009a Sen 2009a Sen 2009a Sen 2009a Sen 2003a Jcak 2011 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = Fest for overall effect	= 39.67; Chi <sup>2</sup> = = 23 26 37.48 51 20 41 23.13 30 41 23.13 30 41 54 45 9 2 15.4 37 = 31.21; Chi <sup>2</sup> = = 2.60 (P =	2.90, df = 0.34) 12 22 27.03 68 31 69 25.71 74.1 14.55 38.66 65 4 3 7 25 36.30, df 0.009) = 748.24,	102 = 1 (P = 35 22 40 25 25 23 91 25 27 20 30 25 27 20 30 25 = 14 (I = 1114	$\begin{array}{c} 0.09); \ l^2 = 66\\ 35\\ 27\\ 34.12\\ 68\\ 31\\ 40.5\\ 23.03\\ 15\\ 42\\ 76\\ 45\\ 29\\ 15\\ 16\\ 51\\ P = 0.0009); \ l^2\end{array}$	% 11 17 20.96 79 54 68 20.99 59.3 8.7 38.66 63 300 15 7 66 = 61%	39 37 21 40 25 25 30 25 22 8 29 25 27 20 29 25 20 29 25 20 433 887	4.8% 3.9% 4.1% 1.1% 2.3% 1.4% 4.3% 1.5% 3.7% 4.8% 4.9% 1.7% 47.3%	-5.05 [-15.45, 5.35] -12.00 [-17.33, -6.67] -1.00 [-12.72, 10.72] 3.36 [-7.24, 13.96] -17.00 [-57.86, 23.86] -11.00 [-35.41, 13.41] 0.50 [-34.47, 35.47] 0.10 [-8.92, 9.12] 15.00 [-22.41, 52.41] -1.00 [-5.35, 3.35] -22.00 [-43.43, -0.57] 0.00 [-44.93, 16.93] -5.86 [-10.28, -1.45] -4.59 [-9.51, 0.34]	

# Supplemental Digital Content 13 Forest plot of nausea from trials with low risk of bias

	Gabape		Conti			Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	M-H, Random, 95% CI
3.15.2 0-350 mg							
Subtotal (95% CI)		0		0		Not estimable	
Total events	0		0				
Heterogeneity: Not ap	•						
Test for overall effect:	Not appl	icable					
3.15.3 351-700 mg							
Misra 2013	4	36	13	37	9.1%	0.32 [0.11, 0.88]	
Moore 2010	12	21	8	23	16.7%	1.64 [0.84, 3.21]	+
Paul 2013	33	52	40	49	36.9%	0.78 [0.61, 0.99]	-
Subtotal (95% CI)		109		109	62.8%	0.81 [0.40, 1.61]	
Total events	49		61				
Heterogeneity: Tau <sup>2</sup> =	0.27; Ch	$i^2 = 7.6$	58, df =	2 (P = 0)	.02); I <sup>2</sup> =	74%	
Test for overall effect:	Z = 0.61	(P = 0)	.54)				
3.15.4 701-1050 mg							
Subtotal (95% CI)		0		0		Not estimable	
Total events	0		0				
Heterogeneity: Not ap	plicable						
Test for overall effect:	Not appl	icable					
3.15.5 > 1050 mg							
Bartholdy 2006	3	38	4	38	5.2%	0.75 [0.18, 3.13]	
Grosen 2014	25	52	37	52	32.0%	0.68 [0.49, 0.94]	
Subtotal (95% Cl)		90		90	37.2%	0.68 [0.49, 0.94]	◆
Total events	28		41				
Heterogeneity: Tau <sup>2</sup> =	0.00; Ch	$i^2 = 0.0$	02, df =	1 (P = 0)	.89); I <sup>2</sup> =	0%	
Test for overall effect:	Z = 2.35	(P = 0)	.02)				
Total (95% CI)		199		199	100.0%	0.77 [0.55, 1.09]	•
Total events	77		102				
Heterogeneity: Tau <sup>2</sup> =	0.07; Ch	$i^2 = 8.4$	47, df = -	4 (P = 0)	.08); I <sup>2</sup> =	53%	0.01 0.1 1 10
Test for overall effect:	Z = 1.45	(P = 0)	.15)				0.01 0.1 1 10 Favours Gabapentin Favours Co
Test for subgroup diff		CL 12		1 (5	0.00	0.00	ravours Gabapenum ravours Co

# Supplemental Digital Content 14 Forest plot of nausea from all trials estimates

	Gabaper		Contro			Risk Ratio	Risk Ratio
Study or Subgroup	Events	rotal	Events	fotal	Weight	M-H, Random, 95% CI	M-H, Random, 95% CI
3.16.1 0-350 mg							
Bang 2009	6	23	8	23	1.7%	0.75 [0.31, 1.82]	-+-
Behdad 2012	5	30	5	31	1.1%	1.03 [0.33, 3.21]	-+
Clarke 2014	26	88	26	77	5.2%	0.88 [0.56, 1.37]	-+
Ghafari 2009	5	33	7	33	1.2%	0.71 [0.25, 2.02]	
Khurana 2013	2	30	0	30	0.2%	5.00 [0.25, 99.95]	
Panday 2004c	5	28	4	28	0.9%	1.25 [0.37, 4.17]	<del></del>
Sekhavet 2009	32	49	37	49	10.2%	0.86 [0.67, 1.12]	-+
Verma 2008	5	25	4	25	1.0%	1.25 [0.38, 4.12]	<del></del>
Yoon 2001	7	16	9	15	2.6%	0.73 [0.36, 1.46]	-+
Subtotal (95% CI)		322		311	24.1%	0.87 [0.72, 1.06]	•
Total events	93		100				
Heterogeneity: Tau <sup>2</sup> = 0. Test for overall effect: Z	.00; Chi <sup>2</sup> =		df = 8 (P	= 0.9	5); I <sup>2</sup> = 09	6	
3.16.2 351-700 mg							
Ajori 2011	8	69	19	69	2.2%	0.42 [0.20, 0.90]	
Bashir 2009	1	50	1	50	0.2%	1.00 [0.06, 15.55]	
Clarke 2009b	24	76	14	38	4.0%	0.86 [0.50, 1.46]	-+
Grover 2009	12	15	6	21	2.4%	2.80 [1.36, 5.76]	
Kavitha 2013	3	28	4	28	0.7%	0.75 [0.18, 3.05]	
Kim 2004	8	21	8	20	2.2%	0.95 [0.44, 2.05]	_ <b>_</b>
Koc 2007	1	20	1	20	0.2%	1.00 [0.07, 14.90]	
Menda 2010	9	30	18	30	3.2%	0.50 [0.27, 0.93]	
Misra 2013	4	36	13	37	1.3%	0.32 [0.11, 0.88]	
Moore 2010	12	21	8	23	2.8%	1.64 [0.84, 3.21]	
	6	40	8 3	23			
Panday 2005					0.8%	1.00 [0.28, 3.59]	
Paul 2013	33	52	40	49	10.8%	0.78 [0.61, 0.99]	
Sava 2009	7	25	11	25	2.2%	0.64 [0.30, 1.37]	
Siddiqui 2013	17	36	17	36	4.6%	1.00 [0.61, 1.63]	
Zaldivar Ramirez 2011	4	18	15	16	1.7%	0.24 [0.10, 0.57]	
<b>Subtotal (95% CI)</b> Total events	149	537	178	482	39.3%	0.78 [0.58, 1.05]	•
Heterogeneity: Tau <sup>2</sup> = 0. Test for overall effect: Z				(12 = 0	.002); I <sup>z</sup>	= >8%	
3.16.3 701-1050 mg	-	25	10	26	2.24	0 61 [0 30 1 30]	
Deniz 2012	7	25	12	26	2.2%	0.61 [0.29, 1.29]	
Pakravan 2012 Padhakrishnan 2005	3	50	0	50	0.2%	7.00 [0.37, 132.10]	
Radhakrishnan 2005	6	30	6	30	1.3%	1.00 [0.36, 2.75]	
Palandran 2014	A	20		20	0.00/		
	4	30 135	4	30 136	0.8% 4.6%	1.00 [0.28, 3.63]	
Subtotal (95% CI)		30 135		30 136	0.8% <b>4.6%</b>		•
<b>Subtotal (95% CI)</b> Total events Heterogeneity: Tau <sup>2</sup> = 0.	20 .01; Chi <sup>2</sup> =	135 3.07,	22 df = 3 (P	136	4.6%	1.00 [0.28, 3.63] 0.83 [0.48, 1.44]	•
Subtotal (95% CI) Total events Heterogeneity: Tau <sup>2</sup> = 0. Test for overall effect: Z 3.16.4 > 1050 mg	20 .01; Chi <sup>2</sup> = = 0.65 (P	135 3.07, = 0.51)	22 df = 3 (P	136 = 0.3	<b>4.6%</b> 8); I <sup>2</sup> = 29	1.00 [0.28, 3.63] 0.83 [0.48, 1.44]	•
Subtotal (95% CI) Total events Heterogeneity: Tau <sup>2</sup> = 0. Test for overall effect: Z 3.16.4 > 1050 mg Bartholdy 2006	20 .01; Chi <sup>2</sup> = = 0.65 (P	135 3.07, = 0.51) 38	22 df = 3 (P ) 4	136 = 0.3 38	<b>4.6%</b> 8); I <sup>2</sup> = 29 0.7%	1.00 [0.28, 3.63] 0.83 [0.48, 1.44] 6 0.75 [0.18, 3.13]	
Subtotal (95% CI) Total events Heterogeneity: Tau <sup>2</sup> = 0. Test for overall effect: Z 3.16.4 > 1050 mg Bartholdy 2006 Dierking 2003	20 .01; Chi <sup>2</sup> = = 0.65 (P	135 3.07, = 0.51 38 39	22 df = 3 (P ) 4 11	136 = 0.3 38 32	<b>4.6%</b> 8); I <sup>2</sup> = 29 0.7% 2.8%	1.00 [0.28, 3.63] 0.83 [0.48, 1.44] 6 0.75 [0.18, 3.13] 0.90 [0.46, 1.75]	
Subtotal (95% CI) Total events Heterogeneity: Tau <sup>2</sup> = 0. Test for overall effect: Z 3.16.4 > 1050 mg Bartholdy 2006 Dierking 2003 Doha 2010	20 .01; Chi <sup>2</sup> = = 0.65 (P 3 12 2	135 3.07, = 0.51 38 39 30	22 df = 3 (P ) 4 11 4	136 = 0.3 38 32 29	<b>4.6%</b> 8); I <sup>2</sup> = 29 0.7% 2.8% 0.5%	1.00 [0.28, 3.63] 0.83 [0.48, 1.44] 6 0.75 [0.18, 3.13] 0.90 [0.46, 1.75] 0.48 [0.10, 2.44]	
Subtotal (95% CI) Total events Heterogeneity: Tau <sup>2</sup> = 0. Test for overall effect: Z 3.16.4 > 1050 mg Bartholdy 2006 Dierking 2003 Doha 2010 Durmus 2007	20 .01; Chi <sup>2</sup> = = 0.65 (P 3 12 2 7	135 3.07, = 0.51) 38 39 30 25	22 df = 3 (P ) 4 11 4 9	136 = 0.3 38 32 29 25	<b>4.6%</b> 8); I <sup>2</sup> = 29 0.7% 2.8% 0.5% 1.9%	1.00 [0.28, 3.63] 0.83 [0.48, 1.44] 6 0.75 [0.18, 3.13] 0.90 [0.46, 1.75] 0.48 [0.10, 2.44] 0.78 [0.34, 1.76]	
Subtotal (95% CI) Total events Heterogeneity: Tau <sup>2</sup> = 0. Test for overall effect: Z 3.16.4 > 1050 mg Bartholdy 2006 Dierking 2003 Doha 2010 Durmus 2007 Fassoulaki 2006	20 .01; Chi <sup>2</sup> = = 0.65 (P 3 12 2	135 3.07, = 0.51) 38 39 30 25 27	22 df = 3 (P ) 4 11 4 9 5	136 = 0.3 38 32 29 25 24	<b>4.6%</b> 8); I <sup>2</sup> = 29 0.7% 2.8% 0.5% 1.9% 0.3%	1.00 [0.28, 3.63] 0.83 [0.48, 1.44] 6 0.75 [0.18, 3.13] 0.90 [0.46, 1.75] 0.48 [0.10, 2.44] 0.78 [0.34, 1.76] 0.18 [0.02, 1.42]	
Subtotal (95% CI) Total events Heterogeneity: Tau <sup>2</sup> = 0. Test for overall effect: Z 3.16.4 > 1050 mg Battholdy 2006 Dierking 2003 Doha 2010 Durmus 2007 Fassoulaki 2006 Gilron 2004	20 .01; Chi <sup>2</sup> = = 0.65 (P 3 12 2 7 1 4	135 3.07, = 0.51) 38 39 30 25 27 20	22 df = 3 (P ) 4 11 4 9	136 = 0.3 38 32 29 25	<b>4.6%</b> 8); I <sup>2</sup> = 29 0.7% 2.8% 0.5% 1.9%	1.00 [0.28, 3.63] 0.83 [0.48, 1.44] 6 0.75 [0.18, 3.13] 0.90 [0.46, 1.75] 0.48 [0.10, 2.44] 0.78 [0.34, 1.76]	
Subtotal (95% CI) Total events Heterogeneity: Tau <sup>2</sup> = 0. Test for overall effect: Z 3.16.4 > 1050 mg Battholdy 2006 Dierking 2003 Doha 2010 Durmus 2007 Fassoulaki 2006 Gilron 2004	20 .01; Chi <sup>2</sup> = = 0.65 (P 3 12 2 7 1	135 3.07, = 0.51 38 39 30 25 27 20 52	22 df = 3 (P ) 4 11 4 9 5	136 = 0.3 38 32 29 25 24	<b>4.6%</b> 8); I <sup>2</sup> = 29 0.7% 2.8% 0.5% 1.9% 0.3%	1.00 [0.28, 3.63] 0.83 [0.48, 1.44] 6 0.75 [0.18, 3.13] 0.90 [0.46, 1.75] 0.48 [0.10, 2.44] 0.78 [0.34, 1.76] 0.18 [0.02, 1.42]	
Subtotal (95% CI) Total events Heterogeneity: Tau <sup>2</sup> = 0. Test for overall effect: Z 3.16.4 > 1050 mg Bartholdy 2006 Dierking 2003 Doha 2010 Durmus 2007 Fassoulaki 2006 Gilron 2004 Grosen 2014	20 .01; Chi <sup>2</sup> = = 0.65 (P 3 12 2 7 1 4	135 3.07, = 0.51) 38 39 30 25 27 20	22 df = 3 (P ) 4 11 4 9 5 12	136 = 0.3 38 32 29 25 24 22	4.6% 8); I <sup>2</sup> = 29 0.7% 2.8% 0.5% 1.9% 0.3% 1.5%	1.00 [0.28, 3.63] 0.83 [0.48, 1.44] 6 0.75 [0.18, 3.13] 0.90 [0.46, 1.75] 0.48 [0.10, 2.44] 0.78 [0.34, 1.76] 0.18 [0.02, 1.42] 0.37 [0.14, 0.95]	
Subtotal (95% CI) Total events Heterogeneity: Tau <sup>2</sup> = 0. Test for overall effect: Z 3.16.4 > 1050 mg Bartholdy 2006 Dierking 2003 Doha 2010 Durmus 2007 Fassoulaki 2006 Gilron 2004 Grosen 2014 lajeda 2014	20 .01; Chi <sup>2</sup> = = 0.65 (P 3 12 2 7 1 4 25	135 3.07, = 0.51 38 39 30 25 27 20 52	22 df = 3 (P ) 4 11 4 9 5 12 37	136 = 0.3 38 32 29 25 24 22 52	4.6% 8); I <sup>2</sup> = 29 0.7% 2.8% 0.5% 1.9% 0.3% 1.5% 7.9%	1.00 [0.28, 3.63] 0.83 [0.48, 1.44] 6 0.75 [0.18, 3.13] 0.90 [0.46, 1.75] 0.48 [0.10, 2.44] 0.78 [0.34, 1.76] 0.18 [0.02, 1.42] 0.37 [0.14, 0.95] 0.68 [0.49, 0.94]	
Subtotal (95% CI) Total events Heterogeneity: Tau <sup>2</sup> = 0. Test for overall effect: Z 3.16.4 > 1050 mg Bartholdy 2006 Dierking 2003 Doha 2010 Durmus 2007 Fassoulaki 2006 Gillron 2004 Grosen 2014 Ajeda 2014 Kosucu 2013	20 .01; Chi <sup>2</sup> = = 0.65 (P 3 12 2 7 1 4 25 0	135 3.07, = 0.51 38 39 30 25 27 20 52 25	22 df = 3 (P ) 4 11 4 9 5 12 37 3	136 = 0.3 38 32 29 25 24 22 52 25	4.6% 8); I <sup>2</sup> = 29 0.7% 2.8% 0.5% 1.9% 0.3% 7.9% 0.2%	1.00 [0.28, 3.63] 0.83 [0.48, 1.44] 6 0.75 [0.18, 3.13] 0.90 [0.46, 1.75] 0.48 [0.10, 2.44] 0.78 [0.34, 1.76] 0.18 [0.02, 1.42] 0.37 [0.14, 0.95] 0.68 [0.49, 0.94] 0.14 [0.01, 2.63] 0.53 [0.11, 2.70]	
Subtotal (95% CI) Total events Heterogeneity: Tau <sup>2</sup> = 0. Test for overall effect: Z 3.16.4 > 1050 mg Bartholdy 2006 Dierking 2003 Doha 2010 Durmus 2007 Fassoulaki 2006 Gilron 2004 Grosen 2014 ajeda 2014 Sosucu 2013 Mikkelsen 2006	20 .01; Chi <sup>2</sup> = = 0.65 (P 3 12 2 7 1 4 4 25 0 2	135 3.07, = 0.51) 38 39 30 25 27 20 52 25 29	22 df = 3 (P ) 4 11 4 9 5 12 37 3 4	136 = 0.3 38 32 29 25 24 22 52 25 31	4.6% 8); l <sup>2</sup> = 29 0.7% 2.8% 0.5% 1.9% 0.3% 1.5% 7.9% 0.2% 0.5%	1.00 [0.28, 3.63] 0.83 [0.48, 1.44] 0.83 [0.48, 1.44] 0.90 [0.46, 1.75] 0.48 [0.10, 2.44] 0.78 [0.34, 1.76] 0.18 [0.02, 1.42] 0.37 [0.14, 0.95] 0.68 [0.49, 0.94] 0.14 [0.01, 2.63]	
Subtotal (95% CI) Total events Heterogeneity: Tau <sup>2</sup> = 0. Test for overall effect: Z 3.16.4 > 1050 mg Bartholdy 2006 Dierking 2003 Doha 2010 Durmus 2007 Fassoulaki 2006 Gilron 2004 Grosen 2014 Grosen 2014 Kosucu 2013 Mikkelsen 2006 Ménigaux 2004	20 .01; Chi <sup>2</sup> = = 0.65 (P 3 12 2 7 1 4 25 0 2 3	135 3.07, = 0.51) 38 39 30 25 27 20 52 25 29 20	22 df = 3 (P ) 4 11 4 9 5 12 37 3 4 3	136 = 0.3 38 32 29 25 24 22 52 25 31 20 20	4.6% 8); l <sup>2</sup> = 29 0.7% 2.8% 0.5% 1.5% 0.3% 0.3% 0.2% 0.5% 0.6%	1.00 [0.28, 3.63] 0.83 [0.48, 1.44] 6 0.75 [0.18, 3.13] 0.90 [0.46, 1.75] 0.48 [0.10, 2.44] 0.78 [0.34, 1.76] 0.18 [0.02, 1.42] 0.37 [0.14, 0.95] 0.68 [0.49, 0.94] 0.14 [0.01, 2.63] 0.53 [0.11, 2.70] 1.00 [0.23, 4.37] 1.00 [0.23, 4.37]	
Subtotal (95% CI) Total events Heterogeneity: Tau <sup>2</sup> = 0. Test for overall effect: Z 3.16.4 > 1050 mg Bartholdy 2006 Dierking 2003 Doha 2010 Durmus 2007 Fassoulaki 2006 Gilron 2004 Grosen 2014 lajeda 2014 Kosucu 2013 Mikkelsen 2006 Ménigaux 2004 Omran 2006	20 .01; Chi <sup>2</sup> = = 0.65 (P 3 12 2 7 1 4 4 25 0 2 3 3 5	135 3.07, = 0.51 38 39 30 25 27 20 52 25 29 20 20 50	22 df = 3 (P ) 4 11 4 9 5 12 37 3 4 3 3 7	136 = 0.3 38 32 29 25 24 22 52 25 31 20 20 50	4.6% 8); I <sup>2</sup> = 29 0.7% 2.8% 0.5% 1.9% 0.3% 0.3% 0.2% 0.5% 0.5% 0.6% 0.6% 1.2%	1.00 [0.28, 3.63] 0.83 [0.48, 1.44] 6 0.75 [0.18, 3.13] 0.90 [0.46, 1.75] 0.48 [0.10, 2.44] 0.78 [0.34, 1.76] 0.18 [0.02, 1.42] 0.37 [0.14, 0.95] 0.68 [0.49, 0.94] 0.14 [0.01, 2.63] 0.53 [0.11, 2.70] 1.00 [0.23, 4.37] 0.71 [0.24, 2.10]	
Subtotal (95% CI) Total events Heterogeneity: Tau <sup>2</sup> = 0. Test for overall effect: Z <b>3.16.4 &gt; 1050 mg</b> Bartholdy 2006 Dierking 2003 Doha 2010 Durmus 2007 Fassoulaki 2006 Gilron 2004 Grosen 2014 Lajeda 2014 Kosucu 2013 Mikkelsen 2006 Ménigaux 2004 Omran 2006 Pathak 2013	20 .01; Chi <sup>2</sup> = = 0.65 (P 3 12 7 1 4 25 0 2 3 3 5 1	135 3.07, = 0.51) 38 39 30 25 27 20 52 25 29 20 50 20 50 40	22 df = 3 (P ) 4 11 4 9 5 12 37 3 4 3 4 3 3 7 4	136 = 0.3 38 32 29 25 24 22 52 25 31 20 20 50 40	4.6% 8); I <sup>2</sup> = 29 0.7% 2.8% 0.5% 1.9% 0.3% 1.5% 7.9% 0.6% 0.6% 0.6% 0.6% 0.6% 0.3%	1.00 [0.28, 3.63] 0.83 [0.48, 1.44] 6 0.75 [0.18, 3.13] 0.90 [0.46, 1.75] 0.48 [0.10, 2.44] 0.78 [0.34, 1.76] 0.18 [0.02, 1.42] 0.37 [0.14, 0.95] 0.68 [0.49, 0.94] 0.14 [0.01, 2.63] 0.53 [0.11, 2.70] 1.00 [0.23, 4.37] 1.00 [0.23, 4.37] 0.71 [0.24, 2.10] 0.25 [0.03, 2.14]	
Subtotal (95% CI) Total events Heterogeneity: Tau <sup>2</sup> = 0. Test for overall effect: Z <b>3.16.4 &gt; 1050 mg</b> Bartholdy 2006 Dierking 2003 Doha 2010 Durmus 2007 Fassoulaki 2006 Gilron 2004 Grosen 2014 Kosucu 2013 Mikkelsen 2006 Ménigaux 2004 Omran 2006 Pathak 2013 Sen 2009a	20 .01; Chi <sup>2</sup> = = 0.65 (P 3 12 2 7 1 1 4 25 0 2 3 3 5 1 9	135 3.07, = 0.51) 38 39 30 25 27 20 52 25 29 20 50 40 20	22 df = 3 (P ) 4 11 4 9 5 12 37 3 4 3 3 4 3 3 7 4 8	136 = 0.3 38 32 29 25 24 22 52 25 31 20 20 50 40 20	4.6% 8); I <sup>2</sup> = 29 0.7% 2.8% 0.5% 1.5% 0.3% 7.9% 0.2% 0.6% 0.6% 1.2% 0.6% 2.4%	1.00 [0.28, 3.63] 0.83 [0.48, 1.44] 6 0.75 [0.18, 3.13] 0.90 [0.46, 1.75] 0.48 [0.10, 2.44] 0.78 [0.34, 1.76] 0.18 [0.02, 1.42] 0.37 [0.14, 0.95] 0.68 [0.49, 0.94] 0.14 [0.01, 2.63] 0.53 [0.11, 2.70] 1.00 [0.23, 4.37] 1.00 [0.23, 4.37] 1.00 [0.23, 4.37] 0.71 [0.24, 2.10] 0.25 [0.03, 2.14] 1.13 [0.55, 2.32]	
Subtotal (95% CI) Total events Heterogeneity: Tau <sup>2</sup> = 0. Fest for overall effect: Z 3.16.4 > 1050 mg Bartholdy 2006 Dierking 2003 Doha 2010 Durmus 2007 Fassoulaki 2006 Gilron 2004 Grosen 2014 Grosen 2014 Grosen 2014 Kosucu 2013 Wikkelsen 2006 Ménigaux 2004 Dmran 2006 Pathak 2013 Sen 2009a Furan 2003a	20 .01; Chi <sup>2</sup> = = 0.65 (P 3 12 2 7 1 1 4 4 25 0 2 3 3 5 1 9 9 5	135 3.07, = 0.51) 38 39 30 25 27 20 52 25 29 20 20 20 50 40 20 25	22 df = 3 (P ) 4 11 4 9 5 12 37 3 4 3 3 7 4 3 3 7 4 8 7	136 = 0.3 38 32 29 25 24 22 52 25 24 20 20 20 50 40 20 25	4.6% 8); I <sup>2</sup> = 29 0.7% 2.8% 0.5% 1.9% 0.2% 0.5% 0.6% 1.2% 0.6% 1.2% 0.6% 1.2% 0.3% 2.4%	1.00 [0.28, 3.63] 0.83 [0.48, 1.44] 6 0.75 [0.18, 3.13] 0.90 [0.46, 1.75] 0.48 [0.10, 2.44] 0.78 [0.34, 1.76] 0.18 [0.02, 1.42] 0.37 [0.14, 0.95] 0.68 [0.49, 0.94] 0.14 [0.01, 2.63] 0.53 [0.11, 2.70] 1.00 [0.23, 4.37] 1.00 [0.23, 4.37] 0.71 [0.24, 2.10] 0.25 [0.03, 2.14] 1.13 [0.55, 2.32] 0.71 [0.26, 1.95]	
Subtotal (95% CI) Total events Heterogeneity: Tau <sup>2</sup> = 0. Test for overall effect: Z 3.16.4 > 1050 mg Bartholdy 2006 Dierking 2003 Doha 2010 Durmus 2007 Fassoulaki 2006 Gilron 2004 Grosen 2014 Jajeda 2014 Kosucu 2013 Mikkelsen 2006 Ménigaux 2004 Omran 2006 Pathak 2013 Sen 2009a Turan 2003a Turan 2003b	20 .01; Chi <sup>2</sup> = = 0.65 (P 3 12 2 7 1 4 4 25 0 2 3 3 5 1 9 5 5	135 3.07, = 0.51] 38 39 30 25 27 20 20 52 25 29 20 20 50 40 20 50 40 25 25	22 df = 3 (P ) 4 11 4 9 5 12 37 37 3 4 3 7 4 8 7 7	136 = 0.3 38 32 29 25 24 22 52 52 25 31 20 20 50 40 20 50 40 25 25	4.6% 8); I <sup>2</sup> = 29 0.7% 2.8% 0.5% 0.5% 0.5% 0.5% 0.6% 0.6% 0.6% 0.6% 0.3% 1.2% 0.3% 1.2% 0.3% 1.2% 0.3% 1.2% 0.3% 1.2% 0.3% 1.2% 0.3% 1.2% 0.3% 0.3% 0.3% 0.3% 0.3% 0.3% 0.5% 0.3% 0.3% 0.3% 0.3% 0.3% 0.5% 0.3% 0.5% 0.3% 0.5% 0.3% 0.5% 0.3% 0.5% 0.5% 0.3% 0.5% 0.3% 0.5% 0.3% 0.3% 0.3% 0.5% 0.3	1.00 [0.28, 3.63] 0.83 [0.48, 1.44] 6 0.75 [0.18, 3.13] 0.90 [0.46, 1.75] 0.48 [0.02, 2.44] 0.78 [0.34, 1.76] 0.18 [0.02, 1.42] 0.37 [0.14, 0.95] 0.68 [0.49, 0.94] 0.14 [0.01, 2.63] 0.53 [0.11, 2.70] 1.00 [0.23, 4.37] 1.00 [0.23, 4.37] 1.00 [0.23, 4.37] 1.00 [0.24, 2.10] 0.25 [0.03, 2.14] 1.13 [0.55, 2.32] 0.71 [0.26, 1.95] 0.71 [0.26, 1.95]	
Subtotal (95% CI) Total events Heterogeneity: Tau <sup>2</sup> = 0. Test for overall effect: Z <b>3.16.4 &gt; 1050 mg</b> Bartholdy 2006 Dierking 2003 Doha 2010 Durmus 2007 Fassoulaki 2006 Gilron 2004 Grosen 2014 Jajeda 2014 Kosucu 2013 Mikkelsen 2006 Ménigaux 2004 Dmran 2006 Pathak 2013 Sen 2009a Turan 2003b Turan 2003b	20 .01; Chi <sup>2</sup> = = 0.65 (P 3 12 2 7 1 4 25 0 2 3 3 5 1 9 5 5 5 4	135 3.07, = 0.51) 38 39 30 25 27 20 52 25 29 20 20 50 40 20 50 40 25 25 25	22 df = 3 (P) 4 11 4 9 5 12 37 3 4 3 3 7 3 4 8 7 7 4	136 = 0.3 38 32 29 25 24 22 52 25 31 20 20 50 40 20 50 40 25 25 25	4.6% 8); I <sup>2</sup> = 29 0.7% 2.8% 0.5% 1.9% 0.5% 1.5% 7.9% 0.5% 0.6% 0.6% 1.2% 0.6% 1.2% 0.3% 0.3% 0.9%	1.00 [0.28, 3.63] 0.83 [0.48, 1.44] 6 0.75 [0.18, 3.13] 0.90 [0.46, 1.75] 0.48 [0.10, 2.44] 0.78 [0.34, 1.76] 0.18 [0.02, 1.42] 0.37 [0.14, 0.95] 0.68 [0.49, 0.94] 0.14 [0.01, 2.63] 0.53 [0.11, 2.70] 1.00 [0.23, 4.37] 1.00 [0.23, 4.37] 1.00 [0.23, 4.37] 0.71 [0.24, 2.10] 0.25 [0.03, 2.14] 1.13 [0.55, 2.32] 0.71 [0.26, 1.95] 0.71 [0.26, 1.95] 1.00 [0.28, 3.56]	
Subtotal (95% CI) Total events Heterogeneity: Tau <sup>2</sup> = 0. Fest for overall effect: Z 3.16.4 > 1050 mg Bartholdy 2006 Dierking 2003 Doha 2010 Durmus 2007 Fassoulaki 2006 Gilron 2004 Grosen 2014 Agieda 2014 Kosucu 2013 Wikkelsen 2006 Ménigaux 2004 Dmran 2006 Pathak 2013 Sen 2009a Furan 2003a Furan 2003b Furan 2004 Furan 2005	20 .01; Chi <sup>2</sup> = = 0.65 (P 3 12 2 7 1 1 4 25 0 2 2 3 3 5 1 9 5 5 5 4 10	135 3.07, = 0.51) 38 39 30 25 27 20 25 29 20 20 50 20 50 20 50 20 20 50 52 52 52 52 52 52 52 52 52 52 52 52 52	22 df = 3 (P ) 4 11 4 9 5 12 37 3 4 3 3 7 4 3 3 7 4 8 7 7 4 8 7 7 4	136 = 0.3 38 32 29 25 24 22 52 25 25 25 25 25 25 20 20 20 20 20 25 25 25 25 20	4.6% 8); I <sup>2</sup> = 29 0.7% 2.8% 0.5% 1.9% 0.5% 1.5% 7.9% 0.2% 0.6% 0.6% 1.2% 0.6% 1.2% 0.6% 1.3% 1.3% 0.9% 4.1%	1.00 [0.28, 3.63] 0.83 [0.48, 1.44] 6 0.75 [0.18, 3.13] 0.90 [0.46, 1.75] 0.48 [0.10, 2.44] 0.78 [0.34, 1.76] 0.18 [0.02, 1.42] 0.37 [0.14, 0.95] 0.68 [0.49, 0.94] 0.14 [0.01, 2.63] 0.53 [0.11, 2.70] 1.00 [0.23, 4.37] 1.00 [0.23, 4.37] 1.00 [0.23, 4.37] 1.00 [0.23, 4.37] 1.13 [0.55, 2.32] 0.71 [0.26, 1.95] 1.00 [0.28, 3.56] 0.71 [0.42, 1.21]	
Subtotal (95% CI) Total events Heterogeneity: Tau <sup>2</sup> = 0. Test for overall effect: Z 3.16.4 > 1050 mg Bartholdy 2006 Dierking 2003 Doha 2010 Durmus 2007 Fassoulaki 2006 Gilron 2004 Grosen 2014 Grosen 2014 Kosucu 2013 Mikkelsen 2006 Ménigaux 2004 Omran 2006 Pathak 2013 Sen 2009a Turan 2003a Turan 2003 Turan 2005 Turan 2005 Turan 2005	20 .01; Chi <sup>2</sup> = = 0.65 (P 3 12 2 7 1 4 4 25 0 2 3 3 5 1 9 9 5 5 4 10 0 6	135 3.07, = 0.51) 38 39 00 25 27 20 25 22 20 20 20 20 20 20 20 20 20 20 20 20	22 df = 3 (P ) 4 11 4 9 5 12 37 3 4 3 3 7 4 8 7 7 4 8 7 7 4 4 8 7 7 4 4 2	136 = 0.3 38 32 29 25 24 22 52 25 31 20 20 20 20 20 20 25 52 52 52 25 20 20 25 25 20 20 25 25 22 25 20 20 25 20 20 20 20 20 20 20 20 20 20 20 20 20	4.6% 8); I <sup>2</sup> = 29 0.7% 2.8% 0.5% 1.9% 0.2% 0.5% 0.6% 0.6% 1.2% 0.6% 1.2% 0.6%	1.00 [0.28, 3.63] 0.83 [0.48, 1.44] 6 0.75 [0.18, 3.13] 0.90 [0.46, 1.75] 0.48 [0.10, 2.44] 0.78 [0.34, 1.76] 0.18 [0.02, 1.42] 0.37 [0.14, 0.95] 0.68 [0.49, 0.94] 0.14 [0.01, 2.63] 0.53 [0.11, 2.70] 1.00 [0.23, 4.37] 1.00 [0.23, 4.37] 0.71 [0.24, 2.10] 0.25 [0.03, 2.14] 1.13 [0.55, 2.32] 0.71 [0.26, 1.95] 0.71 [0.26, 1.95] 1.00 [0.28, 3.56] 0.71 [0.42, 1.21] 3.00 [0.67, 1.3.46]	
Subtotal (95% CI) Total events Heterogeneity: Tau <sup>2</sup> = 0. Test for overall effect: Z 3.16.4 > 1050 mg Bartholdy 2006 Dierking 2003 Doha 2010 Durmus 2007 Fassoulaki 2006 Gilron 2004 Grosen 2014 Lajeda 2014 Kosucu 2013 Mikkelsen 2006 Ménigaux 2004 Dmran 2006 Pathak 2013 Sen 2009a Turan 2003b Turan 2003b Turan 2004 Turan 2005 Turan 2006 Juran 2006 Juran 2006 Juran 2005 Turan 2006	20 .01; Chi <sup>2</sup> = = 0.65 (P 3 12 2 7 1 4 4 25 0 2 3 3 5 1 9 5 5 4 10 6 6 4	135 3.07, = 0.51) 38 39 30 25 27 20 52 25 29 20 50 40 20 50 40 20 50 40 25 25 25 25 25 25 20 50 20 20 20 20 20 20 20 20 20 2	22 df = 3 (P ) 4 11 4 9 5 12 37 37 3 4 3 37 37 4 8 7 7 4 8 7 7 4 14 2 2	136 = 0.3 38 32 29 25 24 22 52 25 31 20 20 50 40 20 50 40 20 50 40 20 50 40 20 50 20 20 50 20 20 20 20 20 20 20 20 20 2	4.6% 8); I <sup>2</sup> = 29 0.7% 2.8% 0.5% 1.9% 0.3% 1.5% 0.6% 0.5% 0.6% 1.2% 0.3% 1.3% 0.9% 4.1% 0.6%	1.00 [0.28, 3.63] 0.83 [0.48, 1.44] 6 0.75 [0.18, 3.13] 0.90 [0.46, 1.75] 0.48 [0.10, 2.44] 0.78 [0.34, 1.76] 0.18 [0.02, 1.42] 0.37 [0.14, 0.95] 0.68 [0.49, 0.94] 0.14 [0.01, 2.63] 0.53 [0.11, 2.70] 1.00 [0.23, 4.37] 1.00 [0.23, 4.37] 1.00 [0.23, 4.37] 1.00 [0.23, 4.37] 1.00 [0.23, 4.37] 1.01 [0.24, 2.10] 0.71 [0.26, 1.95] 1.02 [0.28, 3.56] 0.71 [0.24, 1.21] 3.00 [0.67, 13.46] 2.00 [0.41, 9.71]	
Subtotal (95% CI) Total events Heterogeneity: Tau <sup>2</sup> = 0. Test for overall effect: Z 3.16.4 > 1050 mg Bartholdy 2006 Dierking 2003 Doha 2010 Durmus 2007 Fassoulaki 2006 Gilron 2004 Grosen 2014 Jajeda 2014 Kosucu 2013 Mikkelsen 2006 Ménigaux 2004 Omran 2006 Ménigaux 2003 Turan 2003a Turan 2004 Turan 2004 Turan 2004 Turan 2004 Turan 2005 Turan 2006 Ucak 2011 Ozgencil 2011	20 .01; Chi <sup>2</sup> = = 0.65 (P 3 12 2 7 1 4 4 25 0 2 3 3 5 1 9 9 5 5 4 10 0 6	135 3.0.7, = 0.51) 38 39 30 25 27 20 52 25 20 20 50 20 20 20 20 20 20 20 20 20 2	22 df = 3 (P ) 4 11 4 9 5 12 37 3 4 3 3 7 4 8 7 7 4 8 7 7 4 4 8 7 7 4 4 2	136 = 0.3 38 32 29 25 24 22 25 31 20 20 20 20 20 20 20 20 20 20 20 20 20	4.6% 8); 1 <sup>2</sup> = 29 0.7% 2.8% 0.5% 1.9% 0.5% 7.9% 0.5% 0.6% 0.6% 0.6% 1.2% 0.3% 0.6% 1.3% 1.3% 0.6% 0.6% 0.6% 0.6% 0.6%	1.00 [0.28, 3.63] 0.83 [0.48, 1.44] 6 0.75 [0.18, 3.13] 0.90 [0.46, 1.75] 0.48 [0.10, 2.44] 0.78 [0.34, 1.76] 0.18 [0.02, 1.42] 0.37 [0.14, 0.95] 0.68 [0.49, 0.94] 0.14 [0.01, 2.63] 0.53 [0.11, 2.70] 1.00 [0.23, 4.37] 1.00 [0.23, 4.37] 1.00 [0.23, 4.37] 0.71 [0.24, 2.10] 0.25 [0.03, 2.14] 1.13 [0.55, 2.32] 0.71 [0.26, 1.95] 0.71 [0.26, 1.95] 1.00 [0.28, 3.56] 0.71 [0.42, 1.21] 3.00 [0.67, 13.46] 2.00 [0.41, 9.71] 1.14 [0.47, 2.75]	
Subtotal (95% CI) Total events Heterogeneity: Tau <sup>2</sup> = 0. Test for overall effect: Z 3.16.4 > 1050 mg Bartholdy 2006 Dierking 2003 Doha 2010 Durmus 2007 Fassoulaki 2006 Gilron 2004 Grosen 2014 Jajeda 2014 Kosucu 2013 Mikkelsen 2006 Ménigaux 2004 Omran 2006 Pathak 2013 Sen 2009a Turan 2003a Turan 2004 Turan 2004 Turan 2004 Turan 2004 Turan 2005 Turan 2006 Ucak 2011 Ozgencil 2011 Subtotal (95% CI)	20 .01; Chi <sup>2</sup> = = 0.65 (P 3 12 2 7 1 1 4 25 0 2 2 3 3 5 1 1 9 5 5 5 4 10 6 4 8	135 3.07, = 0.51) 38 39 30 25 27 20 52 25 29 20 50 40 20 50 40 20 50 40 25 25 25 25 25 25 20 50 20 20 20 20 20 20 20 20 20 2	22 df = 3 (P ) 4 11 4 9 5 5 12 37 3 4 3 3 7 4 3 3 7 4 8 7 7 4 14 2 2 7	136 = 0.3 38 32 29 25 24 22 52 25 31 20 20 50 40 20 50 40 20 50 40 20 50 40 20 50 20 20 50 20 20 20 20 20 20 20 20 20 2	4.6% 8); I <sup>2</sup> = 29 0.7% 2.8% 0.5% 1.9% 0.3% 1.5% 0.6% 0.5% 0.6% 1.2% 0.3% 1.3% 0.9% 4.1% 0.6%	1.00 [0.28, 3.63] 0.83 [0.48, 1.44] 6 0.75 [0.18, 3.13] 0.90 [0.46, 1.75] 0.48 [0.10, 2.44] 0.78 [0.34, 1.76] 0.18 [0.02, 1.42] 0.37 [0.14, 0.95] 0.68 [0.49, 0.94] 0.14 [0.01, 2.63] 0.53 [0.11, 2.70] 1.00 [0.23, 4.37] 1.00 [0.23, 4.37] 1.00 [0.23, 4.37] 1.00 [0.23, 4.37] 1.01 [0.24, 2.10] 0.25 [0.03, 2.14] 1.13 [0.55, 2.32] 0.71 [0.26, 1.95] 1.00 [0.28, 3.56] 0.71 [0.42, 1.21] 3.00 [0.67, 13.46] 2.00 [0.41, 9.71]	
Subtotal (95% CI) Total events Heterogeneiity: $Tau^2 = 0$ . Test for overall effect: Z <b>3.16.4 &gt; 1050 mg</b> Bartholdy 2006 Dierking 2003 Doha 2010 Durmus 2007 Fassoulaki 2006 Gilron 2004 Grosen 2014 Jajeda 2014 Kosucu 2013 Mikkelsen 2006 Ménigaux 2004 Omran 2006 Pathak 2013 Sen 2009a Turan 2005 Turan 2005 Turan 2004 Turan 2005 Turan 2005 Turan 2005 Turan 2005 Turan 2006 Ucak 2011 Özgencil 2011 Subtotal (95% CI) Total events Heterogeneity: Tau <sup>2</sup> = 0.	20 .01; Chi <sup>2</sup> = = 0.65 (P 3 12 2 7 1 4 25 0 2 3 3 5 5 5 5 4 10 6 4 4 8 119 .00; Chi <sup>2</sup> =	135 3.07, = 0.51 38 39 30 25 27 20 52 29 20 20 52 29 20 20 52 29 20 20 52 29 20 20 52 29 20 20 52 29 20 50 20 51 20 52 29 20 50 50 20 20 50 20 20 20 20 20 20 20 20 20 2	22 df = 3 (P) 4 11 4 9 5 12 37 3 4 3 3 7 4 8 7 7 4 14 2 2 7 7 , df = 20	136 = 0.3 38 32 29 25 24 22 25 25 25 25 20 20 20 20 20 20 20 20 20 20 20 20 20	4.6% 8); I <sup>2</sup> = 29 0.7% 2.8% 0.5% 1.5% 0.3% 1.5% 0.6% 0.6% 1.2% 0.6% 1.3% 0.3% 2.4% 0.6% 0.3% 1.3% 0.9% 4.13% 0.6% 0.6% 1.7% 32.0%	1.00 [0.28, 3.63] 0.83 [0.48, 1.44] 6 0.75 [0.18, 3.13] 0.90 [0.46, 1.75] 0.48 [0.10, 2.44] 0.78 [0.34, 1.76] 0.18 [0.02, 1.42] 0.37 [0.14, 0.95] 0.68 [0.49, 0.94] 0.14 [0.01, 2.63] 0.53 [0.11, 2.70] 1.00 [0.23, 4.37] 1.00 [0.23, 4.37] 1.00 [0.23, 4.37] 1.00 [0.23, 4.37] 1.00 [0.23, 4.37] 1.00 [0.23, 4.37] 1.00 [0.24, 2.10] 0.25 [0.03, 2.14] 1.13 [0.55, 2.32] 0.71 [0.26, 1.95] 1.00 [0.28, 3.56] 0.71 [0.26, 1.95] 1.00 [0.67, 13.46] 2.00 [0.41, 9.71] 1.14 [0.47, 2.75] 0.75 [0.62, 0.91]	
Rajendran 2014 Subtotal (95% CI) Total events Heterogeneity: Tau <sup>2</sup> = 0. Test for overall effect: Z 3.16.4 > 1050 mg Bartholdy 2006 Dierking 2003 Doha 2010 Durmus 2007 Fassoulaki 2006 Gilron 2004 Grosen 2014 Jajeda 2014 Kosucu 2013 Mikkelsen 2006 Ménigaux 2004 Omran 2006 Pathak 2013 Sen 2009a Turan 2005 Turan 2004 Turan 2005 Turan 2005 Ucak 2011 Ozgencil 2011 Subtotal (95% CI) Total (95% CI)	20 .01; Chi <sup>2</sup> = = 0.65 (P 3 12 2 7 1 4 25 0 2 3 3 5 5 5 5 4 10 6 4 4 8 119 .00; Chi <sup>2</sup> =	135 3.07, = 0.51 38 39 30 25 27 20 52 29 20 20 52 29 20 20 52 29 20 20 52 29 20 20 52 29 20 20 52 29 20 50 20 51 20 52 29 20 50 50 20 20 50 20 20 20 20 20 20 20 20 20 2	22 df = 3 (P ) 4 11 4 9 5 2 37 3 4 3 3 7 4 3 3 7 4 4 8 7 7 4 4 8 7 7 4 4 2 2 7 , df = 20 3)	136 = 0.3 38 32 29 25 24 22 52 25 25 20 20 50 40 20 50 20 20 50 20 20 50 20 20 50 20 20 50 20 20 50 20 20 20 20 20 20 20 20 20 20 20 20 20	4.6% 8); I <sup>2</sup> = 29 0.7% 2.8% 0.5% 1.5% 0.3% 1.5% 0.6% 0.6% 1.2% 0.6% 1.3% 0.3% 2.4% 0.6% 0.3% 1.3% 0.9% 4.13% 0.6% 0.6% 1.7% 32.0%	1.00 [0.28, 3.63] 0.83 [0.48, 1.44] 6 0.75 [0.18, 3.13] 0.90 [0.46, 1.75] 0.48 [0.10, 2.44] 0.78 [0.34, 1.76] 0.18 [0.02, 1.42] 0.37 [0.14, 0.95] 0.68 [0.49, 0.94] 0.14 [0.01, 2.63] 0.53 [0.11, 2.70] 1.00 [0.23, 4.37] 1.00 [0.23, 4.37] 1.00 [0.23, 4.37] 1.00 [0.23, 4.37] 1.00 [0.23, 4.37] 1.00 [0.23, 4.37] 1.00 [0.24, 2.10] 0.25 [0.03, 2.14] 1.13 [0.55, 2.32] 0.71 [0.26, 1.95] 1.00 [0.28, 3.56] 0.71 [0.26, 1.95] 1.00 [0.67, 13.46] 2.00 [0.41, 9.71] 1.14 [0.47, 2.75] 0.75 [0.62, 0.91]	
Subtotal (95% CI) Total events Heterogeneity: $Tau^2 = 0$ . Test for overall effect: Z 3.16.4 > 1050 mg Bartholdy 2006 Dierking 2003 Doha 2010 Durmus 2007 Fassoulaki 2006 Gilron 2004 Grosen 2014 Jajeda 2014 Kosucu 2013 Mikkelsen 2006 Ménigaux 2004 Omran 2006 Ménigaux 2004 Omran 2006 Pathak 2013 Sen 2009a Turan 2005 Turan 2005 Turan 2005 Turan 2005 Turan 2005 Turan 2005 Ucak 2011 Özgencil 2011 Subtotal (95% CI) Total events Heterogeneity: Tau <sup>2</sup> = 0. Test for overall effect: Z	20 .01; Chi <sup>2</sup> = = 0.65 (P 3 12 2 7 1 4 25 0 2 3 3 5 5 5 5 4 10 6 4 4 8 119 .00; Chi <sup>2</sup> =	135 3.07, 3.07, 3.07, 3.0 3.0 3.0 2.5 2.7 2.0 5.2 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2	22 df = 3 (P ) 4 11 4 9 5 2 37 3 4 3 3 7 4 3 3 7 4 4 8 7 7 4 4 8 7 7 4 4 2 2 7 , df = 20 3)	136 = 0.3 38 32 29 25 24 22 52 25 25 20 20 50 40 20 50 20 20 50 20 20 50 20 20 50 20 20 50 20 20 50 20 20 20 20 20 20 20 20 20 20 20 20 20	4.6% 8); l <sup>2</sup> = 29 0.7% 2.8% 0.5% 1.9% 0.3% 1.5% 0.6% 0.6% 1.2% 0.6% 1.2% 0.6% 1.3% 0.6% 1.3% 0.6% 1.3% 0.6% 1.3% 0.6% 1.3% 0.6% 1.3% 0.6% 1.3% 0.6% 1.3% 0.6% 1.3% 0.5% 0.6% 1.2% 0.6% 0.6% 1.3% 0.6% 0.6% 0.2% 0.6% 0.6% 0.2% 0.6% 0.7% 0.7% 0.6% 0.6% 0.6% 0.6% 0.6% 0.6% 0.6% 0.6% 0.6% 0.6% 0.7% 0.7% 0.6% 0.6% 0.6% 0.6% 0.6% 0.6% 0.6% 0.6% 0.6% 0.6% 0.6% 0.7% 0.7% 0.6% 0.6% 0.6% 0.6% 0.7% 0.7% 0.7% 0.6% 0.7% 0.7% 0.7% 0.6% 0.6% 0.7	1.00 [0.28, 3.63] 0.83 [0.48, 1.44] 6 0.75 [0.18, 3.13] 0.90 [0.46, 1.75] 0.48 [0.10, 2.44] 0.78 [0.34, 1.76] 0.18 [0.02, 1.42] 0.37 [0.14, 0.95] 0.68 [0.49, 0.94] 0.14 [0.01, 2.63] 0.53 [0.11, 2.70] 1.00 [0.23, 4.37] 1.00 [0.23, 4.37] 1.00 [0.23, 4.37] 1.00 [0.23, 4.37] 1.00 [0.23, 4.37] 1.00 [0.28, 3.56] 0.71 [0.26, 1.95] 0.71 [0.26, 1.95] 1.00 [0.28, 3.56] 0.71 [0.42, 1.21] 3.00 [0.67, 13.46] 2.00 [0.41, 9.71] 1.14 [0.47, 2.75] 0.75 [0.62, 0.91]	
Subtotal (95% CI) Total events Heterogeneity: Tau <sup>2</sup> = 0. Test for overall effect: Z 3.16.4 > 1050 mg Bartholdy 2006 Dierking 2003 Doha 2010 Durmus 2007 Fassoulaki 2006 Gilron 2004 Grosen 2014 Jajeda 2014 Kosucu 2013 Mikkelsen 2006 Ménigaux 2004 Omran 2006 Pathak 2013 Sen 2009a Turan 2005 Turan 2005 Turan 2005 Turan 2005 Turan 2005 Ucak 2011 Özgencil 2011 Subtotal (95% CI) Total events Heterogeneity: Tau <sup>2</sup> = 0. Test for overall effect: Z	20 $0.01; Chi^2 = 0.65 (P)$ 3 12 2 7 1 4 25 0 2 3 3 5 1 9 5 5 4 10 6 4 8 119 .00; Chi^2 = 0.65 (P)	135 3.07, = 0.51; 38 39 30 25 27 20 52 27 20 52 29 20 20 20 20 20 20 20 20 20 20	22 df = 3 (P) 4 11 4 9 5 12 37 3 4 3 3 7 4 3 3 7 4 8 7 7 4 14 2 2 7 157 , df = 20 3) 457	136 = 0.3 38 32 29 25 24 22 52 25 31 20 20 20 50 20 20 50 20 20 50 20 20 50 8 (P = C 1527	4.6% 8); 1 <sup>2</sup> = 29 0.7% 2.8% 0.5% 1.9% 0.3% 0.5% 0.5% 0.6% 0.6% 0.6% 1.2% 0.3% 0.6% 0.3% 1.3% 1.3% 1.3% 0.6% 0.3% 0.9% 4.1% 0.6% 0.6% 0.7% 1.7% 1.2% 0.5% 1.3% 1.3% 0.5% 1.2% 0.5% 1.5% 0.5	1.00 [0.28, 3.63] 0.83 [0.48, 1.44] 6 0.75 [0.18, 3.13] 0.90 [0.46, 1.75] 0.48 [0.10, 2.44] 0.78 [0.34, 1.76] 0.18 [0.02, 1.42] 0.37 [0.14, 0.95] 0.68 [0.49, 0.94] 0.14 [0.01, 2.63] 0.53 [0.11, 2.70] 1.00 [0.23, 4.37] 1.00 [0.23, 4.37] 1.00 [0.23, 4.37] 1.71 [0.24, 2.10] 0.25 [0.03, 2.14] 1.13 [0.55, 2.32] 0.71 [0.26, 1.95] 1.00 [0.28, 3.56] 0.71 [0.26, 1.95] 1.00 [0.28, 3.56] 0.71 [0.24, 1.21] 3.00 [0.67, 13.46] 2.00 [0.41, 9.71] 1.14 [0.47, 2.75] 0.75 [0.62, 0.91] 0%	
Subtotal (95% CI) Total events Heterogeneity: Tau <sup>2</sup> = 0. Test for overall effect: Z 3.16.4 > 1050 mg Bartholdy 2006 Dierking 2003 Doha 2010 Durmus 2007 Fassoulaki 2006 Gilron 2004 Grosen 2014 Jajeda 2014 Kosucu 2013 Mikkelsen 2006 Ménigaux 2004 Omran 2006 Pathak 2013 Sen 2009a Turan 2005 Turan 2004 Turan 2005 Turan 2004 Turan 2005 Turan 2004 Turan 2005 Turan 2004 Ucak 2011 Özgencil 2011 Subtotal (95% CI) Total events Heterogeneity: Tau <sup>2</sup> = 0. Test for overall effect: Z	20 $20^{-1}$ $20^{-$	135 3.07, = 0.51; 38 39 30 25 27 20 52 25 20 20 52 20 20 20 20 20 20 20 20 20 2	22 df = 3 (P) 4 11 4 9 5 5 12 37 3 4 3 3 7 4 3 3 7 4 3 7 7 4 14 2 2 7 7 157 , df = 20 3) 457 , df = 48	136 = 0.3 38 32 29 25 24 22 52 25 31 20 20 20 50 20 20 50 20 20 50 20 20 50 8 (P = C 1527	4.6% 8); 1 <sup>2</sup> = 29 0.7% 2.8% 0.5% 1.9% 0.3% 0.5% 0.5% 0.6% 0.6% 0.6% 1.2% 0.3% 0.6% 0.3% 1.3% 1.3% 1.3% 0.6% 0.3% 0.9% 4.1% 0.6% 0.6% 0.7% 1.7% 1.2% 0.5% 1.3% 1.3% 0.5% 1.2% 0.5% 1.5% 0.5	1.00 [0.28, 3.63] 0.83 [0.48, 1.44] 6 0.75 [0.18, 3.13] 0.90 [0.46, 1.75] 0.48 [0.10, 2.44] 0.78 [0.34, 1.76] 0.18 [0.02, 1.42] 0.37 [0.14, 0.95] 0.68 [0.49, 0.94] 0.14 [0.01, 2.63] 0.53 [0.11, 2.70] 1.00 [0.23, 4.37] 1.00 [0.23, 4.37] 1.00 [0.23, 4.37] 1.71 [0.24, 2.10] 0.25 [0.03, 2.14] 1.13 [0.55, 2.32] 0.71 [0.26, 1.95] 1.00 [0.28, 3.56] 0.71 [0.26, 1.95] 1.00 [0.28, 3.56] 0.71 [0.24, 1.21] 3.00 [0.67, 13.46] 2.00 [0.41, 9.71] 1.14 [0.47, 2.75] 0.75 [0.62, 0.91] 0%	0.01 0.1 1 100 Favours Gabapentin Favours Cc

# Supplemental Digital Content 15 Forest plot of vomiting from trials with low risk of bias

	Gabape		Conti			Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	M-H, Random, 95% CI
3.17.1 0-350 mg Subtotal (95% Cl)		0		0		Not estimable	
Total events Heterogeneity: Not ap Test for overall effect:		icable	0				
3.17.2 351-700 mg							
Moore 2010 Subtotal (95% CI)	5	21 <b>21</b>	3	25 <b>25</b>	9.5% <b>9.5%</b>	1.98 [0.54, 7.34] <b>1.98 [0.54, 7.34</b> ]	
Total events Heterogeneity: Not ap	5 plicable		3				
Test for overall effect:	Z = 1.03	(P = 0	.30)				
3.17.3 701-1050 mg Subtotal (95% CI)		0		0		Not estimable	
Total events Heterogeneity: Not ap Test for overall effect:	•	_	0	Ū		Notestimable	
3.17.4 > 1050 mg							
Bartholdy 2006	3	38	3	38	6.9%	1.00 [0.22, 4.65]	
Grosen 2014 <b>Subtotal (95% CI)</b>	23	52 <b>90</b>	22	52 <b>90</b>	83.7% <b>90.5%</b>	1.05 [0.67, 1.62] <b>1.04 [0.68, 1.59]</b>	<b>‡</b>
Total events Heterogeneity: Tau <sup>2</sup> = Test for overall effect:	,		,	1 (P = 0	).96); l <sup>2</sup> =	0%	
Total (95% CI) Total events	31	111	28	115	100.0%	1.11 [0.74, 1.66]	+
Heterogeneity: Tau <sup>2</sup> = Test for overall effect: Test for subgroup diff	0.00; Ch Z = 0.50	(P = 0	36, df = .62)	-			0.01 0.1 1 10 1 Favours Gabapentin Favours Control

# Supplemental Digital Content 16 Forest plot of vomiting from all trials estimates

	Gabaper		Contro			Risk Ratio	Risk Ratio
tudy or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	M-H, Random, 95% Cl
8.18.1 0-350 mg							
lang 2009	1	23	3	23	0.5%	0.33 [0.04, 2.97]	
lehdad 2012	5	30	7	31	2.2%	0.74 [0.26, 2.07]	
Chafari 2009	4	33	9	33	2.0%	0.44 [0.15, 1.30]	
Churana 2013	1	30	2	30	0.4%	0.50 [0.05, 5.22]	
Aohammadi 2008	0	35	0	35		Not estimable	
Panday 2004c	3	28	4	28	1.2%	0.75 [0.18, 3.05]	
iekhavet 2009	18	49	19	49	9.1%	0.95 [0.57, 1.58]	-
/erma 2008	3	25	4	25	1.2%	0.75 [0.19, 3.01]	
feen 2001	4	16	1	15	0.5%	3.75 [0.47, 29.87]	
Subtotal (95% CI)		269		269	17.2%	0.81 [0.56, 1.17]	•
Total events	39		49				-
feterogeneity: $Tau^3 = 0$	.00; Chi <sup>2</sup> =	4.52,	df = 7 (P	= 0.77	$2); I^2 = 00$	6	
Test for overall effect: Z							
	,						
3.18.2 351-700 mg							
Ajeri 2011	5	69	16	69	2.6%	0.31 (0.12, 0.81)	I
Sharti 2012	6	40	9	40	2.7%	0.67 [0.26, 1.70]	<b></b> +
Clarke 2009b	9	76	7	38	2.8%	0.64 [0.26, 1.59]	<b></b> +
Grever 2009	ź	25	2	21	3.1%	0.84 [0.35, 2.01]	<b>_</b> _
Cavitha 2013	ó	28	ó	28	2.27	Not estimable	I
Gm 2004	ě.	21	ž	20	0.9%	1.90 [0.39, 9.28]	
Gec 2007	2	20	14	20	5.3%	0.50 [0.26, 0.97]	
Menda 2010	ó	30	14	30	3.2%	Not estimable	-
		30		34	0.00		
detry 2008	2		1	-	0.4%	0.88 [0.08, 9.41]	
Moore 2010	5	21	3	25	1.4%	1.98 [0.54, 7.34]	
Panday 2005	2	40	2	20	0.7%	0.50 [0.08, 3.29]	
iava 2009	5	25	7	25	2.3%	0.71 [0.26, 1.95]	
iddiqui 2013	5	36	6	36	2.0%	0.83 [0.28, 2.49]	
Zaldivar Ramirez 2011	0	18	7	16	0.3%	0.06 [0.00, 0.97]	· · ·
iubtotal (95% CI)		526	-	422	24.6%	0.65 [0.48, 0.89]	•
fotal events Heterogeneity: Tau <sup>3</sup> = 0	57		81				
lest for overall effect: Z							
3.18.3 701-1050 mg						Mar and a file	
3.18.3 701-1050 mg Deniz 2012	0	25	0	26		Not estimable	
8.18.3 701-1050 mg Deniz 2012 tadhakrishnan 2005		25 30	0	30	0.8%	0.67 [0.12, 3.71]	
8.18.3 701-1050 mg Deniz 2012 tadhakrishnan 2005 Subtotal (95% CB	0 Z	25	3		0.8% 0.8%		-
1.18.3 701-1050 mg Deniz 2012 tadhakrishnan 2005 Subtotal (95% C0 Fotal events	0 2 2	25 30		30		0.67 [0.12, 3.71]	-
k.18.3 701–1050 mg Deniz 2012 tadhakrishnan 2005 Kubtotal (95% CD Total events feterogeneity: Not appi	0 2 icable	25 30 55	3	30		0.67 [0.12, 3.71]	-
1.18.3 701-1050 mg Deniz 2012 tadhakrishnan 2005 Subtotal (95% C0 Fotal events	0 2 icable	25 30 55	3	30		0.67 [0.12, 3.71]	-
k.18.3 701–1050 mg Deniz 2012 tadhakrishnan 2005 Kubtotal (95% CD Total events feterogeneity: Not appi	0 2 icable	25 30 55	3	30		0.67 [0.12, 3.71]	-
k.18.3 701–1050 mg Deniz 2012 Kadhakrishnan 2005 Kadhakrishnan 2005 Kadhakrishnan 2005 Kadhakrishnan 2005 Kotal events fotal events fett for overall effect: 2 k.18.4 > 1050 mg	0 2 icable = 0.46 (P	25 30 55	3	30	0.8%	0.67 [0.12, 3.71] 0.67 [0.12, 3.71]	-
k.18.3 701-1050 mg Deniz 2012 kadhakrishnan 2005 kubotal (95% Cl) Total events feterogeneity: Not appl Test for overall effect: Z k.18.4 > 1050 mg Abdelmageed 2010	0 2 icable = 0.46 (P 2	25 30 55 = 0.64) 30	3	30 56 30	0.8%	0.67 [0.12, 3.71] 0.67 [0.12, 3.71] 0.22 [0.05, 0.94]	
k.18.3 701-1050 mg Deniz 2012 tadhakrishnan 2005 kubtotal (95% CD Total events feterogeneity: Not appl Fest for overall effect: Z k.18.4 > 1050 mg Abdelmageed 2010 Fartholdy 2006	0 2 icable = 0.46 (P 2 3	25 30 55 = 0.64) 30 38	3 3	30 56 30 38	0.8N 1.1N 1.0%	0.67 [0.12, 3.71] 0.67 [0.12, 3.71] 0.22 [0.05, 0.94] 1.00 [0.22, 4.65]	
k.18.3 701-1050 mg Deniz 2012 tadhakrishnan 2005 Kubtotal (95% CD Total events feterogeneity: Not appl Test for overall effect: Z k.18.4 > 1050 mg bbdelmageed 2010 fartholdy 2006 Dierking 2003	0 2 icable = 0.46 (P 2 3 18	25 30 55 = 0.64) 30 38 39	3 9 3 15	30 56 30 38 32	0.8N 1.1N 1.0% 9.4%	0.67 [0.12, 3.71] 0.67 [0.12, 3.71] 0.22 [0.05, 0.94] 1.00 [0.22, 4.65] 0.98 [0.60, 1.62]	
k.18.3 701-1050 mg Deniz 2012 Kadhakrishnan 2005 Kubtotal (95% CD) Fotal events feterogeneity: Not appl fest for overall effect: Z k.18.4 > 1050 mg Abdelmageed 2010 Bartholdy 2006 Derking 2003 Doha 2010	0 2 icable = 0.46 (P 2 3 18 3	25 30 55 = 0.64) 30 38 39 30	3 9 3 15 5	30 56 30 38 32 29	0.8N 1.1% 1.0% 9.4% 1.3%	0.67 [0.12, 3.71] 0.67 [0.12, 3.71] 0.22 [0.05, 0.94] 1.00 [0.22, 4.65] 0.98 [0.60, 1.62] 0.58 [0.15, 2.21]	
k.18.3 701-1050 mg Deniz 2012 Kadhakrishnan 2005 Kubotal (95% Cl) Fotal events feterogeneity: Not appl Fest for overall effect: Z k.18.4 > 1050 mg Abdelmageed 2010 Fartholdy 2006 Dierking 2003 Daha 2010 Durmus 2007	0 2 icable = 0.46 (P 2 3 18 3 3	25 30 55 = 0.64) 30 38 39 30 25	3 9 15 5 6	30 56 30 38 32 29 25	0.8N 1.1% 1.0% 9.4% 1.3% 1.5%	0.67 [0.12, 3.71] 0.67 [0.12, 3.71] 0.22 [0.05, 0.94] 1.00 [0.22, 4.65] 0.98 [0.60, 1.62] 0.58 [0.15, 2.21] 0.50 [0.14, 1.78]	
k.18.3 701-1050 mg Deniz 2012 kadhakrishnan 2005 kubotal (95% Cl) Total events feterogeneity: Not appl Total events feterogeneity: Not appl Total events feterogeneity: Not appl fest for overall effect: Z k.18.4 > 1050 mg Abdelmageed 2010 fartholdy 2006 Dierking 2003 Doha 2010 Dumus 2007 Grosen 2014	0 2 icable = 0.46 (P 2 3 18 3 3 23	25 30 55 = 0.64) 30 38 39 30 25 52	3 9 3 15 5 6 22	30 56 30 38 32 29 25 52	0.8N 1.1% 1.0% 9.4% 1.3% 1.5% 12.1%	0.67 [0.12, 3.71] 0.67 [0.12, 3.71] 0.22 [0.05, 0.94] 1.00 [0.22, 4.65] 0.98 [0.60, 1.62] 0.58 [0.15, 2.21] 0.50 [0.14, 1.78] 1.05 [0.67, 1.62]	
k.18.3 701-1050 mg Deniz 2012 tadhakrishnan 2005 kubtotal (95% CD) Total events feterogeneity: Not appl fest for overall effect: Z k.18.4 > 1050 mg Nodelmageed 2010 Dartholdy 2006 Derking 2003 Doha 2010 Durmus 2007 Greeen 2014 ajeda 2014	0 2 icable = 0.46 (P 2 3 18 3 23 23 3 3	25 30 55 = 0.64) 30 38 39 30 25 52 25	3 9 3 15 5 6 22 5	30 56 30 38 32 29 25 52 25	0.8N 1.1% 1.0% 9.4% 1.5% 1.5% 12.1% 1.3%	0.67 [0.12, 3.71] 0.67 [0.12, 3.71] 0.67 [0.12, 3.71] 1.00 [0.22, 4.65] 0.98 [0.60, 1.62] 0.58 [0.15, 2.21] 0.50 [0.14, 1.78] 1.05 [0.67, 1.62] 0.60 [0.16, 2.25]	
k.18.3 701-1050 mg Deniz 2012 Kadhakrishnan 2005 Kubtotal (95% Cl) Fotal events feterogeneity: Not appl Fest for overall effect: Z k.18.4 > 1050 mg Abdelmageed 2010 Bartholdy 2006 Derking 2003 Derka 2010 Dumus 2007 Grosen 2014 ajeda 2014 Gesucu 2013	0 2 icable = 0.46 (P 2 3 18 3 3 23 3 7	25 30 55 = 0.64) 30 38 39 30 25 52 25 29	3 9 3 15 6 22 5 4	30 56 30 38 32 29 25 52 25 31	0.8N 1.1% 1.0% 9.4% 1.3% 12.5% 1.3% 1.3%	0.67 [0.12, 3.71] 0.67 [0.12, 3.71] 1.00 [0.22, 4.65] 0.98 [0.60, 1.62] 0.58 [0.15, 2.21] 0.50 [0.14, 1.78] 1.05 [0.67, 1.62] 0.60 [0.16, 2.25] 1.87 [0.61, 5.73]	
k.18.3 701-1050 mg Deniz 2012 Kadhakrishnan 2005 Kubtotal (95% Cl) Fotal events feterogeneity: Not appl Fest for overall effect: 2 k.18.4 > 1050 mg Abdelmageed 2010 Fartholy 2006 Derking 2003 Derking 2003 Derking 2007 Greece 2014 Agieda 2014 Gesucu 2013 Mikkelsen 2006	0 2 = 0.46 (P 2 3 18 3 23 3 7 6	25 30 55 = 0.640 30 38 39 30 25 52 25 29 22	3 9 3 15 5 6 22 5 4 2	30 56 30 38 32 29 25 52 25 31 27	0.8N 1.1% 1.0% 9.4% 1.3% 12.1% 1.3% 1.3% 1.9%	0.67 [0.12, 3.71] 0.67 [0.12, 3.71] 0.67 [0.12, 3.71] 1.00 [0.22, 4.65] 0.98 [0.60, 1.62] 0.58 [0.15, 2.21] 0.50 [0.14, 1.78] 1.05 [0.67, 1.62] 0.60 [0.16, 2.25] 1.87 [0.61, 5.73] 3.68 [0.82, 16.47]	
k.18.3 701-1050 mg Deniz 2012 Kadhakrishnan 2005 Kubhotal (95% Cl) Fotal events feterogeneity: Not appl Fest for overall effect: Z k.18.4 > 1050 mg Abdelmageed 2010 fartholdy 2006 Dierking 2003 Deha 2010 Dumus 2007 Grosen 2014 ajeda 2014 Gesucu 2013 Mikkelsen 2006 Dmran 2006	0 2 icable = 0.46 (P 2 3 18 3 3 23 3 7 6 1	25 30 55 = 0.64) 30 38 39 30 25 52 25 29 22 50	3 9 3 15 5 6 22 5 4 2 7	30 56 30 38 32 29 25 25 25 31 27 50	0.8N 1.1% 1.0% 9.4% 1.3% 1.5% 1.5% 1.9% 1.0% 0.6%	0.67 [0.12, 3.71] 0.67 [0.12, 3.71] 0.67 [0.12, 3.71] 1.00 [0.22, 4.65] 0.98 [0.60, 1.62] 0.58 [0.15, 2.21] 0.50 [0.14, 1.78] 1.05 [0.67, 1.62] 0.60 [0.16, 2.25] 1.87 [0.61, 5.73] 3.68 [0.82, 1.647] 0.14 [0.02, 1.12]	
k.18.3 701-1050 mg Deniz 2012 kadhakrishnan 2005 kubotal (95% Cl) Total events feterogeneity: Not appl Total events feterogeneity: Not appl Total events feterogeneity: Not appl Total events feterogeneity: Not appl Total events k.18.4 > 1050 mg Abdelmageed 2010 fartholdy 2006 Dierking 2007 Trosen 2014 ajeda 2014 Gesucu 2013 Mikkelsen 2006 Pathak 2013	0 2 icable = 0.46 (P 2 3 18 3 3 23 23 23 7 6 1 0	25 30 55 = 0.64) 30 38 39 30 25 52 25 29 22 50 40	3 9315 5622 54271	30 56 30 38 29 25 25 25 25 25 25 25 40	0.8N 1.18 1.08 9.48 1.58 12.18 1.38 1.98 1.98 1.98 0.68 0.28	0.67 [0.12, 3.71] 0.67 [0.12, 3.71] 0.67 [0.12, 3.71] 0.09 [0.22, 4.65] 0.98 [0.60, 1.62] 0.58 [0.15, 2.21] 0.50 [0.14, 1.78] 1.05 [0.67, 1.62] 0.60 [0.16, 2.25] 1.87 [0.61, 5.73] 3.68 [0.82, 16.47] 0.14 [0.02, 1.12] 0.33 [0.01, 7.95]	
k.18.3 701-1050 mg Deniz 2012 tadhakrishnan 2005 kubtotal (95% Cl) Total events feterogeneity: Not appl fest for overall effect: Z k.18.4 > 1050 mg Nodelmageed 2010 Dartholdy 2006 Derking 2003 Doha 2010 Durmus 2007 Gresen 2014 ajeda 2014 Gesucu 2013 Hikkelsen 2006 Durran 2006 Tathak 2013 Sen 2019 a	0 2 icable = 0.46 (P 2 3 18 3 18 3 23 23 23 3 7 6 1 0 8	25 30 55 30 38 39 30 25 25 25 25 29 22 50 40 20	3 93155622542718	30 56 30 38 32 25 25 25 25 31 27 50 40 20	0.8N 1.1% 1.0% 9.4% 1.5% 12.1% 1.3% 1.9% 1.0% 0.6% 0.2% 4.1%	0.67 [0.12, 3.71] 0.67 [0.12, 3.71] 0.67 [0.12, 3.71] 1.00 [0.22, 4.65] 0.98 [0.60, 1.62] 0.58 [0.15, 2.21] 0.50 [0.14, 1.78] 1.05 [0.67, 1.62] 0.60 [0.16, 2.25] 1.87 [0.61, 5.73] 3.68 [0.82, 1.647] 0.14 [0.02, 1.12] 0.33 [0.01, 7.95] 1.00 [0.47, 2.14]	
k.18.3 701-1050 mg Deniz 2012 Kadhakrishnan 2005 Kubtotal (95% Cl) Fotal events feterogeneity: Not appl Fest for overall effect: 2 k.18.4 > 1050 mg Nodelmageed 2010 Forking 2008 Derking 2008 Derking 2008 Derking 2007 Gressen 2014 Agieda 2014 Gesucu 2013 Mikkelsen 2006 Pathak 2013 Gental 2016 Fathak 2013 Gental 2019 Fathak 2013 Gen 2009a Gen 2009b	0 2 = 0.46 (P 2 3 18 3 23 3 7 6 1 0 8 1	25 30 55 30 30 38 39 30 25 52 25 29 22 50 40 30	3 93155625427181	30 56 30 38 32 25 25 25 31 27 50 40 20 29	0.8N 1.1% 1.0% 9.4% 1.3% 1.5% 1.3% 1.9% 1.0% 0.6% 0.2% 4.1% 0.3%	0.67 [0.12, 3.71] 0.67 [0.12, 3.71] 0.67 [0.12, 3.71] 1.00 [0.22, 4.65] 0.98 [0.60, 1.62] 0.58 [0.15, 2.21] 0.50 [0.14, 1.78] 1.05 [0.64, 1.62] 0.60 [0.16, 2.25] 1.87 [0.61, 5.73] 3.68 [0.82, 16.47] 0.14 [0.02, 1.12] 0.33 [0.01, 7.95] 1.00 [0.47, 2.14]	
k.18.3 701-1050 mg Deniz 2012 Kadhakrishnan 2005 Kubtotal (95% Cl) Fotal events feterogeneity: Not appl Fest for overall effect: 2 k.18.4 > 1050 mg Abdelmageed 2010 Bartholdy 2006 Dierking 2003 Doha 2010 Durmus 2007 Grosen 2014 Gesucu 2013 Mikkelsen 2006 Dartan 2006 Dartak 2013 Genata 2014 Gesucu 2013 Mikkelsen 2006 Dartak 2013 Genata 2009 Dartak 2013 Genata 2009 Dartak 2013 Genata 2009 Dartak 2013 Genata 2009 Dartak 2013 Genata 2009 Dartak 2013 Dartak 2014 Dartak 2014	0 2 2 = 0.46 (P 2 3 18 3 23 3 7 6 1 0 8 1 6	25 30 55 = 0.640 38 39 30 25 52 25 52 25 50 40 20 20 25	3 9315562254271819	30 56 30 38 32 25 25 25 25 31 27 50 40 29 25	0.8N 1.1% 1.0% 9.4% 1.5% 12.1% 1.5% 1.5% 1.0% 0.6% 0.2% 4.1% 0.3% 3.1%	0.67 [0.12, 3.71] 0.67 [0.12, 3.71] 0.67 [0.12, 3.71] 1.00 [0.22, 4.65] 0.98 [0.60, 1.62] 0.58 [0.15, 2.21] 0.50 [0.14, 1.78] 1.05 [0.67, 1.62] 0.60 [0.16, 2.25] 1.87 [0.61, 5.73] 3.68 [0.82, 16.47] 0.14 [0.02, 1.12] 0.33 [0.01, 7.95] 1.00 [0.47, 2.14] 0.97 [0.06, 14.74] 0.97 [0.06, 14.74]	
k.18.3 701-1050 mg Deniz 2012 Kadhakrishnan 2005 Kubtotal (95% Cl) Fotal events feterogeneity: Not appl Fest for overall effect: 2 k.18.4 > 1050 mg Nodelmageed 2010 Forking 2008 Derking 2008 Derking 2008 Derking 2007 Gressen 2014 Agieda 2014 Gesucu 2013 Mikkelsen 2006 Pathak 2013 Gental 2016 Fathak 2013 Gental 2019 Fathak 2013 Gen 2009a Gen 2009b	0 2 = 0.46 (P 2 3 18 3 23 3 7 6 1 0 8 1	25 30 55 30 30 38 39 30 25 52 25 29 22 50 40 30	3 93155625427181	30 56 30 38 32 25 25 25 31 27 50 40 20 29	0.8N 1.1% 1.0% 9.4% 1.3% 1.5% 1.3% 1.9% 1.0% 0.6% 0.2% 4.1% 0.3%	0.67 [0.12, 3.71] 0.67 [0.12, 3.71] 0.67 [0.12, 3.71] 1.00 [0.22, 4.65] 0.98 [0.60, 1.62] 0.58 [0.15, 2.21] 0.50 [0.14, 1.78] 1.05 [0.64, 1.62] 0.60 [0.16, 2.25] 1.87 [0.61, 5.73] 3.68 [0.82, 16.47] 0.14 [0.02, 1.12] 0.33 [0.01, 7.95] 1.00 [0.47, 2.14]	
k.18.3 701-1050 mg Deniz 2012 Kadhakrishnan 2005 Kubtotal (95% Cl) Fotal events feterogeneity: Not appl Fest for overall effect: 2 k.18.4 > 1050 mg Abdelmageed 2010 Bartholdy 2006 Dierking 2003 Doha 2010 Durmus 2007 Grosen 2014 Gesucu 2013 Mikkelsen 2006 Dartan 2006 Dartak 2013 Genata 2014 Gesucu 2013 Mikkelsen 2006 Dartak 2013 Genata 2009 Dartak 2013 Genata 2009 Dartak 2013 Genata 2009 Dartak 2013 Genata 2009 Dartak 2013 Genata 2009 Dartak 2013 Dartak 2014 Dartak 2014	0 2 2 = 0.46 (P 2 3 18 3 23 3 7 6 1 0 8 1 6	25 30 55 = 0.640 38 39 30 25 52 25 52 25 50 40 20 20 25	3 9315562254271819	30 56 30 38 32 25 25 25 25 31 27 50 40 29 25	0.8N 1.1% 1.0% 9.4% 1.5% 12.1% 1.5% 1.5% 1.0% 0.6% 0.2% 4.1% 0.3% 3.1%	0.67 [0.12, 3.71] 0.67 [0.12, 3.71] 0.67 [0.12, 3.71] 1.00 [0.22, 4.65] 0.98 [0.60, 1.62] 0.58 [0.15, 2.21] 0.50 [0.14, 1.78] 1.05 [0.67, 1.62] 0.60 [0.16, 2.25] 1.87 [0.61, 5.73] 3.68 [0.82, 16.47] 0.14 [0.02, 1.12] 0.33 [0.01, 7.95] 1.00 [0.47, 2.14] 0.97 [0.06, 14.74] 0.97 [0.06, 14.74]	
k.18.3 701-1050 mg Deniz 2012 Kadhakrishnan 2005 Kubhotal (95% Cl) Fotal events feterogeneity: Not appl fest for overall effect: Z k.18.4 > 1050 mg Abdelmageed 2010 fartholdy 2006 Dierking 2003 Daha 2010 Durmus 2007 Grosen 2014 ajeda 2014 Gesucu 2013 Mikkelsen 2006 Dartal 2006 Dartal 2006 Dartal 2008 Sein 2009b Furan 2008a Furan 2003a Furan 2003a	0 2 icable = 0.46 (P 2 3 18 3 3 23 3 7 6 1 0 8 1 6 1 0 8 1 1 0	25 30 55 = 0.640 30 38 39 30 25 52 25 52 25 50 40 20 30 25 25 52 25 50 40 25 52 52 55	3 9315622542718196	30 56 30 38 32 29 25 25 25 31 27 50 40 20 29 25 25 25 25 25 25 25 25 25 25 25 25 25	0.8N 1.1% 1.0% 9.4% 1.3% 1.5% 1.3% 1.3% 1.9% 1.0% 0.6% 0.2% 4.1% 0.6%	0.67 [0.12, 3.71] 0.67 [0.12, 3.71] 0.67 [0.12, 3.71] 0.67 [0.12, 3.71] 1.00 [0.22, 4.65] 0.98 [0.60, 1.62] 0.58 [0.15, 2.21] 0.50 [0.14, 1.78] 1.05 [0.67, 1.62] 0.60 [0.16, 2.25] 1.87 [0.61, 5.73] 3.68 [0.82, 16.47] 0.14 [0.02, 1.12] 0.33 [0.01, 7.95] 1.00 [0.47, 2.14] 0.97 [0.06, 14.74] 0.67 [0.28, 1.59] 0.17 [0.02, 1.29]	
k.18.3 701-1050 mg Deniz 2012 kadhakrishnan 2005 kubotal (95% Cl) Total events feterogeneity: Not appl Total events feterogeneity: Not appl for avents feterogeneity: Not appl for avents feterogeneity: Not appl feterogeneity: Not appl for avents feterogeneity: Not appl for avents feterogeneity: Not appl feterogeneity: Not appl feterogene	0 2 icable = 0.46 (P 2 3 18 3 18 3 23 23 23 7 6 1 0 8 1 6 1 9	25 300 55 30 38 39 30 25 25 29 22 25 20 20 20 20	3 93155622542718196 10	30 56 30 38 32 25 52 25 31 27 40 20 29 25 20 20	0.8N 1.1N 1.0N 9.4N 1.5N 1.5N 1.5N 1.5N 1.9N 1	0.67 [0.12, 3.71] 0.67 [0.12, 3.71] 0.67 [0.12, 3.71] 1.00 [0.22, 4.65] 0.98 [0.60, 1.62] 0.58 [0.15, 2.21] 0.50 [0.14, 1.78] 1.05 [0.67, 1.62] 0.60 [0.16, 2.25] 1.87 [0.61, 5.73] 3.68 [0.82, 16.47] 0.14 [0.02, 1.12] 1.00 [0.47, 2.14] 0.97 [0.06, 14.74] 0.67 [0.28, 1.59] 0.17 [0.02, 1.29] 0.90 [0.47, 1.73]	
k.18.3 701-1050 mg Deniz 2012 Kadhakrishnan 2005 Kubtotal (95% Cl) Fotal events feterogeneity: Not appl Fest for overall effect: 2 k.18.4 > 1050 mg Abdelmageed 2010 Bartholdy 2006 Dierking 2003 Daha 2010 Durmus 2007 Fresen 2014 Gesucu 2013 Mikkelsen 2006 Dartan 2006 Pathak 2013 Sein 2009a Sein 2009b Furan 2005 Furan 2005 Furan 2006 Juak 2011	0 2 2 3 18 3 23 3 7 6 1 0 8 1 6 1 9 22 3 8 3 7 6 1 1 0 8 12	25 30 55 30 38 30 38 30 25 52 29 22 50 40 20 30 25 25 20 20 25	3 9315562254271819610 18	30 56 30 38 32 25 25 25 25 25 25 20 29 25 20 25 20 25 25 20 25	0.8N 1.1% 1.0% 9.4% 1.3% 1.5% 1.3% 1.5% 1.9% 1.0% 0.6% 0.2% 4.1% 0.3% 3.1% 0.5% 5.5% 10.4%	0.67 [0.12, 3.71] 0.67 [0.12, 3.71] 0.67 [0.12, 3.71] 1.00 [0.22, 4.65] 0.98 [0.60, 1.62] 0.58 [0.15, 2.21] 0.50 [0.14, 1.78] 1.05 [0.61, 5.73] 3.68 [0.82, 16.47] 0.14 [0.02, 1.12] 0.33 [0.01, 7.95] 1.00 [0.47, 2.14] 0.97 [0.06, 14.74] 0.67 [0.28, 1.59] 0.17 [0.28, 1.59] 0.17 [0.41, 1.07] 2.00 [0.41, 9.71]	
k.18.3 701-1050 mg Deniz 2012 Kadhakrishnan 2005 Kabhakrishnan 2005 Kabhakrishnan 2005 Kabhakrishnan 2005 Kadhakrishnan 2005 Fotal events (eterogeneity: Not appl Fest for overall effect: 2 k.18.4 > 1050 mg Nodelmageed 2010 Bartholdy 2006 Derking 2006 Derking 2007 Gressen 2014 Agieda 2014 Gesucu 2013 Mikkelsen 2006 Pathak 2013 Gen 2009 Fathak 2013 Gen 2009 Fartan 2005 Furan 2005 Furan 2005 Furan 2005	0 2 2 3 18 3 3 23 3 7 6 1 0 8 1 6 1 9 2 2 3 8 3 7 6 1 0 8 1 6 1 9 2 2 3 8 3 7 6 1 8 3 7 6 1 8 4 6 9 7 8 1 8 9 7 8 9 8 9 8 9 8 9 8 9 8 9 8 9 8 9 8	25 30 55 = 0.640 38 39 30 25 52 25 50 40 20 25 20 20	3 93155625427181960182	300 56 302 29 25 52 52 52 52 52 52 52 52 52 52 52 52	0.8N 1.1% 1.0% 9.4% 1.3% 1.5% 1.3% 1.3% 1.3% 1.3% 0.6% 0.2% 4.1% 0.6% 5.5% 10.4% 0.9%	0.67 [0.12, 3.71] 0.67 [0.12, 3.71] 0.67 [0.12, 3.71] 0.67 [0.12, 3.71] 0.98 [0.60, 1.62] 0.98 [0.60, 1.62] 0.58 [0.15, 2.21] 0.50 [0.14, 1.78] 1.05 [0.67, 1.62] 0.60 [0.16, 2.25] 1.87 [0.61, 5.73] 3.68 [0.82, 16.47] 0.14 [0.02, 1.22] 1.00 [0.47, 2.14] 0.97 [0.06, 14.74] 0.67 [0.28, 1.59] 0.17 [0.02, 1.29] 0.90 [0.47, 1.73] 0.67 [0.41, 1.07] 2.00 [0.41, 9.71] 0.60 [0.15, 2.38]	
k.18.3 701-1050 mg Deniz 2012 tadhakrishnan 2005 kubotal (95% Cl) Total events feterogeneity: Not appl fest for overall effect: Z k.18.4 > 1050 mg Abdelmageed 2010 fartholdy 2006 Dierking 2003 Daha 2010 Durmus 2007 Grosen 2014 ajeda 2014 Gesucu 2013 dikkelsen 2006 Dartaik 2013 Gentaik 2011 Dispencil 2011 Gesteval (95% Cl)	0 2 icable = 0.46 (P 2 3 18 3 2 3 7 6 1 0 8 1 6 1 9 12 4 3	25 30 55 = 0.640 30 38 39 30 25 52 25 52 25 50 40 20 30 30 25 52 25 20 25 25 25 50 50 50	3 93155622542718196001825	30 56 30 32 29 25 25 25 25 25 20 20 25 25 20 25 25 25 25 25 25 25 25 25 25 25 25 25	0.8N 1.1% 1.0% 9.4% 1.3% 1.5% 1.3% 1.3% 1.3% 1.3% 1.3% 1.3% 1.3% 1.3% 1.3% 1.5% 1.3% 1.5% 1.3% 1.5% 1.3% 1.5% 1.3% 1.5%	0.67 [0.12, 3.71] 0.67 [0.12, 3.71] 0.67 [0.12, 3.71] 1.00 [0.22, 4.65] 0.98 [0.60, 1.62] 0.58 [0.15, 2.21] 0.50 [0.14, 1.78] 1.05 [0.61, 5.73] 3.68 [0.82, 16.47] 0.14 [0.02, 1.12] 0.33 [0.01, 7.95] 1.00 [0.47, 2.14] 0.97 [0.06, 14.74] 0.67 [0.28, 1.59] 0.17 [0.28, 1.59] 0.17 [0.41, 1.07] 2.00 [0.41, 9.71]	
k.18.3 701-1050 mg Deniz 2012 Kadhakrishnan 2005 Kubtotal (95% CD) Fotal events teterogeneity: Not appl Fotal events teterogeneity: Not appl Fotal events k.18.4 > 1050 mg Abdelmageed 2010 Bartholdy 2006 Derking 2008 Derking 2008 Derking 2008 Derking 2007 Grosen 2014 Agieda 2014 Gesucu 2013 Mikkelsen 2006 Pathak 2013 Gen 2009b Furan 2005 Furan 2005	0 2 2 3 18 3 23 3 7 6 1 0 8 1 6 1 9 12 4 3 113	25 30 55 30 38 30 25 52 29 22 50 40 20 30 25 25 20 25 20 595	3 9315562254271819600 1825 138	30 56 30 38 32 29 25 52 5 25 31 27 50 20 25 20 25 20 25 20 25 593	0.8N 1.1% 1.0% 9.4% 1.3% 1.5% 1.3% 1.5% 1.3% 1.9% 1.0% 0.6% 0.4% 0.3% 3.1% 0.6% 0.5% 5.5% 1.2% 5.7.5%	0.67 [0.12, 3.71] 0.67 [0.12, 3.71] 0.67 [0.12, 3.71] 1.00 [0.22, 4.65] 0.98 [0.60, 1.62] 0.58 [0.15, 2.21] 0.50 [0.14, 1.78] 1.05 [0.67, 1.62] 0.60 [0.16, 2.25] 1.87 [0.61, 5.73] 3.68 [0.82, 16.47] 0.14 [0.02, 1.12] 0.33 [0.01, 7.95] 1.00 [0.47, 2.14] 0.97 [0.06, 14.74] 0.67 [0.28, 1.59] 0.17 [0.02, 1.29] 0.50 [0.47, 1.73] 0.67 [0.41, 1.07] 2.00 [0.41, 9.71] 0.60 [0.15, 2.38] 0.84 [0.67, 1.05]	
k.18.3 701-1050 mg Deniz 2012 Kadhakrishnan 2005 Kabhakrishnan 2005 Kabhakrishnan 2005 Kabhakrishnan 2005 Kadhakrishnan 2005 Katal events (etersgeneity: Not appl Fest for overall effect: 2 k.18.4 > 1050 mg Noteking 2006 Derking 2003 Derking 2003 Derking 2007 Gressen 2014 Agieda 2014 Gesucu 2013 Mikkelsen 2006 Dartan 2006 Pathak 2013 Gesucu 2013 Mikkelsen 2006 Dartan 2005 Guran 2005 Gatal events Heterogeneity: Tau <sup>2</sup> = 0	0 2 2 cable 2 = 0.46 (P 2 3 18 3 3 23 3 7 6 1 0 8 1 6 1 0 8 1 6 1 9 9 2 2 3 3 7 6 1 0 8 1 8 3 3 7 6 1 1 0 8 1 8 3 3 7 6 1 1 9 1 9 1 9 1 9 1 9 1 9 1 9 1 9 1 9	25 30 55 = 0.640 38 39 30 25 52 25 20 25 20 50 50 59 59 59 50 50 50 50 50 50 50 50 50 50 50 50 50	3 9315 5622 54271 8196 1082 5 138 df = 18	30 56 30 38 32 29 25 52 5 25 31 27 50 20 25 20 25 20 25 20 25 593	0.8N 1.1% 1.0% 9.4% 1.3% 1.5% 1.3% 1.5% 1.3% 1.9% 1.0% 0.6% 0.4% 0.3% 3.1% 0.6% 0.5% 5.5% 1.2% 5.7.5%	0.67 [0.12, 3.71] 0.67 [0.12, 3.71] 0.67 [0.12, 3.71] 1.00 [0.22, 4.65] 0.98 [0.60, 1.62] 0.58 [0.15, 2.21] 0.50 [0.14, 1.78] 1.05 [0.67, 1.62] 0.60 [0.16, 2.25] 1.87 [0.61, 5.73] 3.68 [0.82, 16.47] 0.14 [0.02, 1.12] 0.33 [0.01, 7.95] 1.00 [0.47, 2.14] 0.97 [0.06, 14.74] 0.67 [0.28, 1.59] 0.17 [0.02, 1.29] 0.50 [0.47, 1.73] 0.67 [0.41, 1.07] 2.00 [0.41, 9.71] 0.60 [0.15, 2.38] 0.84 [0.67, 1.05]	
k.18.3 701-1050 mg Deniz 2012 tadhakrishnan 2005 kubotal (95% Cl) Total events feterogeneity: Not appl fest for overall effect: Z k.18.4 > 1050 mg Abdelmageed 2010 fartholdy 2006 Dierking 2003 Daha 2010 Durmus 2007 Grosen 2014 ajeda 2014 Gesucu 2013 dikkelsen 2006 Dartaik 2013 Gentaik 2011 Dispencil 2011 Gesteval (95% Cl)	0 2 2 cable 2 = 0.46 (P 2 3 18 3 3 23 3 7 6 1 0 8 1 6 1 0 8 1 6 1 9 9 2 2 3 3 7 6 1 0 8 1 8 3 3 7 6 1 1 0 8 1 8 3 3 7 6 1 1 9 1 9 1 9 1 9 1 9 1 9 1 9 1 9 1 9	25 30 55 = 0.640 38 39 30 25 52 25 20 25 20 50 50 59 59 59 50 50 50 50 50 50 50 50 50 50 50 50 50	3 9315 5622 54271 8196 1082 5 138 df = 18	30 56 30 38 32 29 25 52 25 31 27 50 20 25 20 25 20 25 20 25 20 59 3 6 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9	0.8N 1.1% 1.0% 9.4% 1.3% 1.5% 1.3% 1.5% 1.3% 1.9% 1.0% 0.6% 0.4% 0.3% 3.1% 0.6% 0.5% 5.5% 1.2% 5.7.5%	0.67 [0.12, 3.71] 0.67 [0.12, 3.71] 0.67 [0.12, 3.71] 1.00 [0.22, 4.65] 0.98 [0.60, 1.62] 0.58 [0.15, 2.21] 0.50 [0.14, 1.78] 1.05 [0.67, 1.62] 0.60 [0.16, 2.25] 1.87 [0.61, 5.73] 3.68 [0.82, 16.47] 0.14 [0.02, 1.12] 0.33 [0.01, 7.95] 1.00 [0.47, 2.14] 0.97 [0.06, 14.74] 0.67 [0.28, 1.59] 0.17 [0.02, 1.29] 0.50 [0.47, 1.73] 0.67 [0.41, 1.07] 2.00 [0.41, 9.71] 0.60 [0.15, 2.38] 0.84 [0.67, 1.05]	
k.18.3 701-1050 mg Deniz 2012 Kadhakrishnan 2005 Kubotal (95% Cl) Total events Teterogeneity: Not appl Test for overall effect: Z k.18.4 > 1050 mg Abdelmageed 2010 fartholdy 2006 Dierking 2003 Doha 2010 Durmus 2007 Crosen 2014 ajeda 2014 Gesucu 2013 Mikkelsen 2006 Dartal 2006 Dartal 2008 Turan 2006 Dartal 2008 Turan 2006 Dartal 2011 Degencil 2011 Subtotal (95% Cl) Test for overall effect: Z	0 2 2 cable 2 = 0.46 (P 2 3 18 3 3 23 3 7 6 1 0 8 1 6 1 0 8 1 6 1 9 9 2 2 3 3 7 6 1 0 8 1 8 3 3 7 6 1 1 0 8 1 8 3 3 7 6 1 1 9 1 9 1 9 1 9 1 9 1 9 1 9 1 9 1 9	25 30 55 55 30 30 38 39 30 25 52 25 25 20 25 20 25 20 25 20 25 50 50 50 50 50 50 50 50 50 50 50 50 50	3 9315 5622 54271 8196 1082 5 138 df = 18	30 56 30 38 32 29 25 52 25 31 27 50 20 25 20 25 20 25 20 25 20 59 3 6 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9	0.8% 1.1% 1.0% 9.4% 1.3%	0.67 [0.12, 3.71] 0.67 [0.12, 3.71] 0.67 [0.12, 3.71] 1.00 [0.22, 4.65] 0.98 [0.60, 1.62] 0.58 [0.15, 2.21] 0.50 [0.14, 1.78] 1.05 [0.67, 1.62] 0.60 [0.16, 2.25] 1.87 [0.61, 5.73] 3.68 [0.82, 16.47] 0.14 [0.02, 1.12] 0.33 [0.01, 7.95] 1.00 [0.47, 2.14] 0.97 [0.26, 14.74] 0.67 [0.28, 1.59] 0.17 [0.02, 1.29] 0.90 [0.47, 1.73] 0.67 [0.41, 1.07] 2.00 [0.41, 9.71] 0.60 [0.15, 2.38] 0.84 [0.67, 1.05]	
k.18.3 701-1050 mg Deniz 2012 Kadhakrishnan 2005 Kubtotal (95% Cl) Fotal events teterogeneity: Not appl Fotal events teterogeneity: Not appl Parking 2007 Deniz 2007 Derking 2008 Dekking 2	0 2 2 3 18 3 23 3 7 6 1 0 8 1 3 7 6 1 0 8 1 6 1 0 8 1 2 3 3 7 6 1 1 0 8 1 2 3 3 7 6 1 1 0 8 1 8 3 2 3 3 7 6 1 1 9 1 2 3 1 8 3 7 6 9 7 6 9 7 8 1 8 1 8 1 9 1 8 1 9 1 8 1 9 1 9 1 9 1	25 30 55 = 0.640 338 39 30 25 52 29 22 50 20 50 595 20.166 = 0.13) 1445	3 9 3 15 5 6 22 5 4 2 7 1 8 1 9 6 10 18 2 5 138 df = 18 271	30 56 30 38 32 29 25 52 25 27 50 40 29 25 25 25 25 25 25 25 25 25 25	0.8N 1.1% 1.0% 9.4% 1.3% 1.5% 1.2% 1.3% 1.0% 0.6% 0.2% 4.1% 0.5% 0.5% 5.5% 1.2% 5.7.5% 1.3%	0.67 [0.12, 3.71] 0.67 [0.12, 3.71] 0.67 [0.12, 3.71] 1.00 [0.22, 4.65] 0.98 [0.60, 1.62] 0.58 [0.15, 2.21] 0.50 [0.14, 1.78] 1.05 [0.67, 1.62] 0.60 [0.16, 2.25] 1.87 [0.61, 5.73] 3.68 [0.82, 16.47] 0.14 [0.02, 1.12] 0.33 [0.01, 7.95] 1.00 [0.47, 2.14] 0.67 [0.28, 1.59] 0.59 [0.47, 1.73] 0.67 [0.41, 1.07] 2.00 [0.41, 9.71] 0.60 [0.15, 2.38] 0.84 [0.67, 1.05] 11%	
k.18.3 701-1050 mg Deniz 2012 Kadhakrishnan 2005 Kabhotsihnan 2005 Kabhotsihnan 2005 Kabhotsihnan 2005 Kadhakrishnan 2005 Katal events K.18.4 > 1050 mg Nodelmageed 2010 Katholy 2006 Derking 2003 Derking 2003 Derking 2003 Derking 2003 Derking 2005 Darma 2006 Pathak 2013 Gesucu 2013 Mikkelsen 2006 Daran 2006 Pathak 2013 Gesucu 2013 Kathak 2013 Gesucu 2013 Kathak 2013 Gesucu 2005 Gatal events Heterogeneity: Taw <sup>2</sup> = 0 Fest for overall effect: 2 Fotal events	0 2 2 3 3 18 3 3 23 3 7 6 1 0 8 1 6 1 9 9 2 4 3 113 100 Chi <sup>2</sup> =	25 30 55 = 0.640 338 39 30 25 52 25 50 400 25 25 20 50 50 50 50 50 50 50 50 50 5	3 9 3 15 6 22 5 4 2 7 1 8 1 9 6 0 10 18 2 5 4 2 7 1 8 1 9 6 0 10 18 2 5 4 2 7 1 5 6 22 5 4 2 7 1 5 6 22 5 4 2 7 1 5 5 6 22 5 4 2 7 1 5 5 6 2 2 5 5 6 2 2 5 5 6 2 2 5 6 2 5 6 2 5 5 6 2 2 5 5 6 2 2 5 6 2 5 7 7 1 8 2 5 6 2 5 7 1 8 2 5 9 6 10 10 10 10 10 10 10 10 10 10 10 10 10	30 56 30 38 32 29 25 52 25 27 50 40 29 25 25 25 25 25 25 25 25 25 25	0.8N 1.1% 1.0% 9.4% 1.3% 1.5% 1.2% 1.3% 1.0% 0.6% 0.2% 4.1% 0.5% 0.5% 5.5% 1.2% 5.7.5% 1.3%	0.67 [0.12, 3.71] 0.67 [0.12, 3.71] 0.67 [0.12, 3.71] 1.00 [0.22, 4.65] 0.98 [0.60, 1.62] 0.58 [0.15, 2.21] 0.50 [0.14, 1.78] 1.05 [0.67, 1.62] 0.60 [0.16, 2.25] 1.87 [0.61, 5.73] 3.68 [0.82, 16.47] 0.14 [0.62, 1.12] 0.33 [0.01, 7.95] 1.00 [0.47, 2.14] 0.67 [0.28, 1.59] 0.17 [0.06, 14.74] 0.67 [0.28, 1.59] 0.17 [0.02, 1.23] 0.60 [0.15, 2.38] 0.84 [0.67, 1.05] 11% 0.79 [0.67, 0.92]	0.01 0.1 10 Favours Gebapentin Favours Cent

# Supplemental Digital Content 17 Forest plot of sedation from trials with low risk of bias

	Gabape		Contr			Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	M-H, Random, 95% Cl
3.19.1 0-350 mg							
Spence 2011	20	26	21	31	21.6%	1.14 [0.82, 1.57]	<b>+</b>
Waikakul 2011	1	26	0	24	0.2%	2.78 [0.12, 65.08]	
Subtotal (95% CI)		52		55	21.9%	1.15 [0.83, 1.58]	<b>•</b>
Total events	21		21				
Heterogeneity: Tau <sup>2</sup> =	,		,	1 (P = 0)	).56); I <sup>2</sup> =	0%	
Test for overall effect	: Z = 0.84	(P = 0)	.40)				
3.19.2 351-700 mg							
Kinney 2011	10	57	10	63	3.5%	1.11 [0.50, 2.46]	_ <b>+</b>
Moore 2010	17	21	17	23	21.9%	1.10 [0.80, 1.51]	+
Paul 2013	35	52	35	49	33.2%	0.94 [0.73, 1.22]	+
Srivastava 2010	14	60	8	60	3.6%	1.75 [0.79, 3.86]	+
Subtotal (95% CI)		190		195	62.2%	1.04 [0.86, 1.26]	<b>♦</b>
Total events	76		70				
Heterogeneity: Tau <sup>2</sup> =	= 0.00; Ch	$i^2 = 2.6$	51, df =	3 (P = 0)	).46); I <sup>2</sup> =	0%	
Test for overall effect	: Z = 0.39	(P = 0	.69)				
3.19.3 701-1050 mg	J						
Ghai 2011	10	30	12	30	5.0%	0.83 [0.43, 1.63]	_ <del>_</del>
Subtotal (95% CI)		30		30	5.0%	0.83 [0.43, 1.63]	
Total events	10		12				
Heterogeneity: Not ap	plicable						
Test for overall effect	Z = 0.53	(P = 0	.59)				
3.19.4 > 1050 mg							
Bartholdy 2006	21	38	13	38	8.1%	1.62 [0.96, 2.73]	<b>⊢</b>
Grosen 2014	10	52	7	52	2.8%	1.43 [0.59, 3.47]	- <b> </b>
Subtotal (95% CI)		90		90	10.9%	1.56 [1.00, 2.46]	◆
Total events	31		20				
Heterogeneity: Tau <sup>2</sup> =	= 0.00; Ch	$i^2 = 0.0$	)6, df = 1	1 (P = 0)	).81); I <sup>2</sup> =	0%	
Test for overall effect	: Z = 1.94	(P = 0	.05)				
Total (95% CI)		362		370	100.0%	1.10 [0.95, 1.27]	•
Total events	138		123				ſ
Heterogeneity: Tau <sup>2</sup> =		$i^2 = 6.5$		8 (P = 0	).58): I <sup>2</sup> =	0%	0.01 0.1 1 10
		511					
Test for overall effect	: Z = 1.22	(P = 0)	.22)				0.01 0.1 İ 10 avours Gabapentin Favours Contro

Study or Subgroup		ntin	Contr			Risk Ratio	Risk Ratio
	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	M-H, Random, 95% CI
3.20.1 0-350 mg							
Bang 2009	1	23	1	23	0.6%	1.00 [0.07, 15.04]	
Ghafari 2009	2	33	3	33	1.3%	0.67 [0.12, 3.73]	
Khurana 2013	4	30	0	30	0.5%	9.00 [0.51, 160.17]	
Panday 2004b	52	153	5	153	3.2%	10.40 [4.27, 25.32]	
Sekhavet 2009	26	49	22	49	5.6%	1.18 [0.79, 1.78]	
Vahedi 2011	16	36	0	40	0.6%	36.57 [2.27, 588.35]	
Waikakul 2011	1	26	0	24	0.4%	2.78 [0.12, 65.08]	
Yoon 2001	13	16	13	16	6.0%	1.00 [0.72, 1.39]	+
Subtotal (95% CI)		366		368	18.3%	2.51 [0.89, 7.05]	
Total events	115		44				
Heterogeneity: Tau <sup>2</sup> = 1 Test for overall effect: Z				(P < 0.0	00001); I <sup>2</sup>	= 89%	
3.20.2 351-700 mg							
Ajori 2011	0	69	0	69		Not estimable	
Clarke 2009b	18	76	7	38	3.7%	1.29 [0.59, 2.81]	
Kavitha 2013	3	28	9	28	2.2%	0.33 [0.10, 1.10]	
Kazak 2009	0	30	0	30		Not estimable	
Kim 2004	5	21	5	20	2.6%	0.95 [0.32, 2.80]	-+
Kinney 2011	10	57	10	63	3.6%	1.11 [0.50, 2.46]	- <del> </del>
Moore 2010	17	21	17	23	6.1%	1.10 [0.80, 1.51]	+
Panday 2005	3	40	1	20	0.9%	1.50 [0.17, 13.52]	<del>_</del>
Panday 2006	4	125	2	125	1.4%	2.00 [0.37, 10.72]	
Paul 2013	35	52	35	49	6.4%	0.94 [0.73, 1.22]	↓
Sava 2009		25		25		2.00 [0.19, 20.67]	
	2		1		0.8%		
Siddiqui 2013	28	36	36	36	6.7%	0.78 [0.65, 0.93]	
Spence 2011	20	26	21	31	6.1%	1.14 [0.82, 1.57]	+
Srivastava 2010	14	60	8	60	3.6%	1.75 [0.79, 3.86]	
Zaldivar Ramirez 2011	2	18	0	16	0.5%	4.47 [0.23, 86.77]	
Subtotal (95% CI)		684		633	44.6%	1.00 [0.83, 1.19]	♦
Total events	161		152				
3.20.3 701-1050 mg	10	20	10	20	4.2%	0 0 10 40 1 60	
Ghai 2011 Chai 2012	10	30	12	30	4.2%	0.83 [0.43, 1.63]	
Ghai 2012	8	30	0	30	0.6%	17.00 [1.03, 281.91]	
Neogi 2012	1	30	0	30	0.4%		
						3.00 [0.13, 70.83]	
Radhakrishnan 2005 Subtotal (95% CI)	1	30 120	1	30 120	0.6% <b>5.8%</b>	1.00 [0.13, 70.83] 1.00 [0.07, 15.26] <b>1.87 [0.40, 8.70]</b>	
	1 20 L.23; Chi <sup>2</sup> =	30 <b>120</b> 6.10,	1 13 df = 3 (P	120	5.8%	1.00 [0.07, 15.26] 1.87 [0.40, 8.70]	
Subtotal (95% CI) Total events Heterogeneity: Tau <sup>2</sup> = 1 Test for overall effect: 2 3.20.4 > 1050 mg	1 20 1.23; Chi <sup>2</sup> = 2 = 0.80 (P	30 <b>120</b> = 6.10, = 0.43	1 13 df = 3 (P	120 9 = 0.12	5.8% 1); I <sup>2</sup> = 51	1.00 [0.07, 15.26] <b>1.87 [0.40, 8.70]</b> %	
Subtotal (95% CI) Total events Heterogeneity: Tau <sup>2</sup> = 1 Test for overall effect: 2 3.20.4 > 1050 mg	1 20 1.23; Chi <sup>2</sup> = 2 = 0.80 (P 2	30 120 = 6.10, = 0.43	1 df = 3 (P ) 1	120	5.8%	1.00 [0.07, 15.26] <b>1.87 [0.40, 8.70]</b> % 2.00 [0.19, 20.90]	
Subtotal (95% CI) Total events Heterogeneity: Tau <sup>2</sup> = 1 Test for overall effect: 2 3.20.4 > 1050 mg Abdelmageed 2010	1 20 1.23; Chi <sup>2</sup> = 2 = 0.80 (P	30 <b>120</b> = 6.10, = 0.43	1 13 df = 3 (P	120 9 = 0.12	5.8% 1); I <sup>2</sup> = 51	1.00 [0.07, 15.26] <b>1.87 [0.40, 8.70]</b> %	
Subtotal (95% CI) Total events Heterogeneity: Tau <sup>2</sup> = 1 Test for overall effect: 2 3.20.4 > 1050 mg Abdelmageed 2010 Al-Mujadi 2005	1 20 1.23; Chi <sup>2</sup> = 2 = 0.80 (P 2	30 120 = 6.10, = 0.43	1 df = 3 (P ) 1	120 9 = 0.12 30	5.8% 1); I <sup>2</sup> = 51	1.00 [0.07, 15.26] <b>1.87 [0.40, 8.70]</b> % 2.00 [0.19, 20.90]	
Subtotal (95% CI) Total events Heterogeneity: Tau <sup>2</sup> = 1 Test for overall effect: 2 3.20.4 > 1050 mg Abdelmageed 2010 Al-Mujadi 2005 Bartholdy 2006	1 20 1.23; Chi <sup>2</sup> = 2 = 0.80 (P 2 0	30 120 = 6.10, = 0.43 30 37	1 df = 3 (P ) 1 0	120 9 = 0.12 30 35	5.8% 1); I <sup>2</sup> = 51 0.8%	1.00 [0.07, 15.26] <b>1.87 [0.40, 8.70]</b> % 2.00 [0.19, 20.90] Not estimable 1.62 [0.96, 2.73]	
Subtotal (95% CI) Total events Heterogeneity: Tau <sup>2</sup> = 1 Test for overall effect: 2 3.20.4 > 1050 mg Abdelmageed 2010 Al-Mujadi 2005 Bartholdy 2006 Dirks 2002	1 20 1.23; Chi <sup>2</sup> = 2 = 0.80 (P 2 0 21 21	30 120 = 6.10, = 0.43 30 37 38 31	1 df = 3 (P ) 1 0 13 22	120 9 = 0.12 30 35 38 34	5.8% 1); I <sup>2</sup> = 51 0.8% 5.0% 6.0%	1.00 [0.07, 15.26] <b>1.87 [0.40, 8.70]</b> % 2.00 [0.19, 20.90] Not estimable 1.62 [0.96, 2.73] 1.05 [0.74, 1.48]	
Subtotal (95% CI) Total events Heterogeneity: Tau <sup>2</sup> = 1 Test for overall effect: 2 3.20.4 > 1050 mg Abdelmageed 2010 Al-Mujadi 2005 Bartholdy 2006 Dirks 2002 Grosen 2014	1 20 1.23; Chi <sup>2</sup> = 2 = 0.80 (P 2 0 21 21 10	30 120 = 6.10, = 0.43 30 37 38 31 52	1 df = 3 (P ) 1 0 13 22 7	120 9 = 0.11 30 35 38 34 52	5.8% 1); I <sup>2</sup> = 51 0.8% 5.0% 6.0% 3.2%	1.00 [0.07, 15.26] <b>1.87 [0.40, 8.70]</b> % 2.00 [0.19, 20.90] Not estimable 1.62 [0.96, 2.73] 1.05 [0.74, 1.48] 1.43 [0.59, 3.47]	
Subtotal (95% CI) Total events Heterogeneity: Tau <sup>2</sup> = 1 Test for overall effect: 2 3.20.4 > 1050 mg Abdelmageed 2010 Al-Mujadi 2005 Bartholdy 2006 Dirks 2002 Grosen 2014 Jajeda 2014	1 20 1.23; Chi <sup>2</sup> = 2 = 0.80 (P 21 21 10 8	30 120 = 6.10, = 0.43 30 37 38 31 52 25	1 df = 3 (P ) 1 0 13 22 7 3	120 9 = 0.11 30 35 38 34 52 25	5.8% 1); I <sup>2</sup> = 51 0.8% 5.0% 6.0% 3.2% 2.2%	1.00 [0.07, 15.26] <b>1.87 [0.40, 8.70]</b> % 2.00 [0.19, 20.90] Not estimable 1.62 [0.96, 2.73] 1.05 [0.74, 1.48] 1.43 [0.59, 3.47] 2.67 [0.80, 8.90]	
Subtotal (95% CI) Total events Heterogeneity: Tau <sup>2</sup> = 1 Test for overall effect: 2 3.20.4 > 1050 mg Abdelmageed 2010 Al-Mujadi 2005 Bartholdy 2006 Dirks 2002 Grosen 2014 Jajeda 2014 Kosucu 2013	1 20 1.23; Chi <sup>2</sup> = 2 = 0.80 (P 21 21 10 8 2	30 120 = 6.10, = 0.43 30 37 38 31 52 25 29	1 df = 3 (P ) 1 0 13 22 7 3 1	120 9 = 0.11 30 35 38 34 52 25 31	5.8% 1);   <sup>2</sup> = 51 0.8% 5.0% 6.0% 3.2% 2.2% 0.8%	1.00 [0.07, 15.26] <b>1.87 [0.40, 8.70]</b> % 2.00 [0.19, 20.90] Not estimable 1.62 [0.96, 2.73] 1.05 [0.74, 1.48] 1.43 [0.59, 3.47] 2.67 [0.80, 8.90] 2.14 [0.20, 22.34]	
Subtotal (95% CI) Total events Heterogeneity: Tau <sup>2</sup> = 1 Test for overall effect: 2 3.20.4 > 1050 mg Abdelmageed 2010 Al-Mujadi 2005 Bartholdy 2006 Dirks 2002 Grosen 2014 Jajeda 2014 Kosucu 2013 Omran 2006	1 20 1.23; Chi <sup>2</sup> = 2 = 0.80 (P 21 21 21 10 8 2 2 2	30 <b>120</b> = 6.10, = 0.43 30 37 38 31 52 25 29 50	1 df = 3 (P ) 1 0 13 22 7 3 1 1	120 9 = 0.11 30 35 38 34 52 25 31 50	5.8% 1); l <sup>2</sup> = 51 0.8% 5.0% 6.0% 3.2% 2.2% 0.8% 0.8%	1.00 [0.07, 15.26] <b>1.87 [0.40, 8.70]</b> % 2.00 [0.19, 20.90] Not estimable 1.62 [0.96, 2.73] 1.05 [0.74, 1.48] 1.43 [0.59, 3.47] 2.67 [0.80, 8.90] 2.14 [0.20, 22.34] 2.00 [0.19, 21.36]	
Subtotal (95% CI) Total events Heterogeneity: Tau <sup>2</sup> = 1 Test for overall effect: Z 3.20.4 > 1050 mg Abdelmageed 2010 Al-Mujadi 2005 Bartholdy 2006 Dirks 2002 Grosen 2014 Jajeda 2014 Kosucu 2013 Omran 2006 Rorarius 2004	1 20 1.23; Chi <sup>2</sup> = 2 = 0.80 (P 2 2 2 1 21 10 8 2 2 2 14	30 120 = 6.10, = 0.43 30 37 38 31 52 25 29 50 38	1 df = 3 (P ) 1 0 13 22 7 3 1 1 1 22	120 30 35 38 34 52 25 31 50 37	5.8% 1); l <sup>2</sup> = 51 0.8% 5.0% 6.0% 3.2% 0.8% 0.8% 4.5%	1.00 [0.07, 15.26] <b>1.87 [0.40, 8.70]</b> % 2.00 [0.19, 20.90] Not estimable 1.62 [0.96, 2.73] 1.05 [0.74, 1.48] 1.43 [0.59, 3.47] 2.67 [0.80, 8.90] 2.14 [0.20, 22.34] 2.00 [0.19, 21.36] 1.14 [0.61, 2.12]	
Subtotal (95% CI) Total events Heterogeneity: Tau <sup>2</sup> = 1 Test for overall effect: Z 3.20.4 > 1050 mg Abdelmageed 2010 Al-Mujadi 2005 Bartholdy 2006 Dirks 2002 Grosen 2014 Jajeda 2014 Kosucu 2013 Omran 2006 Rorarius 2004	1 20 1.23; Chi <sup>2</sup> = 2 = 0.80 (P 21 21 21 10 8 2 2 2	30 <b>120</b> = 6.10, = 0.43 30 37 38 31 52 25 29 50	1 df = 3 (P ) 1 0 13 22 7 3 1 1	120 9 = 0.11 30 35 38 34 52 25 31 50	5.8% 1); l <sup>2</sup> = 51 0.8% 5.0% 6.0% 3.2% 2.2% 0.8% 0.8%	1.00 [0.07, 15.26] <b>1.87 [0.40, 8.70]</b> % 2.00 [0.19, 20.90] Not estimable 1.62 [0.96, 2.73] 1.05 [0.74, 1.48] 1.43 [0.59, 3.47] 2.67 [0.80, 8.90] 2.14 [0.20, 22.34] 2.00 [0.19, 21.36]	
Subtotal (95% CI) Total events Heterogeneity: Tau <sup>2</sup> = 1 Test for overall effect: 2 3.20.4 > 1050 mg Abdelmageed 2010 Al-Mujadi 2005 Bartholdy 2006 Dirks 2002 Grosen 2014 Jajeda 2014 Kosucu 2013 Omran 2006 Rorarius 2004 Sen 2009a	1 20 1.23; Chi <sup>2</sup> = 2 = 0.80 (P 2 2 2 1 21 10 8 2 2 2 14	30 120 = 6.10, = 0.43 30 37 38 31 52 25 29 50 38	1 df = 3 (P ) 1 0 13 22 7 3 1 1 1 22	120 30 35 38 34 52 25 31 50 37	5.8% 1); l <sup>2</sup> = 51 0.8% 5.0% 6.0% 3.2% 0.8% 0.8% 4.5%	1.00 [0.07, 15.26] <b>1.87 [0.40, 8.70]</b> % 2.00 [0.19, 20.90] Not estimable 1.62 [0.96, 2.73] 1.05 [0.74, 1.48] 1.43 [0.59, 3.47] 2.67 [0.80, 8.90] 2.14 [0.20, 22.34] 2.00 [0.19, 21.36] 1.14 [0.61, 2.12]	
Subtotal (95% CI) Total events Heterogeneity: Tau <sup>2</sup> = 1 Test for overall effect: 2 3.20.4 > 1050 mg Abdelmageed 2010 Al-Mujadi 2005 Bartholdy 2006 Dirks 2002 Grosen 2014 Jajeda 2014 Kosucu 2013 Omran 2006 Rorarius 2004 Sen 2009a Turan 2003a	1 20 1.23; Chi <sup>2</sup> = 2 = 0.80 (P 2 0 21 21 10 8 2 2 14 3	30 120 = 6.10, = 0.43 30 37 38 31 52 25 29 50 38 20	1 df = 3 (P ) 1 0 13 22 7 3 1 1 1 22 3	120 30 35 38 34 52 25 31 50 37 20	5.8% 1); l <sup>2</sup> = 51 0.8% 5.0% 6.0% 3.2% 2.2% 0.8% 0.8% 4.5% 1.7%	1.00 [0.07, 15.26] <b>1.87 [0.40, 8.70]</b> % 2.00 [0.19, 20.90] Not estimable 1.62 [0.96, 2.73] 1.05 [0.74, 1.48] 1.43 [0.59, 3.47] 2.67 [0.80, 8.90] 2.14 [0.20, 22.34] 2.00 [0.19, 21.36] 1.14 [0.61, 2.12] 1.00 [0.23, 4.37] 3.00 [0.13, 70.30]	
Subtotal (95% CI) Total events Heterogeneity: Tau <sup>2</sup> = 1 Test for overall effect: 2 3.20.4 > 1050 mg Abdelmageed 2010 Al-Mujadi 2005 Bartholdy 2006 Dirks 2002 Grosen 2014 Jajeda 2014 Kosucu 2013 Omran 2006 Rorarius 2004 Sen 2009a Turan 2003a Turan 2003b	1 20 1.23; Chi <sup>2</sup> = 2 = 0.80 (P 2 0 21 21 10 8 2 2 14 3 1 2	30 120 = 6.10, = 0.43 30 37 38 31 52 25 29 50 88 20 25 25	1 df = 3 (P ) 1 0 13 22 7 7 3 1 1 1 2 3 0 0 1	120 30 35 38 34 52 31 50 37 20 25 25	5.8% 1); l <sup>2</sup> = 51 0.8% 5.0% 6.0% 3.2% 0.8% 0.8% 4.5% 1.7% 0.4% 0.8%	1.00 [0.07, 15.26] <b>1.87 [0.40, 8.70]</b> % 2.00 [0.19, 20.90] Not estimable 1.62 [0.62, 2.73] 1.05 [0.74, 1.48] 1.43 [0.59, 3.47] 2.67 [0.80, 8.90] 2.14 [0.20, 22.34] 2.00 [0.19, 21.36] 1.14 [0.61, 2.12] 1.00 [0.23, 4.37] 3.00 [0.13, 70.30] 2.00 [0.19, 20.67]	
Subtotal (95% CI) Total events Heterogeneity: Tau <sup>2</sup> = 1 Test for overall effect: 2 3.20.4 > 1050 mg Abdelmageed 2010 Al-Mujadi 2005 Bartholdy 2006 Dirks 2002 Grosen 2014 Jajeda 2014 Kosucu 2013 Omran 2006 Rorarius 2004 Sen 2009a Turan 2003b Turan 2003b Turan 2003b	1 20 1.23; Chi <sup>2</sup> = 2 = 0.80 (P 21 21 10 8 2 2 14 3 1 2 5	30 120 = 6.10, = 0.43 30 37 38 31 52 25 29 50 38 20 25 25 20	1 df = 3 (P ) 1 0 13 22 7 7 3 1 1 1 2 2 3 0 0 1 2 2 3 0 1 2 2 3 0 1 2 2 3 0 1 2 2 3 1 1 2 2 3 1 2 3 1 2 3 1 2 3 3 1 3 3 2 2 3 3 3 3	120 30 35 38 34 52 25 31 50 37 20 25 25 20	5.8% 1); l <sup>2</sup> = 51 0.8% 5.0% 6.0% 3.2% 0.8% 0.8% 0.8% 1.7% 0.4% 1.6%	1.00 [0.07, 15.26] <b>1.87 [0.40, 8.70]</b> % 2.00 [0.19, 20.90] Not estimable 1.62 [0.96, 2.73] 1.05 [0.74, 1.48] 1.43 [0.59, 3.47] 2.67 [0.80, 8.90] 2.14 [0.20, 22.34] 2.00 [0.19, 21.36] 1.14 [0.61, 2.12] 1.00 [0.23, 4.37] 3.00 [0.13, 70.30] 2.50 [0.55, 11.41]	
Subtotal (95% CI) Total events Heterogeneity: Tau <sup>2</sup> = 1 Test for overall effect: 2 3.20.4 > 1050 mg Abdelmageed 2010 Al-Mujadi 2005 Bartholdy 2006 Dirks 2002 Grosen 2014 Jajeda 2014 Kosucu 2013 Omran 2006 Rorarius 2004 Sen 2009a Turan 2003a Turan 2003b Turan 2005 Ucak 2011	1 20 1.23; Chi <sup>2</sup> = 2 = 0.80 (P 2 0 21 21 10 8 2 2 14 3 1 2 5 2	30 120 = 6.10, = 0.43 30 37 38 31 52 529 50 38 20 25 25 29 50 38 20 25 25 20 20	1 df = 3 (P ) 1 1 0 13 22 7 3 1 1 1 2 3 0 1 2 2 3 0 1 2 1	120 30 35 38 34 52 25 31 50 37 20 25 20 20	5.8% 1); l <sup>2</sup> = 51 0.8% 5.0% 6.0% 3.2% 2.2% 0.8% 0.8% 0.8% 1.7% 0.4% 0.4% 0.8%	1.00 [0.07, 15.26] 1.87 [0.40, 8.70] % 2.00 [0.19, 20.90] Not estimable 1.62 [0.96, 2.73] 1.05 [0.74, 1.48] 1.43 [0.59, 3.47] 2.67 [0.80, 8.90] 2.14 [0.20, 22.34] 2.00 [0.19, 21.36] 1.14 [0.61, 2.12] 1.00 [0.23, 4.37] 3.00 [0.13, 70.30] 2.00 [0.19, 20.67] 2.50 [0.55, 11.41] 2.00 [0.20, 20.33]	
Subtotal (95% CI) Total events Heterogeneity: Tau <sup>2</sup> = 1 Test for overall effect: 2 3.20.4 > 1050 mg Abdelmageed 2010 Al-Mujadi 2005 Bartholdy 2006 Dirks 2002 Grosen 2014 Jajeda 2014 Kosucu 2013 Omran 2006 Rorarius 2004 Sen 2009a Turan 2003a Turan 2003b Turan 2005 Ucak 2011 Özgencil 2011	1 20 1.23; Chi <sup>2</sup> = 2 = 0.80 (P 21 21 10 8 2 2 14 3 1 2 5	30 120 = 6.10, = 0.43 30 37 38 31 52 25 29 50 38 20 25 25 20 30 30 30 37 38 20 25 25 20 38 20 38 20 30 37 38 30 38 20 38 20 38 20 38 20 38 20 38 30 38 20 38 20 38 20 30 38 20 30 38 20 30 38 20 30 38 20 30 38 20 25 20 30 30 30 38 20 25 20 30 30 30 30 38 20 20 30 30 38 20 20 20 20 20 20 20 20 20 20	1 df = 3 (P ) 1 0 13 22 7 7 3 1 1 1 2 2 3 0 0 1 2 2 3 0 1 2 2 3 0 1 2 2 3 0 1 2 2 3 1 1 2 2 3 1 2 3 1 2 3 1 2 3 3 1 3 3 2 2 3 3 3 3	120 30 35 38 34 52 25 31 50 37 20 25 25 20 20 30	5.8% 1); l <sup>2</sup> = 51 0.8% 5.0% 6.0% 3.2% 2.2% 0.8% 0.8% 4.5% 0.8% 1.7% 0.4% 0.8% 1.6% 0.8% 2.8%	1.00 [0.07, 15.26] 1.87 [0.40, 8.70] % 2.00 [0.19, 20.90] Not estimable 1.62 [0.96, 2.73] 1.05 [0.74, 1.48] 1.43 [0.59, 3.47] 2.67 [0.80, 8.90] 2.14 [0.20, 22.34] 2.00 [0.19, 21.36] 1.14 [0.61, 2.12] 1.00 [0.23, 4.37] 3.00 [0.13, 70.30] 2.00 [0.19, 20.67] 2.50 [0.55, 11.41] 2.00 [0.20, 20.33] 1.60 [0.59, 4.33]	
Subtotal (95% CI) Total events Heterogeneity: Tau <sup>2</sup> = 1 Test for overall effect: 2 3.20.4 > 1050 mg Abdelmageed 2010 Al-Mujadi 2005 Bartholdy 2006 Dirks 2002 Grosen 2014 Jajeda 2014 Kosucu 2013 Omran 2006 Rorarius 2004 Sen 2009a Turan 2005 Turan 2003a Turan 2003 Turan 2005 Ucak 2011 Özgencil 2011 Subtotal (95% CI)	1 20 1.23; Chi <sup>2</sup> = 2 = 0.80 (P 2 2 2 21 21 10 8 2 2 14 3 1 2 5 2 8	30 120 = 6.10, = 0.43 30 37 38 31 52 529 50 38 20 25 25 29 50 38 20 25 25 20 20	1 df = 3 (P ) 1 1 0 13 22 7 3 1 1 12 3 0 1 2 3 0 1 2 5	120 30 35 38 34 52 25 31 50 37 20 25 20 20	5.8% 1); l <sup>2</sup> = 51 0.8% 5.0% 6.0% 3.2% 2.2% 0.8% 0.8% 0.8% 1.7% 0.4% 0.4% 0.8%	1.00 [0.07, 15.26] 1.87 [0.40, 8.70] % 2.00 [0.19, 20.90] Not estimable 1.62 [0.96, 2.73] 1.05 [0.74, 1.48] 1.43 [0.59, 3.47] 2.67 [0.80, 8.90] 2.14 [0.20, 22.34] 2.00 [0.19, 21.36] 1.14 [0.61, 2.12] 1.00 [0.23, 4.37] 3.00 [0.13, 70.30] 2.00 [0.19, 20.67] 2.50 [0.55, 11.41] 2.00 [0.20, 20.33]	
Subtotal (95% CI) Total events Heterogeneity: Tau <sup>2</sup> = 1 Test for overall effect: 2 3.20.4 > 1050 mg Abdelmageed 2010 Al-Mujadi 2005 Bartholdy 2006 Dirks 2002 Grosen 2014 Jajeda 2014 Kosucu 2013 Omran 2006 Rorarius 2004 Sen 2009a Turan 2003a Turan 2003a Turan 2003b Turan 2003b Turan 2005 Ucak 2011 Özgencil 2011 Subtotal (95% CI) Total events	1 20 1.23; Chi <sup>2</sup> = 2 = 0.80 (P 2 0 21 10 8 2 14 3 1 2 5 2 8 101	30 120 = 6.10, 30 37 38 31 52 25 29 50 38 80 25 25 20 25 25 20 20 470	1 df = 3 (P ) 1 0 13 22 7 7 3 1 1 1 2 3 0 1 2 2 1 5 7 2	120 30 35 38 34 52 25 31 50 37 20 25 20 20 20 472	5.8% 1); l <sup>2</sup> = 51 0.8% 5.0% 6.0% 3.2% 2.2% 0.8% 4.5% 1.7% 0.4% 0.8% 1.6% 0.8% 2.8% 31.3%	1.00 [0.07, 15.26] <b>1.87 [0.40, 8.70]</b> % 2.00 [0.19, 20.90] Not estimable 1.62 [0.96, 2.73] 1.05 [0.74, 1.48] 1.43 [0.59, 3.47] 2.67 [0.80, 8.90] 2.14 [0.20, 22.34] 2.00 [0.19, 21.36] 1.14 [0.61, 2.12] 1.00 [0.23, 4.37] 3.00 [0.13, 70.30] 2.00 [0.19, 20.67] 2.50 [0.55, 11.41] 2.00 [0.29, 4.33] 1.60 [0.59, 4.33] <b>1.31 [1.04, 1.64]</b>	
Subtotal (95% CI) Total events Heterogeneity: Tau <sup>2</sup> = 1 Test for overall effect: 2 3.20.4 > 1050 mg Abdelmageed 2010 Al-Mujadi 2005 Bartholdy 2006 Dirks 2002 Grosen 2014 Jajeda 2014 Kosucu 2013 Omran 2006 Rorarius 2004 Sen 2009a Turan 2003a Turan 2003b Turan 2005 Ucak 2011 Özgencil 2011	1 20 1.23; Chi <sup>2</sup> = 2 = 0.80 (P 2 0 21 10 8 2 2 14 3 1 2 5 2 8 101 0.00; Chi <sup>2</sup> =	30 120 = 6.10, = 0.43 30 37 38 31 52 25 29 50 38 20 25 25 25 20 20 25 25 20 20 470 **********************************	1 df = 3 (P ) 1 0 13 22 7 3 1 1 1 2 3 0 1 2 1 5 5 df = 13	120 30 35 38 34 52 25 31 50 37 20 25 20 20 20 472	5.8% 1); l <sup>2</sup> = 51 0.8% 5.0% 6.0% 3.2% 2.2% 0.8% 4.5% 1.7% 0.4% 0.8% 1.6% 0.8% 2.8% 31.3%	1.00 [0.07, 15.26] <b>1.87 [0.40, 8.70]</b> % 2.00 [0.19, 20.90] Not estimable 1.62 [0.96, 2.73] 1.05 [0.74, 1.48] 1.43 [0.59, 3.47] 2.67 [0.80, 8.90] 2.14 [0.20, 22.34] 2.00 [0.19, 21.36] 1.14 [0.61, 2.12] 1.00 [0.23, 4.37] 3.00 [0.13, 70.30] 2.00 [0.19, 20.67] 2.50 [0.55, 11.41] 2.00 [0.29, 4.33] 1.60 [0.59, 4.33] <b>1.31 [1.04, 1.64]</b>	
Subtotal (95% CI) Total events Heterogeneity: Tau <sup>2</sup> = 1 Test for overall effect: 2 3.20.4 > 1050 mg Abdelmageed 2010 Al-Mujadi 2005 Bartholdy 2006 Dirks 2002 Grosen 2014 Jajeda 2014 Kosucu 2013 Omran 2006 Rorarius 2004 Sen 2009a Turan 2003a Turan 2003a Turan 2003b Turan 2003b Turan 2005 Ucak 2011 Özgencil 2011 Subtotal (95% CI) Total (95% CI)	1 20 1.23; Chi <sup>2</sup> = 2 0 21 21 10 8 2 2 14 3 1 2 5 2 8 101 0.00; Chi <sup>2</sup> = 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	30 120 = 6.10, = 0.43 30 37 38 31 52 25 29 50 38 20 25 25 25 20 20 25 25 20 20 470 **********************************	1 13 df = 3 (P 1 0 13 22 7 3 1 12 3 0 1 22 7 3 1 1 22 7 3 1 1 22 7 3 1 1 22 7 3 1 1 22 7 3 1 1 22 7 3 1 1 22 7 3 1 1 22 7 3 1 1 22 7 3 1 1 22 7 3 1 1 22 7 3 1 1 22 7 3 1 1 22 7 3 1 1 22 7 3 1 1 22 7 3 1 1 22 7 3 1 1 22 7 3 1 1 22 2 7 3 1 1 22 2 7 3 1 1 2 2 1 2 1 2 2 1 3 0 1 2 2 1 3 0 1 2 2 1 3 0 1 3 0 1 2 1 2 1 2 1 3 0 1 2 1 2 1 3 0 1 3 0 1 3 0 1 3 0 1 3 0 1 3 0 1 3 0 1 2 1 3 0 1 3 0 1 3 0 1 2 1 3 0 1 3 0 1 5 5 7 2 1 1 5 5 7 2 1 1 5 5 7 2 1 1 5 7 2 1 1 5 7 2 1 1 5 7 2 1 1 1 1 1 1 1 1 1 1 1 1 1	120 30 35 38 34 52 25 31 50 025 25 20 00 30 472 (P = 0.1)	5.8% 1); l <sup>2</sup> = 51 0.8% 5.0% 6.0% 3.2% 2.2% 0.8% 4.5% 1.7% 0.4% 0.8% 1.6% 0.8% 2.8% 31.3%	1.00 [0.07, 15.26] <b>1.87 [0.40, 8.70]</b> % 2.00 [0.19, 20.90] Not estimable 1.62 [0.96, 2.73] 1.05 [0.74, 1.48] 1.43 [0.59, 3.47] 2.67 [0.80, 8.90] 2.14 [0.20, 22.34] 2.00 [0.19, 21.36] 1.14 [0.61, 2.12] 1.00 [0.23, 4.37] 3.00 [0.13, 70.30] 2.00 [0.19, 20.67] 2.50 [0.55, 11.41] 2.00 [0.29, 4.33] 1.60 [0.59, 4.33] <b>1.31 [1.04, 1.64]</b>	
Subtotal (95% CI) Total events Heterogeneity: Tau <sup>2</sup> = 1 Test for overall effect: 2 3.20.4 > 1050 mg Abdelmageed 2010 Al-Mujadi 2005 Bartholdy 2006 Dirks 2002 Grosen 2014 Jajeda 2014 Kosucu 2013 Omran 2006 Rorarius 2004 Sen 2009a Turan 2003a Turan 2003a Turan 2003b Turan 2003b Turan 2005 Ucak 2011 Özgencil 2011 Subtotal (95% CI) Total (95% CI)	1 20 1.23; Chi <sup>2</sup> = 2 = 0.80 (P 2 0 21 10 8 2 2 14 3 1 2 5 2 8 101 0.00; Chi <sup>2</sup> =	30 120 = 6.10, = 0.43; 30 37 38 31 52 25 29 50 38 20 25 25 20 50 30 470 = 0.43; 15 25 29 50 30 47 20 50 20 20 20 20 20 20 20 20 20 2	1 df = 3 (P ) 1 0 13 22 7 3 1 1 1 2 3 0 1 2 1 5 5 df = 13	120 30 35 38 34 52 25 31 50 025 25 20 00 30 472 (P = 0.1)	5.8% 1); l <sup>2</sup> = 51 0.8% 5.0% 6.0% 3.2% 2.2% 0.8% 0.8% 4.5% 0.8% 1.7% 0.4% 0.8% 1.7% 0.4% 0.8% 1.6% 0.8% 2.8% 31.3% 94); l <sup>2</sup> = 0	1.00 [0.07, 15.26] 1.87 [0.40, 8.70] % 2.00 [0.19, 20.90] Not estimable 1.62 [0.96, 2.73] 1.05 [0.74, 1.48] 1.43 [0.59, 3.47] 2.67 [0.80, 8.90] 2.14 [0.20, 22.34] 2.00 [0.19, 21.36] 1.14 [0.61, 2.12] 1.00 [0.23, 4.37] 3.00 [0.13, 70.30] 2.00 [0.19, 20.67] 2.50 [0.55, 11.41] 2.00 [0.59, 4.33] 1.60 [0.59, 4.33] 1.31 [1.04, 1.64]	
Subtotal (95% CI) Total events Heterogeneity: Tau <sup>2</sup> = 1 Test for overall effect: 2 3.20.4 > 1050 mg Abdelmageed 2010 Al-Mujadi 2005 Bartholdy 2006 Dirks 2002 Grosen 2014 Jajeda 2014 Kosucu 2013 Omran 2006 Rorarius 2004 Sen 2009a Turan 2003a Turan 2003b Turan 2003b Turan 2003b Turan 2005 Ucak 2011 Subtotal (95% CI) Total events Heterogeneity: Tau <sup>2</sup> = C Total (95% CI) Total events	1 20 1.23; $Chi^2 =$ 2 = 0.80 (P 2 2 1 10 8 2 14 3 1 2 5 2 8 101 .00; $Chi^2 =$ 2 = 2.32 (P 397	30 120 = 6.10, = 0.43; 30 37 38 31 52 25 29 50 38 80 25 25 20 25 20 20 25 25 20 25 25 20 25 25 20 25 25 20 38 80 43 31 52 25 25 20 25 25 20 25 25 20 25 25 20 25 25 20 25 25 20 25 20 25 25 20 25 20 25 20 25 20 25 20 25 20 25 25 20 25 20 25 20 25 25 20 25 20 25 20 25 20 25 20 25 20 25 20 25 20 25 20 25 20 25 20 25 20 25 20 20 25 20 25 20 25 20 25 20 20 25 25 20 20 20 25 25 20 20 20 20 20 20 20 20 20 20	$     \begin{array}{r}       13 \\       df = 3 (P) \\       1 \\       0 \\       13 \\       22 \\       7 \\       3 \\       1 \\       12 \\       3 \\       0 \\       1 \\       2 \\       3 \\       0 \\       1 \\       5 \\       72 \\       df = 13 \\       0 \\       281     \end{array} $	120 30 35 38 34 52 25 31 50 25 20 25 20 20 20 472 (P = 0.1)	5.8% 1); l <sup>2</sup> = 51 0.8% 5.0% 6.0% 3.2% 2.2% 0.8% 2.2% 0.8% 1.7% 0.4% 0.8% 1.6% 0.8% 31.3% 94); l <sup>2</sup> = 0 100.0%	1.00 [0.07, 15.26] 1.87 [0.40, 8.70] % 2.00 [0.19, 20.90] Not estimable 1.62 [0.96, 2.73] 1.05 [0.74, 1.48] 1.43 [0.59, 3.47] 2.67 [0.80, 8.90] 2.14 [0.20, 22.34] 2.00 [0.19, 21.36] 1.14 [0.61, 2.12] 1.00 [0.23, 4.37] 3.00 [0.13, 70.30] 2.00 [0.19, 20.67] 2.50 [0.55, 11.41] 2.00 [0.50, 4.33] 1.60 [0.59, 4.33] 1.31 [1.04, 1.64] % 1.32 [1.07, 1.65]	
Subtotal (95% CI) Total events Heterogeneity: Tau <sup>2</sup> = 1 Test for overall effect: 2 3.20.4 > 1050 mg Abdelmageed 2010 Al-Mujadi 2005 Bartholdy 2006 Dirks 2002 Grosen 2014 Jajeda 2014 Kosucu 2013 Omran 2006 Rorarius 2004 Sen 2009a Turan 2003a Turan 2003a Turan 2003b Turan 2003b Turan 2003b Turan 2003b Turan 2005 Ucak 2011 Özgencil 2011 Subtotal (95% CI) Total events Heterogeneity: Tau <sup>2</sup> = C	1 20 1.23; Chi <sup>2</sup> = 2 = 0.80 (P 2 0 21 10 8 2 14 3 1 2 5 2 8 101 0.00; Chi <sup>2</sup> = 2 = 2.32 (P 397 0.18; Chi <sup>2</sup> =	30 120 = 6.10, = 0.43 30 37 38 31 52 25 29 50 38 80 25 25 20 20 20 20 470 470 1640 10.45	1 13 df = 3 (P 1 0 13 22 7 3 1 1 1 2 3 0 1 2 3 0 1 2 3 0 1 2 2 3 1 1 2 2 3 1 1 2 2 3 1 1 2 2 3 1 2 2 3 1 1 2 2 3 1 1 2 2 3 1 1 2 2 3 1 1 2 2 3 1 1 2 2 3 1 1 2 2 3 1 1 2 2 3 1 1 2 2 3 1 1 2 2 3 1 1 2 2 3 1 1 2 2 3 1 1 2 2 3 0 1 2 2 3 1 1 2 2 3 0 1 2 2 3 1 1 2 2 3 0 1 2 2 3 0 1 2 2 3 0 1 2 2 3 0 1 2 2 2 3 1 2 2 3 0 1 2 2 3 0 1 2 2 2 3 0 1 2 2 3 0 1 2 2 2 3 0 1 2 2 2 2 3 1 2 2 2 3 0 1 2 2 2 2 3 1 2 2 2 2 3 1 2 2 2 2 2 2 2 2 2 2 2 2 2	120 30 35 38 34 52 25 31 50 25 20 25 20 20 20 472 (P = 0.1)	5.8% 1); l <sup>2</sup> = 51 0.8% 5.0% 6.0% 3.2% 2.2% 0.8% 2.2% 0.8% 1.7% 0.4% 0.8% 1.6% 0.8% 31.3% 94); l <sup>2</sup> = 0 100.0%	1.00 [0.07, 15.26] 1.87 [0.40, 8.70] % 2.00 [0.19, 20.90] Not estimable 1.62 [0.96, 2.73] 1.05 [0.74, 1.48] 1.43 [0.59, 3.47] 2.67 [0.80, 8.90] 2.14 [0.20, 22.34] 2.00 [0.19, 21.36] 1.14 [0.61, 2.12] 1.00 [0.23, 4.37] 3.00 [0.13, 70.30] 2.00 [0.19, 20.67] 2.50 [0.55, 11.41] 2.00 [0.50, 4.33] 1.60 [0.59, 4.33] 1.31 [1.04, 1.64] % 1.32 [1.07, 1.65]	0.01 0.1 1 10 Favours Gabapentin Favours Contro

# Supplemental Digital Content 18 Forest plot of sedation from all trials estimates

# Supplemental Digital Content 19 Forest plot of dizziness from trials with low risk of bias

	Gabape		Conti			Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	M-H, Random, 95% Cl
3.21.1 0-350 mg							
Spence 2011	10	26	9	31	4.8%	1.32 [0.64, 2.76]	
Waikakul 2011	0	26	1	24	0.3%	0.31 [0.01, 7.23]	
Subtotal (95% CI)		52		55	5.0%	1.23 [0.60, 2.51]	+
Total events	10		10				
Heterogeneity: Tau <sup>2</sup> :				1 (P = 0)	).37); l <sup>2</sup> =	: 0%	
Test for overall effect	t: $Z = 0.57$	' (P = 0	.57)				
3.21.2 351-700 mg	I						
Kinney 2011	9	57	10	63	3.8%	0.99 [0.44, 2.27]	
Paul 2013	29	52	28	49	21.9%	0.98 [0.69, 1.37]	
Srivastava 2010	5	60	7	60	2.2%	0.71 [0.24, 2.13]	
Subtotal (95% CI)		169		172	27.8%	0.96 [0.70, 1.29]	<b></b>
Total events	43		45				
Heterogeneity: Tau <sup>2</sup>	= 0.00; Ch	$i^2 = 0.3$	31, df =	2 (P = 0	).86); I <sup>2</sup> =	: 0%	
Test for overall effect	t: $Z = 0.30$	) (P = 0	.77)				
3.21.3 701-1050 m	g						
Ghai 2011	8	30	1	30	0.6%	8.00 [1.07, 60.09]	
Subtotal (95% CI)		30		30	0.6%	8.00 [1.07, 60.09]	
Total events	8		1				
Heterogeneity: Not a	pplicable						
neterogeneity. Not a							
Test for overall effect		P = 0	.04)				
<b>J</b>		? (P = 0	.04)				
Test for overall effect 3.21.4 > 1050 mg		2 (P = 0. 38	.04) 10	38	5.1%	1.20 [0.59, 2.44]	
Test for overall effect 3.21.4 > 1050 mg Bartholdy 2006	t: Z = 2.02			38 30	5.1% 0.3%	1.20 [0.59, 2.44] 3.10 [0.13, 73.14]	
Test for overall effect 3.21.4 > 1050 mg Bartholdy 2006 Fassoulaki 2005	t: Z = 2.02	38	10				
Test for overall effect	t: Z = 2.02 12 1	38	10 0	30	0.3%	3.10 [0.13, 73.14]	•
Test for overall effect 3.21.4 > 1050 mg Bartholdy 2006 Fassoulaki 2005 Grosen 2014	t: Z = 2.02 12 1	38 29 52	10 0	30 52	0.3% 61.2%	3.10 [0.13, 73.14] 1.02 [0.84, 1.26]	•
Test for overall effect 3.21.4 > 1050 mg Bartholdy 2006 Fassoulaki 2005 Grosen 2014 Subtotal (95% CI)	t: Z = 2.02 12 1 41 54	38 29 52 <b>119</b>	10 0 40 50	30 52 <b>120</b>	0.3% 61.2% <b>66.5%</b>	3.10 [0.13, 73.14] 1.02 [0.84, 1.26] <b>1.04 [0.86, 1.27</b> ]	•
Test for overall effect 3.21.4 > 1050 mg Bartholdy 2006 Fassoulaki 2005 Grosen 2014 Subtotal (95% CI) Total events Heterogeneity: Tau <sup>2</sup>	12 = 2.02 $12 = 1$ $41 = 0.00; Ch$	$38$ 29 52 119 $3i^2 = 0.7$	10 0 40 50 76, df =	30 52 <b>120</b>	0.3% 61.2% <b>66.5%</b>	3.10 [0.13, 73.14] 1.02 [0.84, 1.26] <b>1.04 [0.86, 1.27</b> ]	•
Test for overall effect 3.21.4 > 1050 mg Bartholdy 2006 Fassoulaki 2005 Grosen 2014 Subtotal (95% CI) Total events	12 = 2.02 $12 = 1$ $41 = 0.00; Ch$	$38$ 29 52 119 $3i^2 = 0.7$	10 0 40 50 76, df =	30 52 <b>120</b> 2 (P = 0	0.3% 61.2% <b>66.5%</b>	3.10 [0.13, 73.14] 1.02 [0.84, 1.26] <b>1.04 [0.86, 1.27</b> ]	•
Test for overall effect 3.21.4 > 1050 mg Bartholdy 2006 Fassoulaki 2005 Grosen 2014 Subtotal (95% Cl) Total events Heterogeneity: Tau <sup>2</sup> Test for overall effect	12 = 2.02 $12 = 1$ $41 = 0.00; Ch$	$38 \\ 29 \\ 52 \\ 119 \\ 11^{2} = 0.7 \\ 1 (P = 0.7)$	10 0 40 50 76, df =	30 52 <b>120</b> 2 (P = 0	0.3% 61.2% <b>66.5%</b> 0.68); I <sup>2</sup> =	3.10 [0.13, 73.14] 1.02 [0.84, 1.26] <b>1.04 [0.86, 1.27]</b>	•
Test for overall effect 3.21.4 > 1050 mg Bartholdy 2006 Fassoulaki 2005 Grosen 2014 Subtotal (95% CI) Total events Heterogeneity: Tau <sup>2</sup> Test for overall effect Total (95% CI)	$\begin{array}{c} 12 \\ 12 \\ 141 \\ 54 \\ = 0.00; \ Ch \\ t: \ Z = 0.41 \\ 115 \end{array}$	38  29  52  119  ni2 = 0.7  1 (P = 0.370  370	10 0 40 50 76, df = .68) 106	30 52 <b>120</b> 2 (P = 0 <b>377</b>	0.3% 61.2% 66.5% 0.68); I <sup>2</sup> = 100.0%	3.10 [0.13, 73.14] 1.02 [0.84, 1.26] 1.04 [0.86, 1.27]	•

# Supplemental Digital Content 20 Forest plot of dizziness from all trials estimates

	Gabape	ntin	Contr	ol		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	M-H, Random, 95% CI
3.22.1 0-350 mg			-				
Bang 2009	3	23	3	23	0.7%	1.00 [0.22, 4.45]	
Behdad 2012	0 4	30 100	0	31 100	1.0%	Not estimable	
Chowdhury 2010 Clarke 2014	4	88	12	77	1.0% 0.7%	0.80 [0.22, 2.89]	
Ghafari 2009	2	33	2	33	0.7%	0.15 [0.03, 0.63] 1.00 [0.15, 6.68]	
Mohammadi 2009	2	40	ō	40	0.2%	5.00 [0.25, 100.97]	<b>,</b>
Panday 2004b	0	153	Ő	153	012/0	Not estimable	
Panday 2004c	1	28	õ	28	0.2%	3.00 [0.13, 70.64]	
Sekhavet 2009	5	49	7	49	1.4%	0.71 [0.24, 2.10]	
Verma 2008	1	25	0	25	0.2%	3.00 [0.13, 70.30]	
Waikakul 2011	0	26	1	24	0.2%	0.31 [0.01, 7.23]	
Yoon 2001	10	16	9	15	4.6%	1.04 [0.59, 1.83]	+-
Subtotal (95% CI)		611		598	9.5%	0.84 [0.54, 1.32]	+
Total events	30		39				
Heterogeneity: Tau <sup>2</sup> =	0.04; Ch	i <sup>2</sup> = 9.7	70, df = 9	9 (P = 0)	.38); I <sup>2</sup> =	7%	
Test for overall effect:	Z = 0.75	(P = 0.	.45)				
3.22.2 351-700 mg							
Ajori 2011	0	69	0	69		Not estimable	
Azemati 2013	14	50	14	50	3.7%	1.00 [0.53, 1.87]	
Clarke 2009b	19	76	8	38	2.9%	1.19 [0.57, 2.46]	
Grover 2009	10	25	7	21	2.6%	1.20 [0.55, 2.60]	
Kavitha 2013	2	28	4	28	0.6%	0.50 [0.10, 2.51]	
Kazak 2009	0	30	0	30	3.00	Not estimable	
Kim 2004	8	21	9	20	2.9%	0.85 [0.41, 1.76]	
Kinney 2011 Mardani, Kivi 2012	9	57	10	63	2.3%	0.99 [0.44, 2.27]	
Mardani-Kivi 2013	3	55	6	53	0.9%	0.48 [0.13, 1.83]	
Paul 2013 Sen 2009a	29 2	52 20	28 2	49 20	10.3% 0.5%	0.98 [0.69, 1.37] 1.00 [0.16, 6.42]	
Spence 2011	10	20	2	31	2.8%	1.32 [0.64, 2.76]	
Srivastava 2010	5	60	7	60	1.3%	0.71 [0.24, 2.13]	
Subtotal (95% CI)	2	569		532	30.7%	0.98 [0.80, 1.22]	
Total events	111	505	104		501170	0100 [0100, 2122]	Ť
Heterogeneity: Tau <sup>2</sup> =		$i^2 = 3.4$		10 (P =	0.97) 12	= 0%	
Test for overall effect:				10 (1 -	0.57), 1	- 0/0	
rescrot overall effect.	2 = 0.14	(r = 0.	.09)				
3.22.3 701-1050 mg							
Deniz 2012	0	25	0	26		Not estimable	
Ghai 2011	8	30	1	30	0.4%	8.00 [1.07, 60.09]	
Ghai 2012	10	30	1	30	0.4%	10.00 [1.36, 73.33]	
Leung 2006	0	12	ô	9	01170	Not estimable	
Neogi 2012	1	30	1	30	0.2%	1.00 [0.07, 15.26]	
Rajendran 2014	3	30	3	30	0.7%	1.00 [0.22, 4.56]	
Subtotal (95% CI)	-	157	_	155	1.7%	2.99 [0.80, 11.22]	
Total events	22		6				-
Heterogeneity: Tau <sup>2</sup> =	0.77; Ch	i <sup>2</sup> = 5.2	24, df = 3	3 (P = 0	.16); I <sup>2</sup> =	43%	
Test for overall effect:							
3.22.4 > 1050 mg							
Abdelmageed 2010	6	30	5	30	1.4%	1.20 [0.41, 3.51]	
Al-Mujadi 2005	0	37	0	35		Not estimable	
Bartholdy 2006	12	38	10	38	3.0%	1.20 [0.59, 2.44]	+
Bekawi 2014	17	30	25	30	9.9%	0.68 [0.48, 0.97]	-
Clarke 2013	16	22	9	22	4.6%	1.78 [1.01, 3.12]	<u>⊢</u>
Dierking 2003	23	39	15	32	6.6%	1.26 [0.80, 1.98]	<u>+-</u>
Dirks 2002	11	31	14	34	3.8%	0.86 [0.46, 1.60]	- <u>-</u> -
Doha 2010	8	30	2	29	0.8%	3.87 [0.90, 16.70]	
Fassoulaki 2005	1	29	0	30	0.2%	3.10 [0.13, 73.14]	
Grosen 2014	41	52	40	52	19.4%	1.02 [0.84, 1.26]	
Omran 2006 Pathak 2012	6	50	4	50	1.1%	1.50 [0.45, 4.99]	
Pathak 2013	0	40	1	40	0.2%	0.33 [0.01, 7.95]	
Rorarius 2004	6	38	4	37	1.1%	1.46 [0.45, 4.76]	
Tirault 2010 Turan 2003a	2 2	69 25	0	66 25	0.2% 0.3%	4.79 [0.23, 97.85]	
Turan 2003a Turan 2003b	6	25	4	25	1.2%	2.00 [0.19, 20.67]	
Turan 2003b Turan 2004	4	25	4	25	1.2%	1.50 [0.48, 4.68] 1.00 [0.28, 3.56]	
Turan 2004 Turan 2005	4	20	4	20	0.4%	7.00 [0.95, 51.80]	
Turan 2006	6	25	2	25	0.4%	3.00 [0.67, 13.46]	
Ucak 2011	2	20	1	20	0.3%	2.00 [0.20, 20.33]	
Özgencil 2011	9	30	6	30	1.9%	1.50 [0.61, 3.69]	
Subtotal (95% CI)	9	705	0	695	58.1%	1.20 [0.96, 1.48]	
Total events	185		148				ľ
Heterogeneity: Tau <sup>2</sup> =		$j^2 = 26$		19 (P -	= 0,13)- F	<sup>2</sup> = 27%	
Test for overall effect:							
Total (95% CI)		2042		1980	100.0%	1.06 [0.94, 1.21]	•
Total events	348		297				
Heterogeneity: Tau <sup>2</sup> =		i <sup>2</sup> = 46		44 (P =	= 0.35); I	<sup>2</sup> = 6%	0.01 0.1 1 10 100
Test for overall effect:	Z = 0.96	(P = 0.	.34)				0.01 0.1 1 10 100 Favours Gabapentin Favours Control
Test for subgroup diff	ferences: (	Chi <sup>2</sup> = !	5.02, df	= 3 (P =	= 0.17), l <sup>2</sup>	<sup>2</sup> = 40.2%	arours ousapentin Tayours Control